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The emergence of multi-resistant strains of bacteria is a critical health problem 
worldwide. Antimicrobial-resistant infections are essentially untreatable and have 
begun to occur as epidemics around the globe. The need for new targets for 
chemotherapeutic agents, and the development of new chemotherapeutic agents 
themselves, is now a greater need than ever. In this study, an iron-uptake ATP-
binding cassette (ABC) transporter, FbpABC, from the Gram-negative human 
pathogen Neisseria gonorrhoeae has been investigated. The periplasmic binding 
protein, FbpA, has been mutated to facilitate investigation of complex formation with 
the two other components of the transporter, FbpB and FbpC. 
FbpBC was PCR-amplified from N. gonorrhoeae genomic DNA, co-
expressed in E. co/i cells, and its purification optimised. FbpA residues R48 and 
V272 have been mutated to allow covalent modification with a linker molecule to 
allow attachment to a sensor surface and used as bait to detect the purified FbpBC 
complex, using surface plasmon resonance. This is the first report of the purification 
of FbpB, and the first demonstration of FbpABC association in vitro. A radioactive 
iron-uptake assay revealed that E. co/i cells expressing the N. gonorrhoeae FbpABC 
operon take-up more iron than control cells. 
The FbpC gene was cloned using recombinant DNA technology and over-
expressed in E. co/i to perform biochemical characterisation of the enzyme. The 
expression and purification of selenomethionine-labelled FbpC allowed 
determination of the X-ray crystal structure of FbpC at Imperial College, London. 
Crystals of FbpC diffracted to a resolution of 2.7 A, and the structure was solved 
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with ATP and calcium bound in the active site, at the interface between two FbpC 
monomers. The structure also revealed a novel C-terminal fold for a nucleotide 
binding domain from an ABC transporter. 
Metal-free apo-FbpA was reloaded with ruthenium(III) and osmium(III) salts 
and characterised by various techniques. Chromatography and ICP-OES analysis of 
Ru- and Os-FbpA showed that there were two main species formed with each metal. 
Both species have four metal atoms bound and differ in that one species may be 
capped by a single phosphate anion, and the other by two phosphate anions. EXAFS 




Aa 	 Amino acid(s) 
ABC transporter 	ATP binding cassette transporter 
ADP Adenosine 5-diphosphate 
ATP Adenosine 5'-triphosphate 
ATPase ATP hydrolysing enzyme 
BCA Bicinchoninic acid 
Bp Base pair(s) 
CM Cytoplasmic membrane 
CTAB Cetyl trimethylammonium bromide 
CV Column volumes 
DDM n-dodecyl--D-maltopyranoside 
DDT Dithiothreitol 
DNTP(s) Deoxy nucleotide triphosphate(s) 
EDTA Ethylenediaminetetracetic acid 
ESI-MS Electrospray ionization mass spectrometry 
FbpA Ferric-ion binding protein A 
FbpB Ferric-ion binding protein B 
FbpC Ferric-ion binding protein C 
FT-ICR Fourier transform ion cyclotron resonance 
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Abbreviations 
Fur Ferric uptake regulator 
g Gravity (centrifugal force) 
HEPES N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) 
IAF 5-iodoacetamidofluoroscein 
IPTG Isopropyl- 1 -thio- -D-ga1actopyranoside 
kbp Kilo base pairs 
keV Kilo electron volts 
kDa Kilo daltons 
LB Luria Bertani 
LC-MS Liquid chromatography mass spectrometry 
M-PE02-B Maleimide-polyethyleneoxide2-biotin 
MALDI Matrix-associated laser desorption ionization 
MDG M9 salts/aspartic acid/glucose media 
NBD Nucleotide binding domain 
OM Outer membrane 
ORF Open reading frame 
PAGE Polyacrylamide gel electrophoresis 
PBP Periplasmic binding protein 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
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Chapter 1: Metals in Biology 
1.1 	Metals in Biological Systems 
It is currently estimated that over 50% of all proteins will turn out to be 
metalloproteins dependent on the metal for structure and/or function (1). Molecules 
containing metal ions are involved in many different functions in biological systems. 
They are involved in electron transfer, metal storage, oxygen binding, enzymatic 
catalysis, structural stability and can be involved in signal transduction (2). 
Metal ions have been used in various drugs for the treatment of many 
diseases. Platinum anticancer, bismuth antiulcer, and gold antiarthritic drugs are just 
some of the metal-ion-containing drugs that have been developed. The study of 
metal ions and their chemistry in life has thus become a major area in bioinorganic 
research (3). 
Iron is an essential element, as it serves as a co-factor in fundamental 
metabolic processes, such as nucleotide biosynthesis and energy production. Iron is 
a key player in the electron transport pathway that is essential for respiration in both 
eukaryotes and prokaryotes, and as such is an essential requirement for Gram-
negative pathogens that infect mammals. Indeed, the acquisition of iron is possibly 
the major determinant as to whether a microorganism can maintain itself within a 
host. The process of iron acquisition is recognised as a key step in the development 
of any pathogen within a host, as without iron the host defence mechanisms would 
effectively eliminate infection or the pathogen would simply die of nutrient 
starvation (4). 
However, in mammals, iron is not freely available and is kept tightly 
associated with proteins such as haemoglobin, the iron storage protein ferritin (up to 
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4 500 Fe 3+  ions per ferritin molecule), and the metal transport protein family of 
transferrins. Gram-negative bacteria have evolved several mechanisms to thrive in 
this iron-depleted environment. Such is the importance of iron acquisition for a 
pathogen, that it is a key target for the development of new chemotherapeutic agents 
(4). It follows that the study and understanding of the mechanisms that bacteria 
utilise to acquire iron are crucially important for the development of such novel 
agents. 
1.2 	Mechanisms of Iron Uptake in Gram-negative Bacteria 
1.2.1 Availability of Iron 
Iron is usually found in the environment as insoluble ferric oxo-hydroxide (rust) and 
the solubility of iron at physiological pH is very low (10.18  M). In the body, free iron 
is efficiently scavenged by various proteins in the blood stream and tissues (5). It 
thus follows that pathogens are limited in their capacity to multiply in vivo because 
of the "iron sequestering" defence mechanism of the infected host. Pathogenic 
bacteria multiply in a host, which implies that they have developed ways of 
overcoming these defence mechanisms (4). These mechanisms and the proteins 
involved are summarised in Table 1.1. 
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Table 1.1. Mechanism of iron uptake by some species of Gram-negative bacteria. 
Although the Neisseria spp do not secrete siderophores, they do express outer membrane 
siderophore receptors that permit uptake of exogenous siderophores from the environment 
(6). 
Iron source Bacteria 	 Protein 	Function 
LbpAB Lf outer membrane receptor 
Haernophilus influenzae TbpAB Tf outer membrane receptor 
Transferrin HitABC Fe 3' ABC transport system 
Lactoferrin LbpAB Lf outer membrane receptor 
Neisseria spp. TbpAB Tf outer membrane receptor 
FbpABC Fe 3' ABC transport system 
Yersinia enterocolitica 
Fe 3+  ABC transport system 
Lactoferrin 	
Actinobacillus Yfu 
Fe 3' ABC transport system 
pleuropneumoniae Afu 
ABC transport system 
Helicobacter pylon 
Escherichia coli 0157 ChuA haem outer membrane receptor 




HpuAB 	 haemlHb outer membrane receptor 
Serratia inarcescens 	SfuABC Fe 3+ ABC transport system 
Shi ge/la dysenteriae ShuA 
Vibrio cholerae 	 haem outer membrane receptor 









haem!Hb outer membrane receptor 
haem/Hb outer membrane receptor 
haem!Hb outer membrane receptor 
haem ABC transport system 
aeruginosa 
rnu I U V W haem receptor, hemophore, ABC 
HasRADEF transporter for HasA export 
Haemoph i/us influenzae 
Azotobacter vinelandii 
FhuBCDG ferrichrome transport 
Bacillus subtilis 
BfeA 
ferrienterobactin outer membrane 
Bordetella pertussis 
receptor 
siderophore outer membrane 
BfrABC 
receptor 
FauA alcaligin outer membrane receptor 
Camphyobacter coli 
CeuBCDE ABC ferrienterobactin transport 





achromobactin ABC transporter 
Siderophores 
FecABCDE ferric citrate transport 
FepABCDG 	ferrienterobactin transport 
FhuABCDE 	
ferrichrome , rhodoturulate 
Escherichia coli 	













(Continued over the page) 
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Table 1.1 (continued). 
Iron source Bacteria 	 Protein 	Function 
siderophore outer membrane 
FrpB 	 receptor 
FptA ferric pyochelin outer membrane 
Neisseria 	
receptor 
Pseudomonas 	 FpvA 	
ferric pyoverdine outer membrane 
aeruoinosa 
receptor 
- ferrioxamine outer membrane 
FiuA receptor 
PfeA (E?), PirA ferric enterobactin outer membrane 
receptor 
Siderophores PiuA,PfuA,UfrA unknown outer membrane receptor 
(continued) 	Pseudomonas putida PupAB Pseuobactin 
Rhizobia FhuA siderophore uptake 
Vibrio vibriobactin outer membrane 
Vibrio cholerae ViuA receptor 
Vibrio anguiliarium FatDCBA ferric anguibactin transport 
FyuA 
yersiniabactin outer membrane 
Yersinia enterocolotica 	FoxA 	
ferrioxamine B outer membrane 
receptor 
FcuA 	
ferrichrome outer membrane 
receptor 
Escherichia coli 
Pseudoinonas 	 FeoAB 	 Fe 2-  transport 
Reduced iron 
aeruginosa FeoAB Fe2 transport 
Streptococcus spp. 
Uptake of iron in Gram-negative bacteria is globally regulated by the Fur 
(ferric uptake regulator) protein, which responds to cellular levels of iron (7,8). The 
Fur protein represses genes that transcribe proteins involved in high affinity iron 
transport under iron-replete conditions, and also controls genes required for 
virulence (9). The model of Fur function speculates that the binding of ferrous (Fe 2 ) 
iron, causes Fur to bind to its specific DNA sequence target within the promotor of 
the regulated gene with high affinity to repress transcription. During iron starvation, 
iron dissociates from Fur, causing the protein to lose its affinity for DNA, triggering 
derepression of gene transcription. 	Strong evidence for this direct iron-Fur 













Chapter 1: Metals in Biology 
reported (10,11). All the proteins described in the following sections that are 
involved with the high affinity transport of iron are regulated by the Fur system. 
1.2.2 Siderophore-Mediated Iron Acquisition 
Siderophores are defined as low molecular mass compounds (<1000 Da) that are 
produced by many, but not all, microorganisms (4). They are excreted into the 
environment in response to iron starvation and have a very high specificity and 
affinity towards Fe 31  ions. Siderophores can remove iron from molecules such as 
ferritin, transferrin and lactoferrin, and can also solubilise the metal from insoluble 
ferric salts, including ferric oxo-hydroxide. Over 500 different siderophores have 
been identified that are produced by bacteria, yeast and fungi (4,5). Examples of 
siderophores from Gram-negative and Gram-positive bacteria are shown in Figure 
Figure 1.1. Structures of two bacterial siderophores. A, Enterobactin from the Gram-
negative bacterium Salmonella typhimurium. B, Corynebactin from the Gram-positive 
bacteria Corynebacterium glutanicum and Bacillus subtilis. Note that both siderophores, 
although from very different species of bacteria, contain a central trilactone ring and three 
catecholate binding moieties (12). 
Chapter 1: Metals in Biology 
After acquiring iron, the ferri-siderophore complex is internalised via specific 
receptor proteins in the outer membrane (OM) in a process that is driven by the 
cytoplasmic membrane (CM) potential (proton motive force) and mediated by the 
energy transducing TonB-ExbB-ExbD system (13). The ferri-siderophore is shuttled 
across the periplasmic space from the OM receptors by periplasmic binding proteins 
to the CM and is then presented to an ATP-binding cassette (ABC) transporter that, 
in turn, delivers the ferri-siderophore to the cytoplasm at the expense of ATP. Here 
the complexes are thought to dissociate via reduction of Fe3 to Fe 2' and the 
siderophore is recycled (5). 
1.2.2.1 Siderophore Receptors 
All known OM siderophore receptors are structurally related. They have a 
monomeric 13-barrel domain consisting of a 22-f3-antiparallel stranded 
transmembrane tube (which forms the pore), a globular 'plug' or 'cork' domain of 
about 160 residues residing in the periplasmic end of the pore and an NH-,-terminal 
extension. Part of the 'plug' domain protrudes to the exterior and contributes part of 
the ligand-binding site, with other important residues being located in loops or in the 
barrel walls (13,14). 
Crystal structures have been determined for the siderophore receptors FepA 
(ferric enterobactin receptor), FecA (ferric citrate receptor) and FhuA (ferrichrome 
receptor) (14-16). The structures of these receptors are presented in Figure 1.2. 
VA 
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A. 	 B. 	 C. 
EXTRACELLULAR SIDE 
PERIPLASMIC SIDE 
Figure 1.2. Crystal structures of the siderophore receptors: A, FecA (PMD: 1KMP); B, 
FepA (PMD: 1FEP) and; C, FhuA (PMD: 1BY5). All three receptors share the 
characteristic P barrel fold containing a central cork domain that facilitates ligand transfer 
(14-16). The top panel shows the receptor from the extracellular side and the bottom panel 
shows a side-on projection. 
1.2.2.2 Ton B-ExbB-ExbD Complex 
TonB-ExbB-ExbD is a protein complex situated in the CM (17,18). TonB (239 
amino acid residues) is periplasmic and anchored to the CM by its hydrophobic N-
terminal domain, whereas ExbB and ExbD are integral CM proteins. Cross-linking 
studies have suggested that, in vivo, the ratio of TonB:ExbB:ExbD subunits in the 
complex is 1:7:2 (5). The intermediate domain of TonB contains Pro-Glu and Pro-
Lys repeats, and the C-terminal domain is composed of a 13-sheet and two a- 
ro] 
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helices (19). To date, the only structural information known about TonB is for the 
small C-terminal domain, and recently the structure of TonB complexed to FhuA (an 
outer membrane siderophore receptor) was solved and revealed a 1:1 
stoichiometry (20-22). This structure highlighted that the C-terminal domain of 
TonB makes extensive contacts with the N-terminal domain 'TonB box' region of 
FhuA, as well as other regions of the cork domain of the protein. This report 
suggested that these contacts with the cork domain of FhuA may mediate 
conformational disruption of the internal cork, allowing passage of the siderophore 
into the periplasm (21). 
TonB forms a complex in the inner membrane with ExbB and ExbD, two 
membrane proteins that potentially act as proton translocators. ExbB is homologous 
to the protein MotA, and ExbD has a similar topology as MotB, both of which are 
proposed to exploit the proton gradient to drive the bacterial flagellum. ExbB has 
been proposed to modulate the conformation of TonB, as well as mediate its 
recycling, but what these structural changes might be remains unknown. Cross-
linking studies have suggested the regions through which TonB might interact with 
its partners in the inner membrane: contact with ExbB is mediated by the signal 
anchor, whereas the residues responsible for the interaction with ExbD are 
unknown (23). 
Although the binding of the ferri-siderophore to the OM receptor is energy 
independent, transport through the receptor pore requires energy. This energy is 
derived from the electrochemical charge gradient of the CM and is delivered by the 
energy transducing TonB complex. This process requires the TonB complex to be in 
Chapter 1: Metals in Biology 
direct contact with the OM receptors. A transport mechanism has been postulated as 
described below (14). 
Stage 1: the siderophore is adsorbed from the medium with low affinity via 
hydrophobic residues residing in the upper part of the external pocket of the 
unliganded receptor. 
Stage 2: the siderophore is transferred to its high-affinity binding site 
comprising residues on the plug domain and on the walls of the barrel domain. The 
interactions with the latter residues cause the plug domain to move downward 
leading to the unwinding and repositioning of the switch helix and the 'TonB box'. 
Stage 3: multiple extracellular loops of the receptor change their relative 
conformation and position which closes the external pocket of the barrel disrupting 
the low-affinity binding site and shielding the high-affinity binding site from the 
solvent. 
Stage 4: conformational changes of the plug and barrel domain are required 
for transport through the receptor pore. These changes are mediated by physical 
interactions between TonB and the 'TonB box'. Formation of a complex with TonB 
results in the transfer of energy to the receptor, which in turn promotes ligand 
transport. 
Recent research proposes a supplemental role for TonB: the protein may also 
coordinate the periplasmic binding protein components of iron transport systems to 
directly orchestrate transport events between the OM and CM (21). As such, TonB 
would act as a periplasm-spanning scaffold that "oversees" the process of substrate 
transfer between members of an iron transfer system (21). 
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1.2.3 Iron Acquisition from Haem and Haemoproteins 
Haem is the most abundant source of iron in the body and thus bacteria have 
developed two basic mechanisms for the removal of iron from haem (24). Some 
bacteria have an absolute requirement for haem or its precursor protoporphyrin IX. 
Extracellular pathogens liberate haem or haemoglobin with haemolysins and 
proteases (5). 
The first, and commonest, of the two mechanisms is that Gram-negative 
bacteria can acquire iron directly from haem, or haem complexes, binding to specific 
OM receptors. The haem is transported across the OM in a TonB-ExbB-ExbD 
dependent fashion. Not surprisingly, these TonB-dependent OM receptors are 
related to those involved in siderophore uptake. Periplasmic binding proteins then 
chaperone the haem complex to the CM where it is transported into the cytoplasm. 
Once inside the cytoplasm, the haem can either be incorporated directly into enzymes 
or the iron removed by degradation of the porphyrin ring (25). 
The other mechanism for acquiring iron from haem is via proteins 
collectively called haemophores (25). These are secreted soluble extracellular 
proteins that acquire iron from haem containing host proteins such as haemopexin (a 
scavenging protein that has the strongest affinity for haem of any known protein) and 
haemoglobin. Gram-negative bacteria produce HasA (Haem-acquiring system) and 
HxuA (Haem-haemopexin binding protein), which, like siderophores, mediate the 
delivery of haem to specific OM receptors (26). Again, these OM receptors (HasR) 
transport the haem-haemophore complex into the periplasm via a TonB-ExbB-ExbD-
dependent system (4). Shuttling across the periplasmic space does not appear to 
11 
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require any periplasmic binding protein but transport across the CM could involve an 
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Figure 1.3. Structure of HasA (PDB: 1DKO) haem binding protein. A, complete 
structure of HasA; B, detail of Has A binding site showing residues involved in haem 
binding. His83 is presumed to be involved in haem capture and release (26). 
1.2.4 Iron Acquisition from Transferrin 
1.2.4.1 Transferrin 
Transferrins are a superfamily of iron binding proteins that can be divided into three 
major classes: serum transferrins, lactoferrins and ovotransferrins (formerly called 
conalbumin) (27). These proteins are known to be at least as ancient as the insect 
phylogenic family (28). All transferrins are —80 kDa monomeric glycoproteins that 
bind two ferric ions (and two C032 as synergistic anions) per molecule with high 
affinity and share significant sequence homology. 	Serum transferrins 
(serotransferrins) transport iron in serum and deliver iron to cells via receptor-
mediated endocytosis (29). Lactoferrins (lactotransferrins) are found in extracellular 
12 
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fluids and in polymorphonuclear lymphocytes. Lactotransferrins are known to have 
antimicrobial and antifungal properties. Ovotransferrins are found in avian egg 
white and are identical to serotransferrins except for their attached 
carbohydrates (30). 
The general structure of the transferrin superfamily is two lobes (which 
represent the C- and N —terminal halves of the protein) with each lobe divided into 
two domains (Figure 1.4). Two high affinity Fe 3' binding sites are located in deep 
clefts between each domain. The iron-binding protein ligands are characteristically 
two tyrosines, a histidine and an aspartate residue. 	A distorted octahedral 
coordination is completed by a bidentate carbonate synergistic anion. The aspartate 
residue is not solely involved in iron binding but also forms hydrogen bonds with 
other residues in the polypeptide chain when iron is bound, thus stabilising the lobe 
in a closed conformation. When iron is absent, the lobe is in an open conformation 
with no such hydrogen-bonding taking place (31). Human transferrin can bind 
various metals under physiological conditions and more than 35 have been identified 
to date (32,33). This has been particularly valuable for the study of the metal-
binding properties of this protein (34). 
Many important human pathogens are capable of acquiring iron directly from 
transferrin and lactoferrin (35,36). Non-siderophore secreting pathogens such as 
Neisseria gonorrhoeae, Neisseria meningitides, Haemophilus influenzae and 
Moraxella catarrhalis have developed this mechanism for iron acquisition. To do 
this they have evolved an outer membrane receptor for transferrin, called the 
13 
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transferrin-binding proteins, TbpA and TbpB (or LbpA and LbpB), to capture and 
remove iron from transferrin (36). 
Figure 1.4. Crystal structure of the di-ferric form of porcine serum transferrin (PDB: 
1H76). Residues involved in iron (blue) binding are represented in ball-and-stick, as is N-
acetyl glucosamine (NAG) that is covalently linked to N497 (37). 
1.2.4.2 Transferrin Binding Proteins 
The OM receptor molecules that bind and extract iron from the transferrin family are 
the so-called transferrin (or lactoferrin) binding proteins (Tbp or Lbp). These 
receptor complexes consist of two components: an integral porin-like OM protein 
TbpA (100 kDa) and an extracellular OM anchored TbpB (65-90 kDa). TbpA is 
proposed to serve as a channel for the transport of iron across the OM and shows 
sequence similarity to FepA and FhuA: both proteins form an antiparallel t3-barrel 
14 
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and TbpA is proposed to have similar structure (15). Both TbpA and TbpB can 
independently bind their ligand, human serum transferrin (38). 
Currently two isotypes of TbpB have been identified: isotype I form of the 
protein has a molecular mass of -68 kDa, whereas the larger isotype II form has a 
molecular mass of —80-90 kDa (39). It remains unclear what role each isoform plays 
in vivo. 
The process of iron transport across the OM requires energy that is derived 
from the electrochemical charge gradient of the CM and is delivered by the energy 
transducing TonB-ExbB-ExbD complex in a similar fashion to the siderophore and 
haem iron acquisition mechanisms (4). A schematic of this transferrin acquisition 
pathway arrangement is provided in Figure 1.5. 
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Figure 1.5. Schematic representation of mechanism of transferrin binding by 
transferrin binding proteins A and B. Energy for iron transport is supplied via the a 
TonB-ExbB-ExbD energy transducing complex. Based on (40). 
1.2.5 The Neisseriaceae 
The Neisseria genus consists of aerobic, non-spore-forming Gram-negative 
coccobacilli, which inhabit the mucous membranes of many animals (including 
humans) (41). These non-motile microbes require a moist environment and warm 
temperatures (37°C) to achieve optimum growth. Neisseria infections are identified 
by the means of the oxidase test, for which all members test strongly positive. 
Additionally, Neisseria grow well on chocolate agar containing antibiotics that 
inhibit growth of other Gram-negative bacteria, Gram-positive bacteria, and moulds. 
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The two most clinically-significant members of the genus Neisseria are N. 
gonorrhoeae and N. meningitides (41,42). 
1.2.5.1 Neisseria gonorrhoeae 
Infection by the diplococcoid bacterium N. gonorrhoeae is referred to as gonococcal 
infection (or gonorrhoea). The organism is an obligate human pathogen and does not 
infect other mammalian species. There are four types of N. gonorrhoeae (Ti, T2, 
T3, and T4) that are classified by their fimbriae; these are extraceilular proteinaceous 
appendages used to adhere to each other and to host cells. Without these fimbriae 
the bacteria are avirulent, and the four types display different levels of clinical 
virulence. The bacteria also produce cytotoxic substances, such as LPS endotoxin, 
that damage ciliated epithelial cells found in fallopian tubes and stimulate the 
immune system. However, to counter the host immune responses, N. gonorrhoeae 
produces an extracellular protease that cleaves a proline-threonine bond in 
immunoglobulin IgA (the major antibody in mucosal tissues) causing loss of 
antibody activity (43,44). The organism is identified clinically by growth on Thayer-
Martin or chocolate agar, being strongly oxidase positive and by the abilty to 
metabolise glucose (but not maltose) (45). 
Gonorrhoea (infection) is transmitted between humans through intimate 
contact of the mucous membrane, and the organism can be carried by both sexes for 
many years without any sign or symptoms. In infected males, the disease is 
characterised by a urethral discharge of pus and can eventually result in other 
complications such as prostatitis and periurethral abscess. 	Females with a 
gonorrhoea infection exhibit vaginal discharge, abdominal pain, and abnormal non- 
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menstrual bleeding. Ironically, the widespread use of birth control devices such as 
the pill has actually increased the number of gonococcal infections in the United 
States, as the use of the pill can lower the glycogen concentration of the vaginal 
membrane. This environmental change inhibits the growth of acid-producing 
bacteria, such as Lactobacillus, which are the natural flora of the vagina. This 
change leads to the vaginal pH being less acidic, allowing a variety of pathogenic 
organisms (including N. gonorrhoeae) to thrive there. As with most other sexually 
transmitted diseases, gonorrhoea is prevalent in young adult and homosexual 
populations (46). N. gonorrhoeae is sensitive to wide range of environmental 
conditions such as ultraviolet radiation, drying, and antibiotics; the current regime of 
treatment is with the third generation cephalosporins, such as ceftriaxone. However, 
the range of antibiotics that are clinically effective against the organism is limited, 
and at present, the third generation cephalosporins are the only antibiotics that are an 
effective treatment of the disease. Should the organism become resistant to these 
drugs there will no longer be an effective clinical treatment for gonorrhoea infection 
(41). 
The bio-availability of iron is a fundamental requirement for N. gonorrhoeae; 
there being no natural reservoir in the environment, the infection is perpetuated 
asymptomatically at low levels in the general population. 
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1.2.6 Iron Uptake in Neisseriaceae 
Iron is an essential requirement for pathogenic Neisseria species to maintain 
virulence, and they acquire it by utilising several of the above mechanisms. 
Although Neisseria spp do not produce their own siderophores, their growth can be 
supported by the addition of exogenous siderophores, thus suggesting that they may 
possess a pathway for utilising iron bound siderophores that have been excreted by 
other microbes (47). Genome analysis of meningococcal and gonococcal species 
reveals at least three open reading frames that share sequence homology with known 
siderophore receptors, further suggesting that Neisseria spp may have a battery of 
siderophore receptors to utilise siderophores secreted by other organisms (47). 
Pathogenic Neisseria are capable of sequestering iron from haemoglobin, 
haptoglobin-haemoglobin and haem, but not from haem-haemopexin or haem-
albumin. There are two kinds of receptor for haem in Neiserria species: HmbR, and 
HpuA and HpuB. HmbR is an 89.5 kDa outer membrane protein that binds and 
acquires iron from haem and haemoglobin. HpuA is an 85 kDa outer membrane 
protein, and HpuB is a 34.8 kDa lipoprotein that forms a complex that binds and 
removes iron from haemoglobin and haptoglobin-haemoglobin. The levels of haem 
and haem-containing proteins in mucosal surfaces are low, but are obviously much 
higher in other body compartments (47,48). 
The Neisseriaceae can acquire iron from transferrin (and lactoferrin) via Tbps 
(and Lbps) expressed in the outer membrane (49). Although iron levels are thought 
to be low, transferrin appears to be a vital source of iron in mucosal surfaces, as Thp-
deficient mutants are avirulent compared with the wild-type organism (50). This 
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certainly indicates that transferrin levels in genitourinary mucosa are of a sufficient 
level to be able to support growth of the organism in this environment. However, 
given the amount of transferrin in the serum and other body compartments, the Tbps 
are probably also important during the invasive phases of infection, and are always 
detected in clinical isolates. Lactoferrin (which is also present in mucosal surfaces) 
can also be utilised for the acquisition of iron, but how essential its requirement is for 
infection is unclear. It has been demonstrated that an Lbp-deficient strain, but not its 
Tbp-deficient derivative is virulent in a human infection model, and that the Lbp 
genes are deficient from a significant number of clinical isolates (47,50). Iron that is 
acquired from this source is then passed to an ATP Binding Cassette (ABC) 
transporter system (FbpABC) that facilitates transport of the iron across the 
periplasmic space and through the cytoplasmic membrane into the cytoplasm (51). 
The exact details of this process remain mostly undescribed. 
20 
Chapter 1: Metals in Biology 
1.3 	Chapter 1 References 
Thomson, A. J., and Gray, H. B. (1998) Curr. Opin. Chem. Biol. 2,155-158 
Shriver, D. F., and Atkins, P. W. (1999) inorganic Chemistry (Third, Ed.), 
Oxford 
Broderick, J. B., and Coucouvanis, D. (2003) Curr. Opin. Chem. Biol. 7, 157-
159 
Ratledge, C., and Dover, L. G. (2000) Annu. Rev. Microbiol. 54, 881-941. 
Andrews, S. C., Robinson, A. K., and Rodriguez-Quinones, F. (2003) FEMS 
Microbiol. Rev. 27, 215-237 
Clarke, T. E., Tarr, L. W., and Vogel, H. J. (2001) Curr. Top. Med. Chem. 1, 
7-30 
Friedman, Y. E., and O'Brian, M. R. (2004) J. Biol. Chem. 279, 32100-5 
Stojiljkovic, I., Baumler, A. J., and Hantke, K. (1994) J. Mol. Biol. 236, 531-
545 
Sebastian, S., Agarwal, S., Murphy, J. R., and Genco, C. A. (2002) J. 
Bacteriol. 184, 3965-3974 
Pecqueur, L., D'Autreaux, B., Dupuy, J., Nicolet, Y., Jacquamet, L., 
Brutscher, B., Michaud-Soret, I., and Bersch, B. (2006) J. Biol. Chem. 281, 
21286-21295 
Pohl, E., Hailer, J. C., Mijovilovich, A., Meyer-Klaucke, W., Garman, E., and 
Vasil, M. L. (2003) Mol. Microbiol. 47, 903-915 
Dertz, E. A., Stintzi, A., and Raymond, K. N. (2006) J. Biol. Inorg. Chem. 11, 
1087-1097 
Ferguson, A. D., and Deisenhofer, J. (2004) Cell. 116, 15-24 
21 
Chapter 1: Metals in Biology 
Ferguson, A. D., Chakraborty, R., Smith, B. S., Esser, L., van der Helm, D., 
and Deisenhofer, J. (2002) Science. 295, 1715-1719 
Buchanan, S. K., Smith, B. S., Venkatramani, L., Xia, D., Esser, L., Palnitkar, 
M., Chakraborty, R., van der Helm, D., and Deisenhofer, J. (1999) Nat. 
Struct. Biol. 6, 56-63 
Locher, K. P., Rees, B., Koebnik, R., Mitschler, A., Moulinier, L., 
Rosenbusch, J. P., and Moras, D. (1998) Cell 95, 771-778 
Bayer, P., and Harjes, S. (2001) Trends Biochem. Sci. 26, 472 
Traub, I., Gaisser, S., and Braun, V. (1993) Mol. Microbiol. 8, 409-423 
Carter, D. M., Gagnon, J. N., Damlaj, M., Mandava, S., Makowski, L., Rodi, 
D. J., Pawelek, P. D., and Coulton, J. W. (2006) J. Mol. Biol. 357, 236-251 
Kodding, J., Killig, F., Poizer, P., Howard, S. P., Diederichs, K., and Welte, 
W. (2005) J. Biol. Chem. 280, 3022-3028 
Carter, D. M., Miousse, I. R., Gagnon, J. N., Martinez, E., Clements, A., Lee, 
J., Hancock, M. A., Gagnon, H., Pawelek, P. D., and Coulton, J. W. (2006) J. 
Biol. Chem. 281, 35413-35424 
Pawelek, P. D., Croteau, N., Ng-Thow-Hing, C., Khursigara, C. M., 
Moiseeva, N., Allaire, M., and Coulton, J. W. (2006) Science 312, 1399-1402 
Chang, C., Mooser, A., Pluckthun, A., and Wiodawer, A. (2001) J. Biol. 
Chem. 276, 27535-27540 
Stojiljkovic, I., and Perkins-Balding, D. (2002) DNA Cell Biol. 21, 281-295 
Sebastian, S., and Genco, C. A. (1999) Infect. Iminun. 67, 3141-3145 
Arnoux, P., Haser, R., Izadi, N., Lecroisey, A., Delepierre, M., Wandersman, 
C., and Czjzek, M. (1999) Nat. Struct. Biol. 6, 516-520 
22 
Chapter 1: Metals in Biology 
Welch, S. (1992) Transferrin: The Iron Carrier (S, W., Ed.), 1 CRC Press, 
Florida 
Gasdaska, J. R., Law, J. H., Bender, C. J., and Aisen, P. (1996) J. Jnorg. 
Biochem. 64,247-258 
Jandi, J. H., Inman, J. K., Simmons, R. L., and Allen, D. W. (1959) J. Clin. 
Invest. 38, 161-185 
Thibodeau, S. N., Lee, D. C., and Palmiter, R. D. (1978) J. Biol. Chem. 253, 
3771-3774 
Grossmann, J. G., Neu, M., Evans, R. W., Lindley, P. F., Appel, H., and 
Hasnain, S. S. (1993) J. Mol. Biol. 229, 585-590 
Zhong, W., Parkinson, J. A., Guo, M., and Sadler, P. J. (2002) J. Biol. Inorg. 
Chem. 7, 589-599 
Sun, H., Li, H., and Sadler, P. J. (1999) Chem. Rev. 99, 2817-2842 
Sigel, A., and Sigel, H. (1998) Metal Ions in Biological Systems, v35, Marcel 
Dekker, New York 
Desai, P. J., Garges, E., and Genco, C. A. (2000) J. Bacteriol. 182, 5586-
5591 
Genco, C. A., and Desai, P. J. (1996) Trends Microbiol. 4, 179-184 
Hall, D. R., Hadden, J. M., Leonard, G. A., Bailey, S., Neu, M., Winn, M., 
and Lindley, P. F. (2002) Acta Crystallogr. D Biol. Crystallogr. 58, 70-80 
Krell, T., Renauld-Mongenie, G., Nicolai, M. C., Fraysse, S., Chevalier, M., 
Berard, Y., Oakhill, J., Evans, R. W., Gorringe, A., and Lissolo, L. (2003) J. 
Biol. Chem. 278,14712-14722. 
23 
Chapter 1: Metals in Biology 
Rokbi, B., Mazarin, V., Maitre-Wilmotte, G., and Quentin-Millet, M. J. 
(1993) FEMS Microbiol. Lett. 110, 51-57 
Bruns, C. M., Anderson, D. S., Vaughan, K. G., Williams, P. A., Nowalk, A. 
J., McRee, D. E., and Mietzner, T. A. (2001) Biochemistry. 40, 15631-15637 
http://textbookofbacteriology.net/neisseria.html.  
http://medic.med.uth.tmc.edu/i)ath/0000 151 0.htm. 
http://www.cehs.siu.edu/fix/medmicro/neiss.htm.  
Chintalacharuvu, K. R., Chuang, P. D., Dragoman, A., Fernandez, C. Z., Qiu, 
J., Plaut, A. G., Trinh, K. R., Gala, F. A., and Morrison, S. L. (2003) Infect. 
Immun. 71, 2563-2570 
http://www.cdc.gov/std/Gonorrhea/lab/default.htm.  
Murray, P. R., Rosenthal, K. S., Kobayashi, G. S., and Pfaller, M. A. (1998) 
Medical Microbiology, 3rd Ed., Mosby, St. Louis 
Schryvers, A. B., and Stojiljkovic, I. (1999) Mol. Microbiol. 32, 1117-1123 
Perkins-Balding, D., Ratliff-Griffin, M., and Stojiljkovic, 1. (2004) Microbiol. 
Mol. Biol. Rev. 68,154-171 
Cornelissen, C. N. (2003) Front. Biosci. 8, d836-847 
Cornelissen, C. N., Kelley, M., Hobbs, M. M., Anderson, J. E., Cannon, J. G., 
Cohen, M. S., and Sparling, P. F. (1998) Mol. Microbiol. 27, 611-616 
Gomez, J. A., Criado, M. T., and Ferreiros, C. M. (1998) Res. Microbiol. 149, 
381-387 
24 
Chapter 2: ATP Binding Cassette (ABC) Transporters 
Chapter 2: ATP Binding Cassette (ABC) Transporters 
2.1 	ATP-Binding Cassette (ABC) Transporters 
ATP-Binding Cassette (ABC) transport systems are a ubiquitous ligand-transporting 
motif present found in mammals, bacteria and fungi (1). The vectorial transport of 
molecules across lipid bilayers is central to cell physiology, including the uptake of 
nutrients, elimination of waste products, protein secretion, energy generation and 
movement of signalling molecules (2). ABC transporters facilitate the unidirectional 
translocation of these chemically diverse substrates across cell or organelle 
membranes and constitute one of the largest superfamily of proteins known (3). In 
E. coli, genes encoding ABC transport systems occupy almost 5% of the genome, 
and in humans, mutations in ABC transporter genes are responsible for many genetic 
disorders, including cystic fibrosis (lung and gut systems; CFTR gene), Tangier 
disease (cardiovascular system; ABC] gene on chromosome 9q3 1) and Stargardt 
disease (eye; ABCR gene on chromosome 1q21-p13) (2,4). Other ABC transporters 
can confer resistance to drugs such as antibiotic, antifungal and anticancer 
compounds (2). 
ABC transporters share a common architecture and basic mechanism of 
action: two nucleotide-binding domains (NBDs) that bind and hydrolyse ATP, and 
energise unidirectional substrate transport, which occurs through a translocation 
pathway provided by two trans-membrane spanning domains (TMDs) (2). It has 
been shown that all ABC transporters share highly conserved motifs that are essential 
for binding and hydrolysis of ATP, and that they have similar structures. By 
contrast, the membrane-spanning domains share very little sequence homology 
unless the substrates are chemically related. Thus, a common engine is attached to a 
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specialized translocation pathway in all ABC transporters. The bacterial ABC 
transporters that function to import ligands to the cytoplasm also have an extra 
soluble domain that resides in the periplasmic space and is thought to be responsible 
for the transport of its ligand from the outer membrane to the cytoplasmic membrane 
and presents the ligand for translocation. 
Most eukaryotic ABC transporters that have been characterized thus far are 
usually composed of a TMD and NBD that are fused into a single polypeptide and 
mediate the export of substrate from the cytoplasm, out of the cell or into 
organelles (5,6). The exceptions are the ABC transporters that transport substrate 
from the mitochondrial matrix, which is the equivalent to the cytoplasm of the 
original symbiot. This can lead to a general designation of "ABC exporters" when 
referring to eukaryotic ABC transporters. 
The bacterial "ABC importers", on the other hand, are generally composed of 
separate subunits, and consist of; a soluble periplasmic binding protein (PBP) that 
delivers the substrate to the TMD for translocation; the membrane spanning domain 
that forms the translocation pathway; and the NBD that hydrolyses ATP to energise 
the translocation of the substrate across the cytoplasmic membrane. The TMD and 
NBD form dimers in the lipid bilayer and cytoplasm, respectively, in the active 
transport complex. The prokaryotic ABC exporter systems show more structural 
homology (though not necessarily sequence homology) to the eukaryotic ABC 
exporters: they consist of a TMD and NBD that are fused into a single polypeptide 
and mediate the export of substrate from the cytoplasm (7,8). Indeed, the lipid 
flippase MsbA from E. coli is more closely related to the mammalian P- 
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glycoproteins (multidrug resistance ABC transporters) than any other bacterial ABC 
transporter by sequence homology (8). Again, the active transporter requires the 
formation of a dimer in the membrane. Although these proteins belong to the same 







Figure 2.1. Schematic representation of the two main types of ABC transporter found 
in eukaryotes and prokaryotes. The ABC exporters (left) have a transmembrane domain 
(blue) that is fused (black coil) to a nucleotide binding domain (green). The active 
transporter is formed by dimer formation of two like subunits It is presumed there is a 
substrate binding site on the cytoplasmic face of the TMD dimer (*). The ABC importers 
(right) have separate TMD and NBD that associate as a tetramer: two TMDs and two NBDs. 
The import systems may or may not have a dedicated periplasmic binding protein (red) that 
transports and presents the ligand (*) to the TMDINBD complex for translocation. The 
cytoplasmic membrane is represented in grey. Direction of transport is represented by the 
yellow arrows. 
There has been biochemical characterisation of many ABC transporters that 
are involved in varied roles such as osmotic regulation (OpuA), uptake of 
macromolecules (A1gSM1M2), amino acids (G1nPQ), and multidrug resistance 
(LmrCD, Sav1866) (7,10-13). However, to date, there have only been a limited 
number of high-resolution structural studies of bacterial ABC importers. The 
Chapter 2: ATP Binding Cassette (ABC) Transporters 
vitamin B12 transporter, BtuCD from E. coli, remains the only (high-resolution) 
structure of a TMD and NBD complex to have been published, and along with the X-
ray crystal structure of the PBP in this system, BtuF, means that the BtuFC2D2 
complex remains the only visual representation of a complete bacterial ABC 
importer published to date (1). However, the crystal structure of the NBD and TMD 
from another metal-chelate-type transporter called H11470/1 from H. influenzae has 
recently been published, but the structure of the PBP from this system has not been 
determined, and the exact nature of the substrate was not described (14). The 
structures of this newly exhibited transporter and the BtuCD share a striking 
similarity, and are proposed to be functionally very closely related. In contrast to the 
situation with the TMD, the structures of many PBPs from other ABC transporter 
systems have been elucidated, as have several of the NBD. The following sections 
are a general review of each of the components of the bacterial ABC importers. 
2.1.1 The Periplasmic Binding Domain 
Gram-negative periplasmic binding proteins (PBPs) are members of a widely 
distributed protein superfamily (15). PBPs have been identified that bind a diverse 
range of ligands, including lipids, metal ions, amino acids, peptides and 
carbohydrates. These proteins on the whole share little sequence homology with 
other members of the family, but do retain a similar fold and overall structure: two 
globular domains connected by a hinge region, with the ligand binding site situated 
at the interface between the two domains. These proteins have been characterised 
into two structural classes defined by the number and arrangement of n-strands in 
each domain of the protein: class I proteins contain six 3-strands (order 213456), 
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class II PBPs contain five 13-strands (order 21354) (16). However, this classification 
system can breakdown when considering members of the metal-binding PBPs, as the 
13-strand content can vary in each domain, and the hinge region is often composed of 
13-strand in this particular family of PBPs. The proteins exhibit large conformational 
changes upon binding of their ligand, being "open" in the apo (ligand-free) form, and 
"closed" in the holo (ligand-bound) form. These conformational changes upon 
ligand binding have led researchers to refer to these proteins as "venus fly-trap" and 
"Pacman" proteins, due to the relatively large rotational motion around the hinge 
region (17). 	Over 100 PBP structures have been determined by X-ray 
crystallography from a wide variety of sources, including E. coli, pathogenic and 
thermophillic bacteria (16). 
The adaptability of this large superfamily is likely to have arisen from the 
positioning of the binding site at the interface between the domains and from the 
large ligand-mediated conformational change. In this arrangement, the ligand 
environment resembles that of a protein interior, but the binding residues are 
positioned on the surface of their domains. These conditions not only allow the 
desirable physiochemical characteristics arising from the placement of ligands in a 
solvent-excluding environment, but also combine the adaptability of evolving sites 
on protein surfaces (16). 
2.1 .1 .1 Iron Binding Periplasmic Binding Proteins 
The importance of the acquistition and proper control of intracellular levels of this 
essential, but potentially toxic, metal ion has driven bacteria to evolve safe methods 
of iron transport and storage. Ferric iron-binding proteins have been identified in 
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many Gram-negative organisms, and several have had their crystal structures 
determined by X-ray crystallography (Table 2.1). They all share a very similar 
tertiary structure but can vary widely, not only in their amino acid sequence, but also 
in the residues involved in complexation of the bound ferric ion (18). However, 
these proteins are defined by the presence of a sequential di-tyrosyl motif that is 
intrinsically involved in coordination of the ferric ion. In addition to the protein 
ligands, there may also be a synergistic anion present that completes the coordination 
of the metal ion. These variations have led at least two groups to classify the iron 
binding PBPs according to their substrate binding residues and/or amino acid 
sequences, and the presence or absence of a synergistic anion (19,20). 
Table 2.1. The iron-binding periplasmic binding proteins from Gram-negative bacteria 
whose X-ray crystal structures are known. 	NTA: nitrilotriacetate, EDTA: 
Ethylenediaminetetracetic acid. 
Organism PDB Code Resolution (A) Mutant Description 
H. inf7uenzae 
IMRP(21) 1.60 - Holo — Fe and PO4  
1QWO (22) 1.90 N175L Holo - Fe4 and PO4 
1QVS (22) 2.10 149A Holo - Fe3 and PO4 
INNF (2 3) 1.14 H9Q Holo - Fe and EDTA 
1139V (24) 1.75 - Apo - PO4 
haemolytica 
1Q3S (25) 1.20 - Apo —2 x formate 
1SIO (26) 1.35 - Holo - Fe and CO3 
ISI1 (26) 1.45 - Holo - Fe 
C. jejuni 1Y4T (19) 1.80 - Holo - Fe 
Y. enterolytica 1XVX (20) 1.53 - Holo - Fe 
S. marscesens 1 XVY (20) 1.74 - Apo - citrate 
B. pertussis 1Y9U (19) 1.39 - Apo 
gonorrhoeae 
1D9Y (27) 2.20 - Holo - Fe and PO4 
107T (28) 1.65 - Hf3, Hf5, and PO4 
1RIN29 ( 	) 1 74 - 
Holo and apo - Fe3, Fe  
and NTA 
1XC1 (30) 1.51 - Zr3  
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FbpA (the iron-binding PBP from N. gonorrhoeae) is categorised as a Class I 
iron binding PBP; it binds a single ferric-ion with two (sequential) tyrosine residues, 
a histidine and a glutamic acid residue, with a monodentate phosphate synergistic 
anion. Pseudo-octahedral coordination of the metal-ion is completed by a water 
molecule. Examples of the other classes are: Class II; Mannheimia haemalytica 
FbpA that coordinates a ferric ion with three tyrosine residues and a bidentate 
carbonate anion: Class III; Yersinia enterolitica YfuA that coordinates ferric ion via 
two tyrosine residues, a histidine, aspartic acid and glutamic acid residues (no 
synergistic anion): Class 4; Campylobacter jejuni FbpA which coordinates its ferric 
ion through four tyrosine residues and a histidine residue (no synergistic anion). It 
should be noted that the two classification systems are mutually exclusive, as YfuA 
is classified, somewhat confusingly, as Class 2 in one system and Class III in the 
other. 
Much work has been published on the ability of these iron-binding sites to 
bind other metal ions with variable affinity. The crystal structures of oxo-Fe3, oxo-
Hf3 & Hf5 clusters, oxo-Zr3 and a Fe-NTA (nitriloacetate) complex bound to nFbpA 
have been published (28,30,3 1). The fact that FbpA can bind metal clusters possibly 
suggests another mechanism for iron uptake: some of these PBPs may be able to 
interact directly with the extracellular environment. This suggestion has been 
supported by work that has shown that anti-FbpA antibodies bind to the surface of 











Figure 2.2. Representation of different classes of iron binding sites in the iron-binding 
periplasmic binding proteins (PBP). A, class 1 binding site of FbpA from N. gonorrhoeae 
(PDB: 1D9Y ); B, class 2 binding site of FbpA from M. haemolytica (PDB: ISII); C, class 3 
binding site of YfuA from Y. enterolytica (PDB: 1XVX); D, class 4 binding site of FbpA 
from C. jejuni (PDB: 1Y4T) (19,20,26). Iron is shown in brown. 
2.1.2 The Transmembrane Domain 
To date the transmembrane domains (TMD) of the ABC transporters have been 
largely ignored in the literature and the only extensive investigations performed on 
these proteins have been the few crystallographic studies, whilst their biochemistry 
remains broadly undescribed. This is probably in no short measure due to the 
difficulty of expressing and purifying such membrane proteins. The membrane-
spanning domains of ABC transporters share very little sequence homology unless 
the substrates are chemically related. However, it is likely that all ABC transporters 
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share the common motif of forming the translocation pathway for their ligand 
between the interface of two TMD subunits (by homo- or hetero-dimer formation). 
The TMD of ABC transporters vary not only in amino acid sequence, but also in the 
number of transmembrane helices that form the translocation pathway: MsbA (a 
bacterial lipid transporter) contains 12 transmembrane helices (6 helices per subunit), 
whereas the FhuD protein is predicted to have up to 20 such helices (8). However, it 
should be noted that recently the published MsbA structure has been retracted due to 
an error in the structural software program used to determine the topology of the 
molecule, and thus a revised structure is currently awaited (35). 
Five crystal structures of full-length bacterial ABC transporters (i.e. 
structures of the TMD) have been reported, and of these structures two are known for 
bacterial importers; the vitamin B12 transporter from E. coli: BtuC and an ABC 
transporter from H. influenzae called H11470 for which the substrate is not known 
(1,14). Recently the 2.4A crystal structure of the TMD and NBD of another 
bacterial ABC transporter (H11470/1) whose substrate is unknown was published. 
The authors reported that the transporter is involved in "metal-chelate"-type 
transport, such as haem and vitamin B12, but the PBP associated with the transporter 
was not described (14,36). 
2.1.2.1 The Vitamin B12 Transmembrane Domain: BtuC 
The 3.2 A crystal structure of BtuC was reported by Locher and co-workers in 
2002 (1). These researchers succeeded in cloning, co-expressing, co-purifying and 
co-crystallising the transmembrane (BtuC) and nucleotide-binding domains (BtuD) 
of this ABC transporter. The structure of BtuF (the periplasmic binding protein of 
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this transporter) has also been determined, making BtuFCD the only complete crystal 











Figure 2.3. Crystal structures of the vitamin B12 ATP transporter BtuFCD from E. coli 
(PDB: 1N4A and 1L7V). This structure remains the only full-length bacterial import ABC 
transporter to be solved (1,37). Vitamin B12 shown in stick representation. 
The structure reveals that BtuC forms a homodimer that traverses the 
membrane, and that each of the two subunits traverses the membrane ten times: thus, 
the active transporter is formed by twenty transmembrane helices. The interface 
between the two BtuC subunits is formed by the antiparallel packing of two pairs of 
helices that create a large cavity that opens to the periplasmic space. This cavity is of 
sufficient size as to accommodate the corrin ring of vitamin 1312, but there is no 
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continuous pathway across the membrane due to the presence of two loops of amino 
acid residues inside the cytoplasmic opening of the tranporter that are proposed to act 
as a gate. It has been suggested that a single translocation pathway formed by the 
interface of a membrane-spanning dimer is likely to be a common feature of ABC-
transporters. 
The bulk of the interface between BtuC2 (TMD dimer) and BtuD, (NBD 
dimer) is formed by two short helical stretches connected by a sharp bend on the 
cytoplasmic surface of BtuC making extensive contacts with BtuD. A small number 
of contacts are also made between the cytoplasmic loops of the transmembrane-
spanning helices and the N-terminus of BtuC (1). 
2.1.3 The Nucleotide Binding Domain 
The nucleotide binding domain (NBD) of ABC transporters, unlike the TMD, are 
highly conserved throughout the family, and whether from prokaryotic or eukaryotic 
origin, and irrespective of substrate, share extensive amino acid sequence and several 
characteristic motifs. Studies of bacterial ABC transporters first showed that the 
NBDs bind and hydrolyse ATP, and that ATP hydrolysis is required for transport. 
At least 15 structures of NBDs from bacterial transporters have been published, and 
they all show a similar architecture, in which the conserved amino acid motifs 
contribute to the nucleotide-binding pocket. 
2.1.3.1 Conserved Motifs 
The Walker A (G--G-GK(S/T)T, also known as the P loop) and Walker B (L-DEP) 
motifs are highly conserved within the ABC transporter family and hydrogen-bond 
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extensively with the bound nucleotide. The Walker B sequence also contributes the 
catalytic base (E) involved in hydrolysis of the bound ATP. The ABC signature 
motif (LSGG--QRV), the D-loop (-LD-), the H loop ((SIT)H(D/E), also called the 
switch region) and Q loop (Q, also called the lid region) are distinctive to ABC 
transporter NBDs, and although they are involved in the coordination of the 
nucleotide or nucleophilic water, their precise role in the catalytic mechanism is less 
clear (2). 
2.1.3.2 Mechanism of Transport 
Several models have been formatted that describe the mechanism of transport for the 
ABC transporters, but there is still much debate as to which proposed mechanism (if 
any) is correct. Studies performed on the mammalian multidrug resistance P-
glycoprotein (P-gp) ABC transporter defined the biochemistry of the ATPase cycle 
and proposed an alternating catalytic sites model (6). In this model, one molecule of 
ATP is first bound to one NBD domain and is hydrolysed, and then the other NBD 
binds a second molecule of ATP. The substrate is translocated during the ATP 
hydrolysis step and binding of the second molecule of ATP holds the NBD dimer in 
a "ready" state to accept another substrate molecule; as such, this mechanism keeps 
the transporter in a permanently "primed" position to immediately transport a 
substrate molecule as soon as one binds. Several related models have since been 
proposed for the bacterial histidine and maltose transporters (4,38). Again, these 
models generally assume that ATP hydrolysis provides the principal energy input 
("powerstroke") for transport and that the two NBDs operate alternately and are 
coupled to distinct steps in the transport cycle. 
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Some recent observations, however, have caused researchers to readdress the 
underlying tenets of the proposed mechanisms. Firstly, biochemical data have 
suggested that it is ATP binding (not hydrolysis) that provides the power stroke for 
transport. Secondly, the finding that for some ABC transporters (the ABCC family) 
the two NBDs are non-equivalent in their ability to hydrolyse ATP and, thirdly, 
structural data have revealed that the ATP binding site is situated at the interface of 
the NBD dimer, suggesting that the two domains act in concert during a single power 
stroke step rather than influencing distinct steps in the transport cycle (39). This 
dynamic communication and synergistic approach between the NBDs in the active 
dimer has spawned a newly-proposed mechanism known as the ATP-switch 
model (2). 
2.1.3.3 The ATP-switch Model 
This mechanism requires repeated communication, in both directions, between the 
NBDs and TMDs in the form of noncovalent conformational changes. The model 
gets its name from the switch between two conformations of the NBDs: a closed 
dimer formation upon the binding of two ATP molecules at the dimer interface, to an 
open dimer facilitated by ATP hydrolysis and release of P1 and ADP. The ATP 
switch model is summarized in Figure 2.4. The kinetics of this "switching" process 
are enhanced by the cooperativity between the two nucleotide-binding pockets and 
can also be tightly regulated by signals from the TMDs (40). Switching between the 
open and closed configurations induces conformational changes in the TMDs that are 
necessary to faciltate vectorial transport of the substrate across the membrane (2,40). 
The mechanism can be summarised as follows: 
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Step I. Binding of substrate to the TMDs initiates the transport cycle by 
facilitating ATP-dependent closed dimer formation. For the bacterial ABC import 
transporter this must be via the docking of a PBP-substrate complex to the 
periplasmic face of the TMDs. Although there is no direct experimental evidence, it 
is expected that binding of the PBP-substrate complex to the TMDs induces a 
conformational change in the NBDs, mediated via changes in the TMDs. These 
conformational changes allow the binding of two ATP molecules to the NBDs. 
Step H. Binding of ATP induces closed dimer formation, the power stroke for 
transport. Upon binding of ATP to the NBDs, it is predicted that closed dimer 
formation transmits a signal to the PBP, inducing it to release the ligand into the 
chamber of the transporter. There are then two possible routes for ligand 
translocation: either the substrate binds to a site on the TMDs that is re-oriented 
during a subsequent step in the cycle so as to expose this site to the cytoplasm, or, 
more probably, the TMDs are analogous to that of a pore of an ion channel. In this 
refinement of the model, the pore merely restricts passage of the substrate but does 
not require the reorientation of a binding site on the TMDs. 
Evidence that it is this step that provides the energy input for translocation is 
supported by the experimental observation that the maltose transporter still releases 
maltose into the cytoplasm in a vanadate-trapped transition state (2). 
Step III. ATP is hydrolysed. The hydrolysis of ATP seems to initiate the 
resetting of the transporter to its basal, open-dimer conformation by destabilizing the 
NBD closed dimer. This may also serve to induce a conformational change in the 
TMDs to open the channel into the cytoplasm and block the periplasmic opening of 
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the TMDs. There may also be dissociation of the apo-PBP from the TMDs at this 
point. 
The trigger for ATP hydrolysis is still unknown. Release of the substrate into 
the TMDs may induce a conformational change that is transmitted to the NBDs, or it 
may be that ATP hydrolysis is autocatalytic - a consequence of the geometry of ATP 
with respect to the specific hydrolytic residues introduced by the closed-dimer 
configuration. This is supported by the evidence that mutation of the catalytic base 
in the Walker B sequence allows crystal structures to be obtained in which ATP is 
bound to the active sites of the NBDs. 
Step IV. Release of P, and ADP. P, and ADP are released, restoring the 
transport complex to its basal state. Hydrolysis of ATP destabilizes the closed dimer 
by introducing electrostatic repulsion between ADP and the residues in the Walker A 
motif of one NBD and P, coordinated to the signature motif of the other NBD. This 
leads to a conformational change that returns the NBDs to an open conformation, 
releasing P1 and ADP in the process. There is some evidence to suggest that ADP 
remains bound in the open configuration of some transporters and that binding of a 
new substrate imbues conformation changes that cause ADP to dissociate, allowing 
ATP to bind, and thus, beginning the cycle over again. 
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2.1.4 NBDs from Three Bacterial ABC Transporters 
There have been many crystal structures of bacterial NBDs deposited in the RCSB 
Protein Data Bank (PDB). The best studied of these are MalK, HisP and BtuD from 
the maltose, histidine and vitamin B12 bacterial ABC transporters, 
respectively (4,41,42). There follows a brief description of the structures in the PDB. 
MaIK: Six crystal structures of Ma1K have been deposited in the PDB since 
2003 (PDB codes: 1Q1E, 2ANO, 2AWN, 1G29, 1Q12, 1Q1B): five of the E. coli 
protein and one from the thermophilic organism Thermococcus litoralis. Three 
structures are of the nucleotide-free forms of the protein (including T.1.Ma1K), two 
are of the ADP-Mg bound form and one is of the ATP-bound form (4,42). 
HisP: There is one structure of the histidine ABC transporter NBD from 
Salmonella iyphimurium (PDB code: 1BOU). The structure was determined with 
ATP bound at the dimer interface (41). 
BtuD: There is one structure of the vitamin B12 ABC transporter from E. coli 
(PDB code: 1L7V). Interestingly, the researchers managed to co-crystallise the 
transmembrane domain (BtuC) with the NBD (BtuD). The BtuD structure was 
crystallised with ortho-vanadate (a non-hydrolys able ATP analogue) bound in the 
active site (1). 
Sequence alignment of the polypeptide chains of all three of these proteins 
reveals a high consensus identity (64.8%), but low sequence identity (6.7%), and all 
three proteins adopt a similar fold, suggesting they are descended from a common 
"ATPase" ancestor that diverged into specific substrate translocation systems over 
the course of millions of years. The Ma1K structures differ markedly from the HisP 
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and BtuD structures in that Ma1K contains a —100 amino acid extension at its C-
terminus. This so called regulatory domain shares structural identity to the C-
terminal aminoacyl-tRNA-binding domains of bacterial elongation factors EF-Tu, 
the C-terminal barrel domain of bacterial methionyl-tRNA formyltransferase and 
other proteins of the so-called OB-fold. These domains function as binding modules 
for aminoacyl-tRNA, carbohydrates and DNA, and the existence of the C-terminal 
domain in T.l.MalK indicates that the NBD domain of this ABC-transporter may be 
involved in regulatory circuits. Indirect evidence for a similar fold is shared by other 
members of the bacterial ABC-type ATPase domains, which also possess an 
extension of —110 residues at the C-terminus of their ATPase domain. This strongly 
suggests that many of these proteins have a dual function within the bacteria cell; not 
only do they provide the energy input for vectorial transport of a substrate across the 
inner membrane, but may also be involved in signal transduction within the 
cytoplasm. However, it should be noted that not all NBDs of the ABC transporters 
possess such a C-terminal extension: BtuD from the E. coli vitamin B12 transporter 
does not have such a domain. When this C-terminus extension is excluded from 
these sequence alignments, the consensus identity rises to 81.9% and sequence 
identity increases to 10.1%. Consensus and sequence analysis is summarized in 
Figure 2.5. 
When the secondary structure is mapped onto the amino acid sequence of all 
four proteins, it reveals that they all contain conserved secondary structure for much 
of the protein: the exception to this is MalK, which contains the extended C-terminal 
domain (Figure 2.6). However, all four proteins do contain the critical conserved 
motifs that define the ABC transporter NBD family: the Walker A (P loop), Walker 
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B, Q loop (or lid), H loop (or swith), D loop and ABC signature motifs (Figure 2.7). 
When all four proteins are modelled it reveals that the NBD adopt a similar fold 
(Figure 2.8). 
Biochemical studies on the Ma1FGK2, BtuFC2D2 and HisJQMP2 systems 
have shown that the functional complexes can be reconstituted in vitro (43-45). The 
functional complexes were incorporated into proteoliposomes and uptake assays 
performed using radiolabelled substrate. The BtuFC2D2 (vitamin B12 transporter) 
study revealed that BtuD (NBD) incorporated into proteoliposomes had a high basal 
rate of ATP hydrolysis that was stimulated when BtuF (PBP) and substrate (57Co-
vitamin B12) was added. However, this research also highlighted that when the 
transporter was solubilsed in different detergents, the rate of ATP hydrolysis varied 
widely (43). 
The Hi5JQMP2 (histidine) transporter was reconstituted into proteoliposomes 
by dialysis and revealed that substrate (L-[H3]histidine) transport was entirely 
dependent upon the presence of ATP and liganded HisJ (PBP), and was sensitive to 
pH, temperature and salt concentration changes. These researchers found that the 
transport of radiolabelled substrate was inhibited by ADP and high concentrations of 
histidine inside the proteoliposomes, suggesting that the membrane-bound HisQMP 
complex contained a substrate-binding site. This is strong evidence that the 
membrane complexes of other ABC transporters may also contain a similar substrate 
binding site (41). Similar experiments using the reconstituted Ma1FGK2 complex 
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2.2 	The Iron Uptake ABC Transporter from N. gonorrhoeae: FbpABC 
2.2.1 The FbpABC Operon 
The FbpABC proteins are encoded on a three-gene operon in the genomic DNA of 
Neiserria gonorrhoeae called FbpABC (46). This operon encodes a member of the 
ABC transporter family that is involved in the specific uptake of iron into the 
cytoplasm. FbpA is a 993 bp gene that encodes an iron-binding periplasmic binding 
protein that, in its mature form, is a 309 amino acid long globular protein with a mass 
of 33.6 kDa. FbpB is a 1527 bp gene that is predicted to encode a cytoplasmic 
transmembrane protein 511 amino acids long, with a calculated mass of 56.3 kDa. 
FbpC is a 1056 bp gene that that is predicted to encode a nucleotide binding protein 
that is 309 amino acids in length, with a predicted mass of 37.9 kDa (Figure 2.9 and 
Appendix 1). 
FbpA 






33 637 kDa 
	
56 317 kDa 	 37 900 kDa 










Figure 2.9. Schematic representation of the FbpABC iron-uptake operon from the 
Gram-negative human pathogen Neisseria gonorrhoeae. 
FbpABC is proposed to facilitate the transfer of iron from the transferrin 
binding protein in the outer membrane, across the periplasm and into the cytoplasm 
(Figure 2.10). 
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ATP 	ADP Pi  
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Figure 2.10. The proposed mechanism for iron transfer into the cytoplasm. The exact 
mechanism of iron transport across the outer membrane, periplasmic space and cytoplasmic 
membrane remains undescribed. Based on (21). 
The gene cluster in N. meningitidis was identified as an operon using RT-
PCR amplification transcription assays, and thus the same can be assumed for N. 
gonorrhoeae (47). Expression of the operon is tightly regulated by the ferric uptake 
regulator (Fur; see above), and the gene encoding FbpA is separated from the 
downstream two genes by a putative stem-loop structure that suggests there is rho-
independent transcriptional regulation (48-50). This is a protein (rho) independent 
mechanism for terminating transcription of DNA and is characterized by a dGdC rich 
sequence followed by a short dT connecting sequence to a pallindromic dCdG 
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sequence complementary to the first. The motif is terminated by a longer dT 
sequence at the 3' end. The effect is that base-pairing is observed within the nascent 
RNA chain between the two dGdC regions that form a stem loop structure. The base 
pairing is so strong that the sequence "zippers" down to the RNA-DNA structure in 
the transcription bubble of the RNA polymerase/DNA helix complex. As the RNA-
RNA helices are more stable than RNA-DNA helices, some of the RNA-DNA base 
pairing in the bubble is disrupted. The remaining base pairs, being A-U pairs, are not 
strong enough to maintain the RNA-DNA association and the RNA product is 
released, terminating transcription (Figure 2.11). This has the overall effect of 
upregulating the FbpA gene expression with respect to the FbpB and FbpC genes by 
several orders of magnitude. Work by other researchers supports this finding and 
shows that the ratio of FbpA to FbpABC mRNA (as determined by quantatitive RT-
PCR) is 10- to 20-fold greater in N. meningitidis grown in iron limiting 
conditions (47). This is indeed what is observed when N. gonorrhoeae is cultured 
under iron limiting conditions - FbpA is the most upregulated protein in the cell, an 
observation that highlights the importance of iron acquisition to this species (51). 















RNAP pause site 
 
Figure 2.11. Schematic representation of rho-independent transcription termination. A 
general rho-independent termination DNA sequence is shown at the top. This sequence 
forms a stem-loop structure when the nascent RNA chain is formed that "zippers down" into 
the transcription bubble and disrupts the A-U pairing in the bubble causing the release of the 
RNA product, thus terminating transcription. RNAP: RNA Polymerase (52). 
The FbpABC gene cluster in Neisseria spp. is homologous to iron import 
transporters found in many Gram-negative pathogens. FbpABC pathways have been 
identified in Haemophilus influenzae, Mannheimia haemolytica, Campylobacter 
jejuni and Actinobacillus pleuropneumoniae (19,20,50). Functional homologues of 
FbpABC have also been found in Serratia marscesens and Yersina spp (19). 
2.2.2 Ferric-Binding Protein A: FbpA 
The FbpA gene (933 bp) was identified in 1990 and the encoded protein was first 
purified two years later (53,54). Since that time much work has been published on 
this protein. It is this protein that is proposed to receive the iron acquired from 
transferrin via the transferrin-binding protein complex in the outer membrane (34). 
Exactly how and in which form the iron is transported across the outer membrane 
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and then transferred to FbpA remains unclear, although several researchers have 
studied the kinetics of iron binding and release to elucidate this process (55-60). 
FbpA is transcribed as a pre-protein that contains a 23 amino acid signal (or 
leader) peptide (Figure 2.12) at its N-terminus that directs the protein for 
translocation into the periplasm, presumably via a SecA-dependent pathway. SecA 
mediates the translocation of the nascent protein chain by targeting it to a 
translocation channel composed of SecYEG in the cytoplasmic membrane. During 
the process of translocation the signal peptide is cleaved by a signal peptidase (LepB) 
located on the periplasmic side of the cytoplasmic membrane (61). The mature 
FbpA protein is a 309-amino-acid, 33.6 kDa globular protein with an isoelectric 
point (p1) of 9.35, making the protein cationic at physiological pH. FbpA has been 
referred to as a "bacterial transferrin" due to the possession of an iron-binding site 
that is almost identical to that found in human serum transferrin. The FbpA protein 
contributes four ligands to coordinate a single ferric-iron ion with high affinity: 
tyrosinate oxygen ligands from Tyr195 and Tyr196, an imidazole nitrogen ligand 
from His9, and a carboxylate ligand from G1u57. Two additional oxygen ligands are 
provided by a phosphate synergistic anion and water to complete almost perfect 
octahedral coordination of the ferric ion (Figure 2.12). Upon iron binding there is a 
rotational conformational movement around the hinge region. Figure 2.13 shows the 
binding sites of the apo and holo forms of FbpA. It can be observed that, although 
the apo form of the protein does not have iron bound (by definition), it does have a 
phosphate ion associated with the two tyrosine residues in the binding site. This 
"pre-prepared" binding site could possibly act to accept an incoming iron ion, 
allowing the other protein ligands (H9 and E57) to swing into the binding site, thus 
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completing coordination of the ion. Upon iron binding a ligand-metal charge transfer 
(LMCT) band is observed at 481 nm by UV-visible spectroscopy, although this can 
vary depending on the iron-binding environment (59). No such LMCT is observed 
in the apo form of the protein. Similarly, the binding site of transferrin contains two 
tyrosines and a histidine residue coordinated to the iron, however, the fourth 
coordinating protein ligand is an aspartate residue instead of glutamate. There is also 
a single bidentate carbonate synergistic anion in transferrin making up the two 
remaining coordinating oxygen ligands (Figure 2.12). Although the sites are similar, 
the residues involved in binding come from different parts of the polypeptide chain, 
suggesting that FbpA and transferrin are descended from a common iron-binding 
ancestor. 
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1 	MKTSIRYALL AAALTAATPA LAD ITVYNGQ HKEAAQAVAD AFTRATGIKV 
51 KLNSAKGDQL AGQIKEEGSR SPADVFYSEQ IPALATLSAA NLLEPLPAST 
101 INETRGKGVP VAAKKDWVAL SGRSRVVVYD TRKLSEKDLE KSVLNYATPK 
151 WKNRIGYVPT SGAFLEQIVA IVKLKGEAAA LKWLKGLKEY GKPYAKNSVA 
201 LQAVENGEID AALINNYYWH AFAREKGVQN VHTRLNFVRH RDPGALVTYS 
251 GAAVLKSSQN KDEAKXFVAF LAGKEGQRAL TAVRAEYPLN PHVVSTFNLE 

















Figure 2.12. A, Amino acid sequence of FbpA. The signal peptide shown in red, mature 
protein sequence shown in black, iron-binding residues shown in blue. Note that FbpA 
contains no cysteine residues B, Diagram showing arrangement of residues involved in 
iron binding in FbpA (left) and transferrin (right). Note the similarity between the 
arrangements of binding residues. C, Modelled iron-binding sites of FbpA (PDB: 1D9Y) 
and the N-lobe of (porcine) transferrin (PDB: 1H76) showing iron-binding residues. 
Note that, although the residues are identical or similar, they arise from different parts of the 
polypeptide chain. Iron is shown in brown. 
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A. 	 B. 
Figure 2.13. Structure of the apo-Fbp (A) and holo-FbpA (B) binding sites with protein 
ligands labelled (62). There is -.14° rotation around the hinge region between the two 
conformations. A phosphate ion is bound in the binding site of the apo form of the protein 
and is proposed to "prime" the site for iron binding. Upon iron binding the other two protein 
ligands swing into the binding site, completing pseudo-octohedral coordination of the iron 
ion. The exact mechanism of iron binding and release is still not fully understood. 
Like transferrin, the promiscuity and flexibility of the metal-binding site of 
FbpA has been investigated by several researchers, and has shown that, although 
in vivo the protein will preferentially bind a single ferric-ion with high affinity 
(1018 M 1 ), in vitro the protein can be "re-loaded" with not only clusters of iron, but 
also with other metal ions and clusters, as well as iron-complexing ligands. Crystal 
structures of oxo-Fe3, oxo-Hf3 & Hf5 clusters, oxo-Zr3 (Figure 2.14), Ti, and a Fe-
NTA (nitriloacetate) complex bound to FbpA have been published (22,28-30,63). 
There have also been structures determined for FbpA and its homologues in different 
conformations, such as the apo-open form, and the holo-open and closed forms 
(26,29). This is also the case for FbpA homologues from other bacteria, in which 
other synergistic anions have been crystallised in the binding site. 
MR 
ro 
Chapter 2: ATP Binding Cassette (ABC) Transporters 
Hf3-PO4 	 I 	 Hf 
Hf5-PO4 	 Zr3-PO4 
Figure 2.14. Crystal structures of oxo-
metal clusters bound to FbpA from N. 
gonorrhoeae. A, oxo-hafnium3 cluster 
capped by phosphate; B, oxo-hafnium5 
cluster (no phosphate); C, oxo-hafnium5 
cluster capped by phosphate; D, oxo-
zirconium3 cluster capped by phosphate, 
and; E, oxo-iron3 cluster. In all cases the 
oxo-metal cluster is bound via the tyrosine 
residues, but not the histidine or glutamic 
acid residues, and thus the protein is in an 
"open" conformation. PDB codes: 107T, 
IR1N and lXCl, respectively (28-30). 
Fe3 
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The finding that FbpA can bind metal clusters suggests another mechanism 
for iron uptake: FbpA may be able to interact directly with the extracellular 
environment; a suggestion has been supported by work that has shown that anti-
FbpA antibodies bind to the surface of whole cells expressing FbpA from N. 
menigitidis and the canine pathogen Ehrlichia canis (33,34). 	However, 
bioinformatic analysis of the amino acid sequence of FbpA yields a soluble protein 
that contains no predicted transmembrane-spanning domains. As such, this, and the 
lack of experimental evidence, means that this proposed mechanism of iron 
acquistion remains unproven. 
Holo-FbpA is proposed to complex with the TMD component of the ABC 
transporter in the cytoplasmic membrane to facilitate translocation of the iron across 
this membrane. How these proteins associate and which residues are involved in 
docking is unknown, and little is known about how and in what form the iron is 
removed from FbpA. 
2.2.3 Ferric Binding Protein B: FbpB 
The FbpB gene (1527 bp) encodes the TMD that is proposed to form a dimer in the 
cytoplasmic membrane. The gene was first described and sequenced in 1996 as an 
extension of the original work performed on FbpA (46,47,64). The mature protein is 
predicted to be a 509-amino-acid long 56.3 kDa integral membrane protein that is 
proposed to form a homodimer in the functional ABC transporter complex 
(Appendix 1). The only previously published work on this protein was in one of the 
original FbpA papers. In that report the authors suggested that FbpB should contain 
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11 transmembrane spanning regions, meaning that the active permease would be 
composed of 22 transmembrane- spanning helices (46). This analysis was performed 
by sequence alignment with HitB and SfuB permease proteins from the homologous 
iron transporters from Haemophilus influenzae and Serratia marcescens 
(respectively), and revealed significant homology between the three proteins (64.4% 
and 34.9% identity, and 77.5% and 58.2% similarity, respectively). These 
researchers also identified the consensus permease motif EAA---G --------- I-LP in 
these three proteins predicted to be located on cytoplasmic loops that interact with 
the NBD component of the transporters. Similar motifs have also been identified in 
other well-characterised TMD of ABC transporters that transport different ligands 
(46). These researchers also found that the protein was composed of 62% of 
hydrophobic residues, indicative of membrane proteins, and suggests that the protein 
would be insoluble in aqueous buffers (46). 
2.2.4 Ferric Binding Protein C: FbpC 
The FbpC gene (1056 bp) encodes the NBD. The gene was first described and 
sequenced in 1996 as an extension of the work performed on FbpA (46,47,64). The 
mature protein is predicted to be a 352-amino-acid 37.9 kDa membrane associated 
protein that would form a homodimer in the functional ABC transporter complex 
(Appendix 1). Previous investigations of this protein showed that FbpC can bind a 
non-hydrolysable radioactive ATP analogue and could hydrolyse ATP (65). 
Mutagenesis studies also revealed that the ATP-hydrolysing activity of the enzyme 
could be reduced 10-fold by mutation of the catalytic base in the Walker B motif 
(E1641)), certainly suggesting that FbpC is a member of the ABC ATPase 
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family (65). However, the work did not specifically identify the protein by peptide 
mass fingerprinting, and no accurate mass was determined for the protein by mass 
spectrometry. Previous bioinformatic analysis published as part of the original 
FbpABC operon (from N. gonorrhoeae F62) work revealed that FbpC contained the 
characteristic Walker A and B motifs, but did not identify the other conserved motifs 
found in ABC ATPases (46). Sequence alignment with the HitC and SfuC NBD 
proteins from the homologous iron transporters from Haemophilus influenzae and 
Serratia marcescens (respectively) revealed significant homology between the three 
proteins (51% and 40% identity, and 68% and 58% similarity, respectively). These 
researchers also demonstrated that the protein was composed of 50.5% hydrophobic 
residues, suggesting that the protein may be relatively insoluble in aqueous buffers 
(46). 
2.3 Aims 
The aims of this thesis are as follows. 
To further understanding of the complex transportation mechanisms of the 
FbpABC operon by cloning genomic DNA from a clinical isolate of 
Neisseria gonorrhoeae. 
To overexpress the genes in E. coli and purify and characterise these 
proteins. 
To mutate FbpA to allow attachment, via a linker molecule, to a sensor chip 
(and other solid phases) to facilitate investigation of the association of the 
protein complex. 
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4. 	To crystallise FbpC and the FbpBC complex in order to allow X-ray structure 
determination. 
This study constitutes the first expression and purification of the 
transmembrane domain (FbpB) of this ABC transporter, and the first exploration of 
the crystal structure of FbpC. It is also the first investigation of the intact FbpABC 
complex in vitro. 
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3.1 	General Materials 
3.1.1 General Reagents 
Chemicals and solvents were of the appropriate quality and were purchased from GE 
Healthcare, Promega, Sigma, Pierce, BioRad, Gibco BRL, Vivascience, New 
England Biolabs, Waters Micromass, Anatrace or Invitrogen unless otherwise stated. 
Plasmid pTrc99A/FBP/NG (Figure 3.1) was a kind gift from Prof. Ross 
MacGillivray (University of British Columbia, Vancouver, Canada) and was 
renamed pTrc99AIFbpA/Ng to avoid confusion with other plasmids constructed for 




5272 bp 	 Hind III 
Figure 3.1. Plasmid pTrc99A/FbpA/Ng map. 
Neisseria gonorrhoeae genomic DNA was a kind gift from Dr Helen Palmer 
(Scottish Neisseria Gonorrhoeae Research Laboratory, Edinburgh Royal Infirmary) 
and was purified from a clinical isolate of the bacteria by the author. 
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3.1.2 Solutions and Media 
Buffers - All buffers were prepared fresh, as required, and were 0.2 pm filtered 
before use. Buffer recipes are described in the text where appropriate. 
Sterilisation of media - All media was autoclaved at 121 °C for 15 min at 15 psi 
prior to use. 
Agar plates - bacto-agar (15 gIL) was added to the specified media to prepare agar 
plates. 
S-Gal/LB/amp plates - a pack of S-Gal/LB Agar Blend (Sigma) was dissolved in 
deionised water (1000 mL) and autoclaved. Ampicillin (100 tg/mL) was added to 
the solution to prepare plates. 
Luria Bertani (LB) - tryptone (10 g/L), yeast extract (5 g/L), NaCl (10 g/L); pH 
adjusted to 7.5 with NaOH. 
2xYT - tryptone (16 g/L), yeast extract (10 g/L), NaCl (5 g/L); pH adjusted to 7.5 
with NaOH. 
SOC - tryptone (20 g/L), yeast extract (5 g/L), NaC1 (0.5 g/L), MgSO4 (5 g/L), 
glucose (3.2 g/L); pH adjusted to 7.5 with NaOH. 
Terrific Broth - tryptone (12 g/L), yeast extract (24 g/L), glycerol (4 mL/L), 
NaH2PO4 (2.31 g/L) and Na2HPO4 (12.54 g/L). 
5x M9 Salts - Na7HPO4 (30 g/L), KH2PO4 (15 g/L), NaC1 (2.5 g/L) and (NH4)C1 
(5 g/L). 
50x M - Na2HPO4 (177.5 g/L), KH1PO4 (170 g/L), NH4C1 (134 g/L) and NaSO4 
(35.5 g/L) 
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250x Mg - 0.2 metals - 800 jiL sterile water, 1000 iL sodium citrate (1 M), 
2000 iL MgSO4 0  M), 200 .iL 1000x trace metals (see below) (1). 
1000x trace metals - 50 mM FeC13, 50 mM CaC12, 25 mM MnCl2, 25 mM ZnSO4, 
2 mM CoC12, 5 mM CuSO4, 2 mM NiC12, 2 mIvi Na2MoO4, 2 mM Na2Se03, and 
2 mM H31303, all in 50 mM HC1 (1). 
MDG media - 50x M, 40% glucose, 25% aspartic acid, 250x Mg-0.2 metals (1). 
SeMet labelling media - 5x M9 salts (200 mL), 40% glucose (10 mL), 1 M MgSO4 
(1 mL), I 000 trace metals (200 giL), 0.1 M FeC13 in 0.1 M HC1 (250 ML), biotin 
(10 mg/L), thiamine (10 mg/L), 100 pM vitamin B12 0  mL), L-lysine (100 mg/L), L-
phenylalanine (100 mg/L), L-threonine (100 mg/L), L-valine (50 mg/L), L-leucine 
(50 mg/L), L-isoleucine (50 mg/L) and L-selenomethionine (50 mg/L). Sterile water 
was added to the required volume. 
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3.2 	Molecular Biology: DNA Manipulation 
3.2.1 Bacterial Cell Lines 
Table 3.1. Bacterial cell lines used in this study. 
Strain 	Genotype 	 Applications 
Top IOTM 	
F'mcrA D(mrr-hsdRMS-mcrBC) 	 Used For transforming 
(Invitrogen) 
T801acZAM15 AlacX74 deoR recAl araDl39 DNA ligations. Expression 
i(ara-leu)7 697 gal/U gal/K rpsL endA 1 nupG host 
BL2 I (DE3) General purpose expression F omp Ihsdsh (rB m13 ) gal dcm (DE3) (Novagen) 	 host. 
3.2.2 Oligonucleotide Primers 
The following oligonucleotide primers were using in this study (Table 3.2). 
Restriction sites are highlighted. 
Table 3.2. Oligonucleotide sequences used in this study. Mutant codons and 
restriction sites are shown in bold italics. 
Name Sequence (5'-3') 
FbpA R48C For AAA GAA GAA GGC AGC TGC AGC CCC GCC 
FbpA R48C Rev GGC GGG GCT GCA GCT GCC TTC TIC ITT 
FbpA R83C For ATC AAC GAA ACA TGC GGC AAA GGC GIG 
FbpA R83C Rev CAC GCC TTT GCC GCA TGI TIC Gil GAT 
FbpA Ki 1 1C For GIl TAC GAC ACC CGC TGC CTG TCT GAA AAA 
FbpA Ki 1 1C Rev ITT TIC AGA CAG GCA GCG GGT GIC GTA AAC 
FbpA V272C For AAT CCG CAC GIG TGC ICC ACC TIC AAI TTG 
FbpA V272C Rev CAA All GAA GGT GGA GCA CAC GIG CGG AlT 
FbpB BamHI For ACT GTC CGC CCG hG GAT CCG AIG AAA AAC 
FbpB Hindill Rev GGC GGT CAT AGC GAA GCT TCC ICA AGC IGI 
FbpC NdeI For ACA GCT TGA GGA AGC ACC CATATG ACC GCC 
FbpC Stop XhoI Rev Clii' GTG GAT GCT GCC TCG AGT CAG AGG GTA 
FbpB NcoI For CCC Gil IIG CCC A TG GGA AAC ACT ATG ICI 
FbpB XhoI Rev IIC CTC AAG CTC GAG ITT GAA GGC GTA Ill 
FbpA NcoI For GAG GAA ATC GCC ATG GGA ACA TCT ATC CGA 
FbpC NcoI For AGC ACC GCC ATG GGG GCC GCC CIG CAC ATC 
FbpC XhoI Rev CTC GAG GGT All ICC GGG GAA GAA CAG GGC 
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3.2.3 Storage of Bacterial Stocks 
Colonies of bacteria were stored on inverted agar plates at 4 °C for up to 28 days. 
Overnight cultures grown in non-inducing MDG media were stored at 4 °C for up to 
six weeks. LB or 2xYT medium containing the appropriate antibiotics was used for 
the short-term storage of E. co/i. 
3.2.4 Transformation of E. coil Competent Cells 
Competent cells were transformed according to the manufacturers instructions. DNA 
(up to 40 ng) was added to an aliquot of competent cells and gently mixed. This was 
left on ice for 5 or 30 minutes before the cells were heat shocked (42 °C, 30 s). The 
cells were then grown in 80-250 iL SOC medium at 37 °C for 1 h. Finally, the cells 
were spread to dryness on selective agar plates and incubated at 37 °C overnight. 
3.2.5 Preparation of Plasmid DNA 
Plasmid DNA was prepared using QiAprep® Spin Miniprep Kit (Qiagen) following 
the manufacturers instructions. 
3.2.6 Digestion of DNA with Restriction Endonucleases 
The required amount of DNA (0.5-1 jig) was treated with the appropriate amount of 
endonuclease and buffer and incubated for at least 2 hours at 37 °C. Blue/orange 
loading dye (Promega) was added and the sample was subjected to electrophoresis 
on agarose. The gels were viewed and photographed under UV-light. 
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3.2.7 Electrophoresis of DNA 
The required amount of agarose was added to lx TAE buffer (typically 
1.2 g/100 mL) and heated at 100 °C until it dissolved. The solution was allowed to 
cool to 55 °C and ethidium bromide was added to a final concentration of 0.5 jig/mL. 
The gel was then poured into the casting mould and allowed to set at room 
temperature. DNA was loaded and electrophoresed using a potential difference of 
100 V for an adequate time to achieve separation of visible bands. 
3.2.8 Purification of DNA 
DNA was purified from agarose using QlAquick® Gel Extraction Kit (Qiagen) 
following the manufacturers instructions. 
3.2.9 Amplification of DNA by PCR 
Polymerase chain reactions (PCRs) and sequencing reactions were performed using a 
Perkin Elmer 480 thermal cycler. A typical reaction contained: 2 Ready-to-Go 
PCR TM beads (GE Healthcare), DNA template (1 jiL), primer 1 (forward) (5 pL 
10 tM), primer 2 (reverse) (5 iL, 10 jiM), and distilled water (39 jiL). Reactions 
were overlayed with oil and cycled 30 times at 95 °C for 1 mm, 54 °C for 1 min and 
72 °C for 2 mm. Heating at 72 °C for 10 min terminated the reaction. The PCR 
product was then subjected to agarose gel electrophoresis and the required band 
excised and the DNA purified as described as above. 
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3.2.10 Site-Directed Mutagenesis PCR 
The muatations were introduced by using the Quikchange Site-Directed Mutagenesis 
Kit (Stratagene). This is a cloneless system that uses the parent plasmid as a 
template and forward and reverse complementary primers designed to encode for the 
desired mutation. 
Reactions were performed as follows: to a 0.5 ml PCR tube was added 5 iL 
(parent) plasmid DNA, 5 iL lOx reaction buffer, 1 pL forward mutagenic primer, 
1 tL reverse mutagenic primer, 1 iL dNTPs, 36 pL water and 14 PJ1Turbo DNA 
polymerase. This was mixed and overlaid with oil and cycled 17 times at 95 °C for 
30 s, 55 °C for 30 s and 68 °C for 1 min/kbp. After the reaction was complete, 1 jiL 
of DpnI (restriction endonuclease) was added and the mixture and incubated for 1 h 
at 37 °C. DpnI digested PCR product (10 iL) was then subjected to agarose gel 
electrophoresis to check the efficiency of the reaction, and 2 tL of the PCR product 
was then transformed into TOP 10 E. co/i as described above. 
3.2.11 Cloning of PCR Products 
PCR products were cloned into the pGEM T-Easy cloning vector (Promega) using 
the manufacturer's guidelines. 
3.2.12 DNA Sequencing 
Automated DNA sequencing was performed on an ABI prism 377 DNA sequencer 
using the Sanger dideoxy chain termination method. Each sequencing reaction 
typically contained: DNA template (-5 pmol, 2 pL), primer (10 jiM, 1 jiL), distilled 
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water (13 pL) and Big Dye 4.1 (4 iL; FE Biosystems, UK). The reaction performed 
on an Eppendorf Mastercycler Personal hot-lid PCR cycler and cycled 30 times at 
96 °C for 30 sec, 45 °C for 15 sec and 60 °C for 4 mm. Sequence data were analysed 
using Contig Express within the Vector NTI Advance TM  v9 software package. 
3.2.13 Cloning into Plasmid Vectors 
The DNA fragment cut with suitable restriction enzymes (13 jiL), the host vector cut 
with suitable restriction enzymes (4 tL), lOx T4 DNA ligase buffer (2 iL), and 
T4 DNA ligase (1 000 000 U, 2 pL) were gently mixed and incubated overnight at 
16 °C. Reaction mixture (2 .iL) was used to transform suitable competent cells. 
3.3 	Molecular Biology: Protein Expression & Purification 
3.3.1 Polyacrylamide Gel Electrophoresis (PAGE) 
SDS-PAGE was used to analyse proteins on the basis of their molecular mass. The 
technique used was the discontinuous buffer system of Laemmeli. Alternatively, 
proteins were analysed on precast 12% Bis-Tris Nu-PAGE gels (Invitrogen) 
according to manufacturers instructions. 
Gels were visualised using Coomassie blue, GelCode Blue Stain reagent or 
Imperial stain (Pierce) in accordance with the manufacturers instructions. 
3.3.2 Western Blot Analysis 
Western Bolt analysis was performed to positively identify very small amounts of 
expressed tagged protein. 
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SDS-PAGE was performed and the gel fixed in transfer buffer (25 mM Tris 
buffer pH 8.3, 150 mM glycine and 10% methanol) for at least 15 mm. The proteins 
were then transferred onto a nitrocellulose membrane (GE Healthcare) for 30 min at 
a potential difference of 15 V using a BioRad TransBlot according to the 
manufacturers instructions. The membrane was blocked for 1 hour at room 
temperature with PBS-0.05% Tween containing 5% non-fat dried milk (Marvel) 
followed by at least three washes (10 min each) with PBS-0.05% Tween. The 
membrane was hybridised for 1-16 hours with the relevant primary HRP-conjugated 
antibody dilution made up in PBS-0.05% Tween containing 5% non-fat dried milk, 
followed by at least three washes (10 min each) with PBS-0.05% Tween. The 
membrane was drained of excess PBS-tween and developed using ECL Plus Western 
Blotting Detection System (GE Healthcare) according to the manufacturers 
instructions. Radiographic films (BioMax XAR film, Kodak) were exposed in a dark 
room for 1 s-10 min and then developed using on a Compact X4 Automatic X-ray 
film processor (Xograph). The antibodies used for Western blot analysis were anti-
C-terminal-His6 (Invitrogen) or anti-his6 (Sigma). 
3.3.3 Large-Scale Expression of N. gonorrhoeae FbpA and Mutants in 
E. co/i 
TOP 10 cells (Invitrogen) transformed with pTrc99AJFbpAINg were used to 
aseptically inoculate up to 500 ml of 2xYT medium containing ampicillin. This was 
then incubated for 16 h at 37 °C and 250 rpm. The cells were harvested by 
centrifugation at 4 000 x g for 10 min at 4 °C. The FbpA expressing pellet (red- 
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brown in colour) was collected and frozen at -20 °C before extraction and 
purification. 
3.3.4 Purification of N. gonorrhoeae FbpA and Mutants 
FbpA was purified by a slight modification of methods described previously (2). 
The pellet from the large-scale preparation was defrosted at room temperature and 
re-suspended (5 mL/g pellet) in 50 mM HEPES (pH 8.0) and 1% CTAB 
(cetyltrimethylammonium bromide, Fluka). This mixture was then stirred gently for 
3-6 h at 37 °C. The white insoluble material was removed by centrifugation at 
12 000 x g for 25 min at 4 °C. The supernatant (red) was 0.45 Mm-filtered and 
dialysed overnight into 10 mM HEPES buffer (pH 8.0) to precipitate excess CTAB 
and re-filtered (0.45 Mm). A 26/10 SP Sepharose Fast Flow (55 mL, GE Healthcare) 
column was washed according to the manufacturers instructions and equilibrated 
with 10 mM HEPES buffer (pH 8.0). The CTAB extract was loaded onto the column 
by FPLC (AKTABasic]OO, GE Healthcare) and eluted with a high salt gradient (0-
1 M) using a 10 mM HEPES, 1 M NaCl buffer (pH 8.0). Fractions (variable 
volumes) showing absorbance at 280 and 481 nm were collected and analysed by 
SDS-PAGE. 	FbpA containing fractions were concentrated by ultrafiltration 
(VivaSpin concentrator, 10 kDa molecular weight cut-off) and then desalted by 
either PD 10 column or dialysis. 
FbpA and mutants of the protein were also purified by a novel batch method 
using Fractogel EMD S03 -650(M) chromatography media (Merck). The bacterial 
pellet of overexpressed FbpA was treated in an identical fashion as described above, 
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but purification was performed by using 1-5 mL of washed and equilibrated (using 
the above buffers) with the Fractogel media. Protein was loaded onto the media by 
incubation at room temperature for 5 mm, and the bound protein washed with 30 CV 
of wash buffer in a batch fashion using a centrifuge (1 mm, 500 x g) to pellet the 
media between washes. The media was then washed with 20 CV of wash buffer 
containing 100 mM NaCl, and then bound protein eluted in an appropriate volume of 
wash buffer containing 250 mM NaCl. 
3.3.4.1 Preparation of apo-FbpA 
Apo-FbpA was prepared by dialysing the holo form of the protein against 50 mM tn-
sodium citrate (pH 6.0) for 2 hours. The apo-FbpA was then dialysed (8 000 Mr cut-
off) against 3 x 1 L of 10 mM HEPES buffer (pH 8.0) and then treated with 
Chelex 100'l'M  resin to remove any trace metals. The protein was stored at -20 °C 
until required. 
3.3.5 Expression of N. gonorrhoeae FbpC in E. coil 
The FbpC construct pET-28aJFbpC/Ng, was used to transform E. coli expression 
strain BL21(DE3) and grown on LB/kanamycin (30 tg/mL) agar plates. Small-scale 
induction screens (20 mL) were performed at 25 °C using 0.2 mM IPTG overnight to 
verify the FbpC protein expression (by SDS-PAGE) of the clones. 
For large-scale expression, one colony was picked and used to inoculate 
200 mL of 2xYT or MDG media containing kanamycin (30 pg/mL) and grown 
overnight at 37 °C with agitation (250 rpm). The 200 mL overnight culture was used 
to inoculate 5 L of Terrific broth (TB) and grown to an 0D600 of 0.8 at 25 °C and 
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then induced with 0.2 mM IPTG for three hours at 25 °C. Cells were harvested by 
refrigerated centrifugation at 4 000 x g for 10 min immediately after induction. Cell 
pellets were frozen in liquid nitrogen and stored at -20°C until required. 
3.3.6 Expression of SeMet Labelled N. gonorrhoeae FbpC in E. coil 
The FbpC construct pET-28aIFbpC/Ng was transformed into E. coli expression strain 
BL2 1 (DE3) and grown on LB/kanamycin (30 tg/mL) agar plates. 
For large-scale expression, one colony was picked and used to inoculate 
200 mL of MDG media containing kanamycin (30 tg/mL) and grown overnight at 
37 °C with agitation (250 rpm). The 200 mL overnight culture was used to inoculate 
5 L of M9 media supplemented with MgSO4, glucose, thiamine, biotin and trace 
metals and grown to an 0D600 of 0.7-0.8 at 25 °C. Amino acids were added (K, F, T, 
I, L, V and selenomethionine) and vitamin B12, and the cells grown for a further 
15 min before being induced with 0.2 mM IPTG for three hours at 25 °C. Cells were 
harvested by refrigerated centrifugation at 4 000 x g for 10 mins immediately after 
induction. Cell pellets were frozen in liquid nitrogen and stored at -20°C until 
required. 
3.3.7 Purification of Wild-Type and SeMet Labelled N. gonorrhoeae 
FbpC 
The FbpC expressing pellet was resuspended (5 mL/g wet cell pellet) in 25 mM Tris 
buffer (pH 8.0) containing ATP (5 mM), EDTA (0.1 mM), 20% glycerol 
(resuspension buffer (RB)) with 1 protease inhibitor cocktail tablet (EDTA-free), and 
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10 mg of DNase added, and then homogenised. The resuspended pellet was 
sonicated for 15 mm (30 s on/30 s off) on ice and was then centrifuged at 25 000 x g 
for 30 mins at 4 °C to remove insoluble debris. 
Ni-NTA silica (1-5 mL; Promega) was used to purify the extracted FbpC. 
The resin was first washed with water and then equilibrated with 10 column volumes 
(CV) of RB containing 20 mM imidazole at 4 °C. The filtered (0.45 pm) sonication 
supernatant was added to the resin and stirred gently at 4°C for 1-2 hours. 
The resin was packed by centrifugation (1 min at 500 x g). The flow through 
fraction was collected and the packed beads washed with 30 CV of 25 mM tris buffer 
(pH 8.0) containing NaCl (500 mM), imidazole (50 mM), ATP (5 mM), EDTA 
(0.1 mM) and 20% glycerol (wash buffer (WB)), and the wash fractions collected. 
Bound protein was eluted with imidazole (250 mM, 5mL fractions) in wash buffer. 
SDS-PAGE was used to determine fractions containing FbpC, and these fractions 
were pooled and frozen at -20 °C. 
A second round of purification using TALON resin (cobalt-affinity 
chromatography) was performed if necessary. Fractions containing FbpC were 
diluted in RB containing no EDTA to a final imidazole concentration of 20 mM 
(-10-fold dilution), and incubated at 4 °C with washed and equilibrated TALON 
resin for 1-2 hours with gentle stirring. Bound protein was washed and eluted as 
described above and the purity of the eluted protein checked by SDS-PAGE. 
Purification of SeMet labelled FbpC was identical except that all buffers also 
contained 0.5-1 mM tris(carboxyethyl)phosphine (TCEP) as a reducing agent to 
avoid oxidation of incorporated selenomethionine residues. 
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3.3.8 Co-Expression of N. gonorrhoeae FbpBC in E. coil 
The FbpBC constructs, pETDuet-1/FbpB/FbpC/Ng or pET-28aJFbpBC/Ng, were 
used to transform E. coli expression strain BL21(DE3) and grown on LB/kanamycin 
(30 tg/mL) agar plates, for the pET-28a construct and LB/ampicillin (100 pg/mL), 
for the pETDuet-1 construct. Small-scale inductions (20 mL) were performed at 
25 °C using 0.2 mM IPTG for 3 hours to verify expression (by SDS-PAGE) of FbpB 
and FbpC. 
For large-scale expression, one colony was picked and used to inoculate 
200 mL of 2xYT or MDG media containing kanamycin (30jig/mL) or ampicillin 
(100 tgImL), as appropriate, and grown overnight at 37°C with agitation (250 rpm). 
The 200 mL overnight culture was used to inoculate 6 L of Terrific broth (TB) and 
grown to an 0D600 of 0.8 at 25°C and then induced with 0.2 mM IPTG for three 
hours at 25°C. Pre- and post-induction aliquots were taken to check protein 
expression level by SDS-PAGE. Cells were harvested by refrigerated centrifugation 
at 4 000 x g for 10 min immediately after induction. Cell pellets were frozen in 
liquid nitrogen and stored at -20°C until required. 
3.3.9 Purification of the N. gonorrhoeae FbpBC Complex 
The FbpBC expressing pellet was resuspended (5 mL/g wet cell pellet) in 25 mXVI tris 
buffer (pH 8.0) containing ATP (5 mM), EDTA (0.1 mM) (resuspension 
buffer(RB1)) with 5 mM benzamidine, and then homogenised. DNase (10 mg) and 
lysozyme (5 mg/mL) were added to this and the mixture stirred briskly at 4 °C for 
30 mins. This was then sonicated for 15 mm (30 s onl30 s off) on ice and then 
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centrifuged at 25 000 x g for 30 min at 4 °C to remove insoluble debris. The opaque 
supernatant was decanted and ultracentrifuged at 120 000 x g for 2 hours at 4 °C. 
The resulting dense golden pellets were resupended in a minimal amount of 25 mM 
tris (pH 8.0) and frozen in 1 mL aliquots at -20 °C until required. A BCA assay was 
performed to determine the total protein concentration in these enriched inner 
membranes. 
Aliquots of enriched inner membranes were solubilised (6 mg/mL total 
protein, final concentration) in 25 mM tris buffer (pH 8.0) containing 500 mlvi NaCl, 
ATP (5 mM), 20% glycerol and 1% n-dodecyl-J3-D-maltopyranoside (DDM) at 4°C 
for 3 hours with gentle agitation (resolubilisation buffer (RB2)). The extraction 
mixture was centrifuged for 30 min at 25 000 x g and 4 °C to remove any remaining 
unsolubilised material. TALON metal affinity resin (1-5 mL; Clontech) was washed 
three times in water and then three times in RB2. The extract supernatant was 
incubated with the equilibrated TALON resin for 1-2 hour at 4 °C with gentle 
agitation. The resin was then pelleted by centrifugation (1 mm, 500 x g). The flow 
through fraction was collected and the packed beads washed with 30 column 
volumes of 25 mM tris buffer (pH 8.0) containing NaCl (500 mM), ATP (5 mM), 
20 % glycerol, 0.1 % DDM and 20 mM imidazole (wash buffer). Bound protein was 
eluted with a 250 mM imidazole in wash buffer. Fractions were collected and SDS-
PAGE and Western blot analysis performed to check the purity of the eluted 
proteins. 
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3.4 	Protein Chemistry 
3.4.1 Modification of FbpA Cysteine-Containing Mutants 
3.4.1.1 Modification with lodoacetamide 
lodoacetamide (Figure 3.2) and iodoacetic acid are widely used to alkylate 
sulfhydryl groups irreversibly, thus covalently modifying reactive cysteine residues 
(3). This procedure is used to assess the ability for modification of the free thiol in 
the protein with a useful prosthetic group. 
Figure 3.2. Structure of iodoacetamide. 
The procedure was performed as follows: the protein was first reduced by 
addition of TCEP (1 mM final concentration) to 2.5 mL of protein (1 mg/mL) and 
incubated for 5-10 min at room temperature. lodoacetamide (20 pL, 1 M made up in 
1 M NaOH) was added and the mixture incubated for 30 min in the dark, at room 
temperature. Unreacted iodoacetamide and excess TCEP was removed by PD1O 
column chromatography (GE Healthcare) which was used to exchange the modified 
protein into ammonium acetate buffer (10 mM, pH 8.0) for mass spectrometry (4). 
LC-MS was performed as described in Section 3.5.2. 
Protein modified with iodoacetamide should yield a mass increase of 57 Da. 
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3.4.1.2 Modification with AMS 
4-Acetamido-4' -maleimidylstilbene-2,2' -disulfonic acid (AMS, Figure 3.3) is a 
thiol-reactive reagent that is water-soluble, with high polarity and membrane 
impermeability (5). This polysulfonated dye is useful for determining whether thiol-
containing proteins and polypeptide chains are exposed at the extracellular or 
cytoplasmic membrane surface. This molecule was used in this study to assess the 
reactivity of the surface thiol group on the mutant protein. 
H 3 
Figure 3.3. Structure of 4-acetamido-4'-maleimidylstilbene-2,2'-disujfonic acid. 
The procedure for modifying a protein containing a reactive thiol was as 
follows: 1 mg/mL of mutant FbpA in 25 mM HEPES (pH 7.5) was reduced with 
1 mM TCEP for 5-10 min at room temperature. AMS (20-fold molar excess) 
dissolved in 25 mM HEPES (pH 7.5) was added dropwise with stirring, and the 
reaction allowed to procede for 2 hours at room temperature. Unreacted AMS was 
quenched with TCEP. The mixture was centrifuged and the supernatant applied to a 
PD1O column (GE Healthcare) to remove excess AMS and TCEP and to exchange 
the modified protein into ammonium acetate buffer (10 mM, pH 8.0) for mass 
spectrometry (6). 
Protein modified with AMS should yield a 425 Da mass increase by LC-MS. 
Chapter 3: Materials and Methods 
3.4.1.3 Modification with EZLinkTM Maleimide-PE02-Biotin 
Maleimide-PE02-biotin (Pierce, Figure 3.4) is a water-soluble sulfhydryl-reactive 
biotinylation reagent that covalently modifies reactive cysteine residues. The reagent 
is used to modify a reactive thiol group on the surface of a protein, via the maleimide 
moiety, by Michael addition. The molecule contains a maleimide moiety and a 
biotin moiety that are linked by a polyethyleneoxide (PE02) chain, rendering the 
biotin group —29 A away from the reactive thiol group on protein surface. Biotin is a 
small naturally occurring vitamin that binds with high affinity to avidin and 
streptavidin proteins: the bond formation between biotin and avidin is rapid and, 
once formed, is unaffected by most extremes of pH, organic solvents and other 
denaturing agents. As such maleimide-PEO2-biotin is an excellent molecule for the 
biotinylation of reactive thiol containing proteins for attachment to a 
avidin/streptavidin coated surface (sensor chip), as the protein of interest is held 
away from the surface due to the length of the PE02 linker (7). 
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Figure 3.4. Structure of maleimide-polyethyleneoxide2-biotin. The maleimide moiety on 
the left is linked to the biotin moiety on the right by a polyethyleneoxide2 chain. 
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The procedure for modifying a protein containing a reactive thiol was as 
follows: 1 mg/mL of mutant FbpA in PBS (pH 7.2) was reduced with 1 mM TCEP 
for 10 min at room temperature. To this was added maleimide-PE02-biotin (20 mM; 
final concentration 0.8 mM) dissolved in PBS (pH 7.2), and the reaction allowed to 
procede overnight at room temperature (7). Unreacted maleimide-PE02-biotin and 
excess TCEP were removed by PD1O column chromatography (GE Healthcare). 
This was also used to exchange the modified protein into ammonium acetate buffer 
(10 mM, pH 8.0) for mass spectrometry. The biotinylated FbpA (named FbpA-
V272C-(M-PE02-B)) was stored at 4 °C for up to 2 weeks. 
LC-MS was performed as described in Section 3.5.2. A protein modified 
with maleimide-PE02-biotin should yield a 525 Da mass increase by LC-MS. 
3.4.1.4 Modification with lodoacetamidofluorescein (IAF) 
This molecule relies on the same chemistry as iodoacetamide to modifiy a reactive 
thiol containing protein with the fluorescent molecule fluoroscein (Figure 3.5). 
Fluorescein has an absorption maximum at 490 nm and an emission maximum at 
514 nm, making the molecule fluoresce green when excited with the correct 
wavelength of light. Modification of a protein with IAF is useful for studying the 
formation of protein complexes in vitro, and for tracking proteins within a cell. The 
procedure for modification with lAP is identical to that described above for 
iodoacetamide. 
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Figure 3.5. Structure of iodoacetamidofluorescein. 
3.4.2 Reloading of apo-FbpA with Ruthenium and Osmium 
3.4.2.1 Preparation of Ruthenium Reloaded FbpA 
Reloaded Ru-FbpA was prepared by adding a 5-fold molar excess of Ru(III), in the 
form of RuC13.xH20 (1 mM stock solution, made up in water; pH 4.5), to apo-FbpA 
in 50 mM HEPES, pH 8.0. The mixture was incubated at room temperature for 3 h 
and was then dialysed into 3 x 1 L of 10 mM HEPES, pH 8.0. Chromatography was 
then performed using a TricornTM  MonoS cation exchange column (GE Healthcare) 
on a AKTABasic100 (GE Healthcare). The load and wash buffer was 10 mM 
HEPES, pH 8.0 and bound protein was eluted with a 0-1 M salt gradient in wash 
buffer. 
3.4.2.2 Preparation of Osmium Reloaded FbpA 
Reloaded Os-FbpA was prepared by adding a 5-fold molar excess of Os(llI), in the 
form of OsC13.3H20 (1 mM, made up in water, pH 4.5), to apo-FbpA in 10 mM 
HEPES, pH 8.0. The mixture was incubated at room temperature for 3 hours and 
M. 
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was then dialysed into 3 x 1 L of 10 mM HEPES, pH 8.0. Chromatography was then 
performed using a Tricorn TM  MonoS cation exchange column (GE Healthcare) on a 
AKTABasicIOO (GE Healthcare). The load and wash buffer was 10 mM HEPES, 
pH 8.0 and bound protein was eluted with a 0-1 M salt gradient in wash buffer. 
3.4.2.3 Preparation of Ru-FbpA samples for EXAFS 
The proteins contained in two major peaks from cation exchange chromatography were 
collected and concentrated to -1 mM by ultrafiltration (Viva Life Sciences, 10 000 Mr cut-
off). These were stored at 2-8 °C until transported to the Central Laboratory for the 
Research Councils (CLRC) Synchrotron Radiation Source (SRS) at Daresbury Laboratory 
(UK) for EXAFS. Samples were frozen in liquid nitrogen prior to being mounted and loaded 
into the cryostat for analysis. Analysis was performed at 100 K with X-ray scan traversing 
22.1214 keV (0.56047 A, ruthenium edge position) by Dr Ian Harvey (Station Scientist; 
Daresbury Lab). 
3.4.3 ATPase Assay of FbpC 
An ATPase assay was performed to determine that the purified FbpC protein was 
correctly folded and could hydrolyse ATP. The method uses the properties of 
molybdenum (as molybdate) to complex inorganic phosphate (Pt ) in a specific 
manner at acidic pH values. This method was used because the assay, unlike other 
phosphate determination assays, is not affected by high concentrations of ATP and 
glycerol (8). 
An ATPase assay was performed as previously reported (8), and the amount 
of inorganic phosphate (P1 ) liberated determined by colourimetric assay (8-10). 
Briefly, FbpC or FbpBC in 25 mM tris buffer (pH 8.0) containing NaCl (40 mM), 
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ATP (5 mM), DTT (1 mM), EDTA (0.1 mM) and 20% glycerol was incubated at 
37°C for 3 min and the reaction initiated by the addition of 100 mM MgCl2  to a final 
concentration of 2 mM. Aliquots were removed from the reaction at specific time 
points and added directly to an equal volume of 12% SDS and mixed. An equivalent 
volume of 6% SDS, 0.5% ammonium molybdate and 3% ascorbic acid in 0.5 N HCI 
was then added. The mixture was incubated at room temperature for 5 min before 
the addition of an equivalent volume of 2% sodium citrate, 2% sodium 
(meta)arsenite and 2% acetic acid. This was incubated at 37 °C for 10 min to allow 
any colour to develop, and the absorbance of each reaction read at 850 nm on a 
Varian Cary 300 fitted with a temperature control system. A negative control was 
also assayed and a standard curve of KH2PO4 was used to determine the amount of P 
liberated. 
3.4.4 FbpBC Pull-Down with Biotinylated FbpA 
Magnetic streptavidin beads (100 tL, New England Biolabs) were washed three 
times (1 mL each) in water and then equilibrated with three washes (1 mL each) of 
PBS using a magnetic separation rack (New England Biolabs). 0.05 mg of FbpA-
V272C-(M-PEO2-B) (biotinylated FbpA) was incubated with the beads for 10 min at 
room temperature and then the beads washed three times (1 mL each) in PBS. The 
FbpA-V272C-(M-PEO2.-B) flow through and wash fractions were retained for 
analysis by SDS-PAGE and Western blot. To the washed beads coated with FbpA-
V272C-(M-PEO2-B) was added —0.5 mg of the FbpBC complex. This was incubated 
for 10 min at room temperature, and then the beads washed three times (1 mL each) 
in 25 mM tris (pH 8.0) containing 2 mM ATP, 20 % glycerol, 150 mM NaCl and 
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0.1 % DDM. The FbpBC flow through and wash fractions were retained for analysis 
by SDS-PAGE and Western blot. Bound protein was eluted from the streptavidin 
beads by boiling for 5 mm. The elution supernatant was analysed by SDS-PAGE 
and Western blot. 
3.4.5 Surface Plasmon Resonance of the FbpABC Complex 
Surface plasmon resonance (SPR) is a phenomenon that occurs when light is 
reflected off thin metal films (11). A fraction of the light energy incident at a sharply 
defined angle can interact with the delocalised electrons in the metal film (plasmon) 
thus reducing the reflected light intensity. The precise angle of incidence at which 
this occurs is determined by a number of factors, but the principal determinant is the 
refractive index close to the backside of the metal film, to which target molecules are 
immobilised and addressed by ligands in a mobile phase running along a flow cell. 
If binding occurs to the immobilised target the local refractive index changes, leading 
to a change in SPR angle, which can be monitored in real-time by detecting changes 
in the intensity of the reflected light, producing a sensorgram. The rates of change of 
the SPR signal can be analysed to yield apparent rate constants for the association 
and dissociation phases of the reaction. The ratio of these values gives the apparent 
equilibrium constant (affinity). The size of the change in SPR signal is directly 
proportional to the mass being immobilised and can thus be interpreted crudely in 
terms of the stoichiometry of the interaction. Signals are easily obtained from sub-
microgram quantities of material. Since the SPR signal depends only on binding to 
the immobilised template, it is also possible to study binding events from molecules 
in extracts, and thus it is not necessary to have highly purified components (12). 
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Figure 3.6. Diagrammatic representation of surface plasmon resonance. A, a light 
source is shone through a prism at the back of a sensor surface onto which a capture 
molecule (green) is immobilised. Changes of mass upon binding of partner (cyan) causes the 
incident angle (SPR angle) of refracted light to change. This change in SPR angle is 
deconvoluted and displayed in real time as a sensogram (B) from which affinity and kinetic 
data can be extrapolated (13). 
SPR was performed on the FbpABC complex using a BiaCore T100 
instrument in a similar manner to the pull-down experiment described above. A 
streptavidin derivatised SPR sensor chip was used to bind FbpA-V272C-(M-PEO2-
B) (40 nM) to maximum of -100 Response Units (RU), manually at 10 iL/min, 
using the control software (14). Six serial dilutions of the FbpBC complex were 
prepared from 0-2400 nM, and a method written in the Biacore Tl00 control 
software to inject set volumes (88 IlL)  of each dilution, waiting 3000 s between 
injections, and the method was run overnight. Analysis of the results was performed 
using the Biacore T 10 control software. 
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3.4.6 FbpABC Iron-59 Uptake Assay 
Iron-59 (59Fe) was bought from GE Healthacre in the form of 59FeC13 in 0.5 M HC1. 
59Fe is a 3 radiation emitter with some associated low energy y emissions, and has a 
half-life of 44.5 days (15), making it useful for performing in vivo iron-uptake 
assays. 
The ability of cells expressing FbpABC to take up radioactive 59Fe (GE 
Healthcare) into the cytoplasm was compared to a non-FbpABC expressing negative 
control. BL21(DE3) cells were transformed with pET-28aIFbpABC/Ng and grown 
overnight in TB media containing kanamycin. Cells were diluted to 0D600 of —0.2 in 
fresh TB medium and grown at 25 °C to an 0D600 of 0.7. The cells were then 
induced with 0.2 mM IPTG for 2 hours at 25 °C. This procedure was repeated with 
pET-28aJFbpCINg expressing cells as a negative control. An uninduced sample of 
FbpABC transformed cells was also retained as a negative control. After induction 
the cells were washed in MDG medium containing no iron and resuspended in the 
same medium to an 0D600 of 1.0. Cultures were pre-incubated at 37 °C before the 
addition of 59FeC13 in 0.1 mM HCI to a final concentration of 2 MM. Aliquots (1 mL) 
were removed from the cultures at specific time points and immediately centrifuged 
for 2 mins at 11 000 x g, after which the supernatant was thoroughly removed and 
added to 2 mL of scintillation fluid. The pellets were immediately incubated with 
50 mM HEPES (pH 8.0) and 1% CTAB for 2 hours at 37 °C to extract the 
periplasmic fraction. The periplasmic extraction was centrifuged for 5 min at 
11 000 x g after which the supernatant was thoroughly removed and added to 2 mL 
of scintillation fluid. Scintillation fluid (2 mL) was also added to the remaining 
93 
Chapter 3: Materials and Methods 
cytoplasmic pellet. Radioactivity of all fractions was counted on a Packard liquid 
scintillation counter. Results were then plotted as a percentage (average of 
triplicates) of radioactivity taken up into the periplasm and cytoplasm. 
3.5 	Protein Charcterisation 
3.5.1 UV-Visible Spectroscopy 
The UV-Vis spectra were obtained on a Varian Cary 300 fitted with a temperature 
control system or a Hewlett Packard 8452A diode array spectrophotometer in 1 cm 
quartz cuvettes. Solvent was used as reference unless otherwise stated. 
UV-Vis spectroscopy was used to determine the concentration of some 
proteins. Proteins have characteristic absorbance at 280 nm, and their concentrations 
can be determined if the molar extinction coefficient (r) is known at these 
wavelengths. This is achieved by using the Beer-Lambert Law (c = A/81, c is 
concentration, A is absorbance, e is the extinction coefficient at a specific 
wavelength [M'cm'], and 1 is the path length (4)). 
The molar extinction coefficient at 280 nm can be calculated for proteins with 
known amino acid constituents by using the equation E = 5 500NTrp + 1 490NTyr + 
125N. (16). 
3.5.2 Liquid Chromatography-Mass Spectrometry (LC-MS) 
LC-MS was performed on a MicroMass Platform II quadrupole mass spectrometer 
equipped with an electrospray ion source. The spectrometer cone voltage was 
ramped from 40 to 70 V and the source temperature set to 90 °C. Protein samples 
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were separated with a Waters HPLC 2690 with a Jupiter C5 reverse phase column 
(5 gm, 250 x 4.6 mm, Phenomenex) directly connected to the spectrometer. Proteins 
were eluted from the column with a 5-95% acetonitrile (containing 0.01% TFA) 
gradient at a flow rate of 0.2 mL/min. The total ion count in the range 500-2000 mlz 
was scanned at 0.1 s intervals. The scans were accumulated, spectra combined and 
the molecular mass determined by the MaxEnt and Transform algorithms of the 
Mass Lynx software (Micromass, U.K.). 
3.5.3 Inductively Coupled Plasma Optical Emission Spectrometry (ICP-
OES) 
Inductively coupled plasma optical emission spectrometry (ICP-OES) is a technique 
used for the detection and quantification of elements in a sample. Up to 40 elements 
can be analysed simultaneously, and detection limited for most elements is typically 
at the jtg/L (ppm) level for aqueous solutions. 
ICP-OES was performed on a Thermo Jarrell Ash IRIS instrument and 
standards for the analytes under investigation were prepared to give a standard curve 
for each of those analytes. Concentrations of analytes in the samples were 
extrapolated from the relevant standard curves. 
3.5.4 Extended X-ray Absorbance Fine Structure (EXAFS) 
EXAFS is a technique for determining the atomic number, distance and coordination 
number of the atoms surrounding a metal. A monochromatic X-ray beam (from a 
synchrotron radiation source) is directed at the sample. The photon energy of the X- 
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rays is gradually increased, by a monochromator, such that it passes through the 
absorption edge of the element of interest contained in the sample. Below the 
absorption edge, the photons cannot excite the electrons of the relevant atomic level 
and thus absorption is low. However, when the photon energy is sufficient to excite 
the electrons, a large increase in absorption is observed; this is known as the 
absorption edge. The resulting photoelectrons with low kinetic energy can be 
backscattered by the atoms surrounding the emitting atom. This backscattering is 
dependent on the energy of the photoelectrons. Hence, the observed X-ray 
absorption will depend on the photon energy (as the photoelectron energy will 
depend on the photon energy). The net result is a series of oscillations on the high 
photon energy side of the absorption edge, and it is these oscillations that can be used 
to determine the atomic number, distance and coordination number of the atoms 
surrounding the element whose absorption edge is being examined (17). 
EXAFS was performed on the ruthenium reloaded form of FbpA at the 
CCLRC synchrotron radiation source at Daresbury laboratory, UK, in collaboration 
with Dr Ian Harvey. 
3.5.5 Peptide Mass Fingerprinting of SDS-PAGE Bands 
A NuPAGE gel was run on the samples to be identified and then stained using a 
(colloidal) Coomassie stain compatible with mass spectrometric analysis, as 
described above. The bands of interest were cut out and placed in clean Eppendorf 
tubes. To one gel slice was added 200 jtL of 50% acetonitrile followed by a 5 mm 
incubation at RT. The liquid was removed and discarded and the procedure repeated. 
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The tubes were then placed in a Gyrovap for 15 min or until the slice was dry and 
moved freely in tube. An aliquot of 10 mM DTT, 0.2% EDTA in 100 mM 
ammonium bicarbonate was added to just cover the dried gel slice and then incubated 
at 56 °C for 30 mm, after-which the mixture was cooled to RT. The DTT solution 
was removed and 50 mM iodoacetamide (made up in 100 mM ammonium 
bicarbonate) was added to just cover the gel slice, and this incubated in the dark for 
30 min at RT. This liquid was then removed and the slices washed with 200 tL of 
100 mM ammonium bicarbonate for 10 mm. The slices were then dehydrated with 
the addition of 200 .iL of neat acetonitrile for 10 mins and then the liquid discarded. 
This was repeated once and then the slices dried in a Gyrovap for 15 min. Trypsin 
solution was added directly to the slice and incubated at 2-8 °C for 30 min and then 
37 °C for 15 min or until all the liquid was absorbed. A volume of ammonium 
bicarbonate (50 mM) was added to just cover the slice and then the tube sealed and 
placed on a shaker set at 250 rpm for 12-16 hours at 37 °C. 
The digest liquid was removed from the tube and placed in a fresh Eppendorf 
tube. Just enough 5% trifluoroacetic acid made up in 50% acetonitrile was added to 
cover the gel slice and this then incubated with shaking at RT for 30-60 mm. This 
was centrifuged for 2 min at 11 000 x g and the supernatant combined with the 
supernatant from above. The sample was then placed in a Gyrovap until dry and 
then resuspended in 20 iL of 0.1% formic acid made up in water (ZipTip wash 
buffer) and a washed and equilibrated C18 ZipTip (Millipore Corp,) used according to 
the manufacturers instructions to load the peptides onto the ZipTip resin. Peptides 
were eluted from the ZipTip with 10 p  of 50% acetonitrile made up in 0.1% formic 
acid in water (ZipTip elution buffer). This elution procedure was repeated twice. 
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Samples were spotted onto a MALDI plate and analysed on a MALDI-TOF 
spectrometer (Tof-Spec 2E, Micromass, U.K). Spectrum analysis was performed 
using Voyager software and peptide fragment analysis performed using either the 
MS-Fit or ProFind databases. 
3.5.6 Bioinformatics 
3.5.6.1 Basic Local Alignment Search Tool (BLAST) 
Similar protein sequences were identified using BLASTp [BLAST 1 .5.4-Paracel] 
accessed via ExPASy/SIB (http://ca.expasy.org/tools/blastl), against the 
ExPASy/UniprotKB database (18,19). Amino acid sequences of FbpB and FbpC 
from N. gonorrhoeae were used as query sequences. 
3.5.6.2 Vector NTI 9 
Vector NTI version 9 suite (Invitrogen) was used for drawing plasmid maps, 
manipulating nucleic acid and amino acid sequences, designing primers and for 
performing amino acid sequence alignments (using the Align X function). 
3.5.6.3 Structure Analysis 
Structure analysis of the FbpB and FbpC sequences was performed using topology 
programmes TMHMM version 2 (http://www.cbs.dtu.dklservices/TMHMM-2.0) and 
TopPred (http://bioweb.pasteur.fr/seqanal/interfaces/toppred/html) (20-23). 
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3.5.6.4 Structure Modelling 
A model of the FbpC predicted structure was generated by submitting the amino acid 
sequence of the protein to the Swiss-Model database on the ExPASy Proteomics 
server using T.l.Ma1K as a template. 
3.5.7 Crystallisation Trials of FbpC 
Crystallisation trials of FbpC were performed in collaboration with Dr Simon 
NewsteadlProf. So Iwata at Imperial College, London, in the Membrane Protein 
Crystallography Group. FbpC was prepared in Edinburgh as described above and 
transported to London on dry ice. Clean-up purification was performed if required as 
described above and the protein exchanged into crystallisation buffer: 10 mM 
HEPES buffer (pH 7.5), 5 mM ATP, 2 mM EDTA and 20% glycerol (>99.5 pure). 
FbpC was then concentrated to 5 mg/mL using a spin concentrator (10 000 MWCO, 
VivaSpin). 
A Cartesian crystallisation robot was used to set up nanolitre-scale sitting-
drop crystal trials in either a 1:1 or 2:1, precipitant: protein volume ratio (-800 
conditions screened in total). The commercial screens used are listed in Table 3.3. 
Conditions that yielded small crystals were repeated on a microlitre scale, and 
crystals that grew were taken to the ESRF synchrotron radiation source in Grenoble, 
France. Diffraction images were collected on beamline 1D23eh2 microfocus. 
SeMet labelled protein was prepared in the same way and trials were set up 
using crystallisation conditions that had been optimised for the unlabelled protein. 
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Table 3.3. Table of commercial crystallisation screens used for structural investigation 
of FbpC. 
Commercial Screens 	 Number of conditions 
Hampton Research Crystal Screen 1 50 
Hampton Research Crystal Screen 2 48 
Wizard I random sparse matrix crystallization screen 48 
Wizard II random sparse matrix crystallization screen 48 
PEG/Ion screen 48 
JCSG+ refill-hit solutions 96 
PACT Suite refill-hit solutions 96 
Molecular Dimensions MemSys 48 
Molecular Dimensions MemStart 48 
Natrix 48 
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4.1 	Results: FbpA 
4.1.1 Purification of N. gonorrhoeae FbpA Wild-Type and Mutants 
Purification of FbpA was optimised as part of this study. A novel procedure for the 
purification of FbpA and mutants of the protein was devised to speed up the 
purification process. The protein extraction process was retained except that the 
method of purification that had previously been used included high concentrations 
(1 M) of Tris buffer in the extraction buffer. The buffer was changed to HEPES 
(100 mM), due to the possible metal chelating properties of Tris buffer, and the 
concentration of HEPES was kept low throughout the purification. The previous 
method also involved an overnight dialysis step at 4 °C of the crude extract to 
precipitate excess cetylmethylammonium bromide (CTAB) which is the cationic 
detergent used in the extraction of the protein from E. coli, and to dilute the 
concentrated tris buffer (1,2). This step was replaced with a 30 min incubation on ice 
of the crude cell-free extract, followed by centrifugation and purification. Previous 
purification was performed on various cation exchange columns (GE Healthcare) 
using an AKTABasic FPLC system, followed by clean-up purification on a gel 
filtration column if required. The new purification method was performed using a 
batch method, in a centrifuge tube, with Fractogel EMD S03 -650(M) 
chromatography resin (Merck) and produced protein that was > 98% pure, judged by 
SDS-PAGE, in a single purification step. The new method also cut the purification 
time to one day, from two-three days. 
This improved method was used for purification of all mutant FbpA proteins 
described in the following sections. 
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4.1.2 Production of N. gonorrhoeae FbpA Mutants 
4.1.2.1 Identification of Potential Residues for Mutational Studies 
The fact that FbpA from N. gonorrhoeae does not contain any cysteine residues was 
exploited to investigate the interactions with the proposed protein partners from the 
FbpABC operon. By introducing a cysteine residue on the surface of the protein, 
thus introducing a reactive thiol group, the protein can be derivatised using 
commercially available compounds that selectively irreversibly modify such groups. 
The use of members of the PBP family as tools and biosensors has been investigated 
in detail by Hellinga and co-workers (3-5). In this research the authors classify 
mutations dependent upon where the mutation is located on the PBP surface. 
Mutations in, or very close to, the substrate-binding site are termed endosteric sites; 
mutations located on the binding rim, close by the substrate-binding site are referred 
to as peristeric sites; and mutations located some distance away from the substrate-
binding site are classed as allosteric sites (3). 
Mutants of FbpA were produced by site-directed mutagenesis in order to 
perform protein-protein interaction studies with the other components of the 
FbpABC ABC transporter complex. Potential residues for mutation were identified 
by modelling the wild-type N. gonorrhoeae protein (PDB code 1 D9Y) in WebLab 
and Swiss-pdb viewer programmes. As the protein was to be modified with a linker 
molecule for attachment to a sensor surface, only residues on the surface of the 
protein were chosen as potential candidates for mutation. To limit the potential 
structural effects of introducing mutants on the surface of the protein, only residues 
that were not thought to be involved in maintaining tertiary structure or in iron 
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coordination were chosen as suitable candidates, and residues that were not highly 
conserved throughout the ferric-ion binding protein PBP family were selected. 
Residues that were suitable candidates were arginine residues in positions 48 
and 83, a lysine residue in position 111 and a valine residue in position 272. These 
residues were classified as either peristeric or allosteric in position (Table 4.1 and 
Figure 4.1). 
Table 4.1. Mutation sites on FbpA and a description of their location and classification. 
Mutation residues are colour coded to those shown in Figure 4.1 below. 
Mutation Description 	 Classification 
R48C N-terminal domain, outside rim of binding site Peristeric 
R83C Lower face, hinge region Allosteric 
KI 1 lC C-terminal domain, outside rim of binding site Peristeric 
V272C Lower face, hinge region Allosteric 
Figure 4.1. Model of FbpA from N. gonorrhoeae showing residues selected for mutation 
to cysteine. Left, side view; and right, bottom view. The residues are colour coded to those 
presented in Table 4.1 above. 
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4.1.2.2 Site-Directed Mutagenesis of N. gonorrhoeae FbpA 
PCR reactions were performed using the wild-type pTrc99A/FbpAINg plasmid as a 
template. The QuikChange Stratagene site-directed mutagenesis kit utilises a 
mutated version of the Pyrococcusfurians DNA polymerase, renamed Pfu Turbo, in a 
single PCR reaction to insert, remove or mutate single amino acid DNA base pair 
codons. The basic procedure utilizes a supercoiled double-stranded DNA (d5DNA) 
vector with an insert of interest (eg pTrc99A/FbpA/Ng) and two synthetic 
oligonucleotide primers containing the desired mutation (6). Oligonucleotide 
primers containing the required mutant codon were designed, each complementary to 
the opposite strand of the vector, and were extended during temperature cycling by 
PfiTurbo DNA polymerase. Incorporation of the oligonucleotide primers generated 
a mutated plasmid containing staggered nicks. Following the PCR reaction, the 
product was treated with the restriction endonuclease DpnI. DpnI endonuclease 
(target sequence: 5 '-Gm6ATC-3') is specific for methylated and hemimethylated 
DNA and is used to digest the original parental DNA template (pTrc99AIFbpA/Ng) 
and to select for synthesised DNA containing the desired mutation (7). 
FbpA mutants were generated using the Stratagene QuikChange site-directed 
mutagenesis kit in accordance with the manufacturer's instructions. Reactions were 
performed with the relevant mutagenic primers as described above. DNA agarose 
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Figure 4.2. Agarose DNA gels showing products from site-directed mutagenesis PCR 
reactions after DpnI digest. I, R48C; 2, R83C; 3, Kill C; and 4, V272C. M, hyperladder I 
marker (Bioline). 
DNA from reactions was used to transform TOP 10 E. coli cells, and the DNA 
purified from the cells using a Qiagen mini-prep kit. The mutant DNA was verified 
by DNA sequencing and was used for expression trials of the mutant proteins. 
PCR reactions for the R48C, R83C and V272C mutants yielded DNA that 
contained the correct specific mutations, however, the DNA sequenced from the 
Ki 1 IC reaction yielded only wild-type DNA. The reaction was repeated five times 
with no success: suggesting there was a problem with the DNA primers. 
4.1.2.3 Small-Scale Expression of Mutant of FbpA in E. co/i 
Expression trials of the mutant FbpA proteins were performed using small-scale 
(10 mL) cultures. The mutant protein was expressed in an identical fashion to the 
wild-type protein. Briefly, single colonies from a freshly transformed LB/amp agar 
plate were picked and used to inoculate 10 ml, of LB or 2xYT media containing 
ampicillin (100 1g/mL) and grown for 16 hours at 37 °C with agitation (250 rpm). 
Cultures were centrifuged for 10 min at 4000 x g and expression of the mutant 
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protein first checked visually by looking for the deep brown-red colour that is 
characteristic of the wild-type holo-protein, and then by SDS-PAGE. 
FbpA-R48C expressing pellets were brown-red in colour and two large bands 
were observed at the expected molecular mass of FbpA (-35 kDa; on SDS-PAGE), 
and at a mass twice that of FbpA (-67 kDa). This mutant was deemed suitable for 
further studies. 
FbpA-R83C expressing pellets were creamy-white in colour and no band was 
observed at the expected molecular mass of FbpA by SDS-PAGE (data not shown). 
It was assumed that the mutant DNA did not express. Several expression attempts 
were performed with no success, and thus, this mutant was deemed unsuitable for 
further study. 
FbpA-V272C expressing pellets were brown-red in colour and a large band 
was observed at the expected molecular of FbpA by SDS-PAGE. This mutant was 
deemed suitable for further studies. 
4.1.2.4 Large-Scale Expression of FbpA-R48C and FbpA-V272C in E. co/i 
Large-scale expression was carried out in an identical fashion to the wild-type 
protein. Two-litre cultures were prepared on both mutants and the resulting large 
cell pellets (-.7 g) were dark brown-red in colour, suggesting good expression of the 
mutant holo forms of the proteins. The pellets were stored at —20 °C until further 
purification. 
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4.1.2.5 Purification of FbpA-R48C and FbpA-V272C 
Purification of the mutant proteins was carried out in an identical fashion to the wild-
type protein, as described above. SDS-PAGE of the purification of FbpA-R48C and 
FbpA-V272C are shown in Figure 4.3. 
A. 
 






















Figure 4.3. A, SDS-PAGE of purified FbpA-R48C. 1, non-reducing conditions; 2, 
reduced (3-mercaptoethanoI) sample. The non-reduced sample revealed a band that was not 
present in the reduced sample. The band at 67 kDa (red arrow) was therefore assigned as a 
FbpA-R48C dimer and the other band assigned as monomer (yellow arrow). B, SDS-PAGE 
of purified FbpA-V272C. 1, non-reducing conditions; 2, reduced (3-mercaptoethano1) 
sample. Only the monomer (green arrow) was observed in the unreduced sample of FbpA-
V272C. 
Interestingly, the purification of the R48C mutant yielded two highly pure 
bands when run under partially denaturing conditions (no reducing agent in the 
loading buffer). The lower band was observed at a molecular mass of —34 kDa, 
which was the expected mass of FbpA-R48C, and the upper band was observed at 
—67 kDa. The upper band was assigned as FbpA-R48C dimer, as reducing SDS-
PAGE conditions yielded a single band at —34 kDa. The finding that —20% of the 
as purified" protein was in a dimeric form strongly suggested that the introduced 
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thiol group on the surface of the protein was both solvent exposed and reactive. The 
yield of the FbpA-R48C protein was estimated to be 30-40 mg/L culture. 
No such corresponding dimer was observed in the purified FbpA-V272C 
protein, as the SDS-PAGE yielded only one highly pure band at —34 kDa when non-
reducing and reducing conditions were tested. The finding that no dimer was present 
in the purified protein suggested that the introduced cysteine residue may not be 
solvent exposed and/or not reactive. The yield of the FbpA-V272C protein was 
estimated to be 40-50 mg/L culture. 
4.1.3 UV-Visible Spectroscopy of N. gonorrhoeae FbpA Mutants 
To investigate whether the mutant FbpA proteins showed the same UV-vis spectrum 
as the wild-type FbpA, both mutants were scanned over a range of 250-700 nm. The 
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Figure 4.4. Comparison of the UV-Visible spectra of wild-type FbpA (blue) compared 
to FbpA-R48C (pink) and FbpA-V272C (green); all -0.4 mglmL. Note the identical 
shape of all three curves, suggesting that iron binding is not altered in the mutant proteins. 
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The UV-vis spectra show that the holo forms of FbpA-R48C and FbpA-
V272C have almost identical UV-visible spectra when compared to wild-type holo-
FbpA, suggesting that the iron-binding site in the mutant proteins do not differ 
greatly from the wild-type protein. UV-visible spectra were also obtained of FbpA-
V272C modified with both maleimide-polyethylene-biotin (M-PE02-B) and 
iodoacetamidofluoroscein (JAF) to investigate if the modification interfered with iron 
binding. The spectra are shown in Figure 4.5. 
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Figure 4.5. A. UV-Visible spectra of wild-type FbpA (blue) compared to FbpA-V272C 
(pink) (both 0.4 mg'mL) and FbpA-V272C-(M-PE02-B) (red, 0.7 mg/mL). Note the 
virtually identical shape of all three curves, suggesting that iron binding is not altered in the 
modified mutant proteins. B. UV-Visible spectra of FbpA-V272C (red) compared to 
FbpA-V272C-IAF (green). The modified protein shows a large absorbance peak at 
—490 nm due to the presence of the iodoacetamidofluorescein moiety. 
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4.1.4 Mass Spectrometry of N. gonorrhoeae FbpA Mutants 
4.1.4.1 	Mass Spectrometry of Purified Mutants 
The accurate mass of the two mutant proteins was determined by electro-spray 
ionisation mass spectrometry (ESI-MS). All masses obtained are presented in Table 
4.2 and all spectra are provided in Appendix 2. 
FbpA-R48C: Due to the presence of the dimer observed by SDS-PAGE, an 
unreduced and reduced (using 1 mM TCEP) sample of the protein was subjected to 
ESI-MS. When the unreduced sample was analysed by ESI-MS a mass 
corresponding to the dimer (67 198 ± 11.4 Da) was observed, as well as masses for 
the monomer and several other peaks that suggested FbpA-R48C had also been 
modified by other molecules in vivo. The theoretical mass for FbpA-R48C is 
33 588 Da and a peak was observed at 33 583 ± 4.9 Da along with peaks at 
33 706.50 ± 4.9 Da (+118 Da) and 33 886.50 ± 4.9 (+300 Da) which were assigned 
as cysteinylation and glutathionylation (y-Glu-Cys-Gly) of the protein, respectively. 
On reduction with TCEP the ESI-MS spectra obtained yields only a single mass 
(33 585 ± 5.0 Da) that is in agreement with the theoretical mass of the R48C mutant. 
From this it was clear that the introduced cysteine mutation was reactive and had 
been modified in vivo by cysteine and glutathione. 
FbpA-V272C: On reduction with TCEP the mass obtained for FbpA-V272C 
was 33 640.86 ± 2.3 Da which is concordant with the theoretical mass expected for 
this mutant (33 643 Da). Since the theoretical mass for the mutant protein was four 
Daltons different from wild-type FbpA, it was not possible to prove from the mass 
spectrometry data alone that the V272C mutation had been correctly inserted. 
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4.1.4.2 Mass Spectrometry of Modified Mutants 
To verify that the mutant proteins could be derivatised using thiol reactive molecules, 
both mutant proteins were modified with a number of different prosthetic groups. 
FbpA-R48C: This mutant was modified with iodoacetamide and AMS (4- 
acetamido-4' -maleimidylstilbene-2,2' -disulfonic 	acid). 	Modification 	with 
iodoacetamide is an example of a S-amidomethylation reaction, whereas 
modification with AMS is via a maleimide moiety, by Michael addition to the 
reduced thiol group. Both derivatisations were successfully performed, but there 
were solubility issues with both modified proteins. Approximately 30% of the 
iodoacetamide modified protein, and more than 90% of the AMS modified protein 
precipitated during the reaction. Nevertheless, sufficient quantities of modified 
protein could be isolated for binding studies. Accurate masses were determined for 
both conjugated mutants. Masses obtained for the modified proteins are shown in 
Table 4.2. The iodoacetamide modified protein remained stable at 2-8 °C for several 
weeks, but the AMS modified protein continued to precipitate for several days after 
storage. 
Due to the solubility issues for the modified protein, and the position of the 
mutation on the rim of the metal-binding site, it was decided not to pursue binding 
studies with other component proteins of the ABC transporter with this particular 
protein. 
FbpA-V272C: This protein was successfully modified with iodoacetamide, 
iodoacetamidofluorescein and maleimide-polyethyleneoxide2-biotin (M-PE02-B). 
M-PEO2-B was the molecule to be used for attachment of the mutant protein to a 
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streptavidin-coated surface (chip) to perform protein-binding studies. The mass 
spectrum for the reaction product showed there was a mixture of modified and 
unmodified protein, with a ratio of about 65%:35% modified: unmodified protein. 
There was no precipitation of the protein during the reaction, and the modified 
protein was stable at 2-8 °C for several weeks. Accurate masses were obtained for 
the iodoacetamide and M-PEO2-B derivatised proteins, but no mass was obtained for 
the protein modified with iodoacetamidofluorescein. Masses obtained for the 
modified proteins are shown in Table 4.2. 
Due to the stability of the modified proteins, and the position of the mutation 
(away from the metal binding site) on the "underside" of the molecule, this protein 
was used to perform binding studies with the BC component proteins of the FbpABC 
ABC transporter. 
Table 4.2. Masses obtained for mutant proteins and derivatives. AMS: 4-acetamido-4'-
maleimidylstilbene-2,2' -disulfonic acid; M-PE02-B: maleimide-polyethyleneoxide-biotin; 
IAA: iodoacetamidofluorescein -: no mass obtained. 
Modification FbpA-R48C 	 FbpA-V272C 
Theoretical 
33 588 	 33 643 
mass 
67 198 ± 11.4 (dimer) 
33 585 ± 5.0 (monomer) 
As Purified 
	
	 33 640 ± 2.3 
33 706 ± 4.9 (cysteinylation) 
33 886 ± 4.9 (glutathionylation) 
lodoacetamide 33 644 ± 5.0 	 33 707 ± 6.7 
AMS 	33094±5.9 	 - 
M-PE02-B 	- 	 34 180 ± 4.9 
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4.1.5 Loading FbpA with Ruthenium 
4.1.5.1 Characterisation of Reloaded Ru-FbpA by UV-Vis 
UV-Visible spectra were recorded of a sample of apo-FbpA at various times after 
addition of RuC13. A peak was observed that appeared at 410 nm and which shifted 
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Figure 4.6. UV-visible spectra of FbpA incubated with RuCI3. Over time there is a band 
shift from 410-425 nm. Bands in this region are probably due to Ru d-d or charge-transfer 
transitions. 
4.1.5.2 Characterisation of Ru-FbpA by Chromatography 
Chromatography was performed by FPLC on a AKTA Basic] 00 (Amersham 
Biosciences) using a TricornTM  MonoS (GE Healthcare) cation exchange column. 
Two major peaks were observed at 280 nm (protein absorbance) and 430 nm 
(ruthenium absorbance) and several other minor peaks were also present: all peaks 
eluted between 190-220 mM NaCl (Figure 4.7). This revealed that ruthenium had 
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bound to FbpA and had resulted in at least three different species. Peak 1 and 2 were 
collected and concentrated by ultrafiltration (Viva Life Sciences, 10 000 Mr cut-off). 
I 
Figure 4.7. Chromatogram of Ru-FbpA purified by cation ion-exchange. Two main 
species were observed. Peaks 1 and 2 were resolved, collected and analysed by ICP-OES. 
Both protein species were associated with four ruthenium metal ions. Blue line: A280 
(protein absorbance); red line: A430 (ruthenium absorbance); green line: concentration 
percentage of buffer B. 
4.1.5.3 Characterisation of Ru-FbpA by ICP-OES 
The Ru:P:S ratio for the Ru-FbpA species in peaks 1 and 2 from the above 
chromatogram was determined by ICP-OES; the molar concentration of sulphur was 
used to assess the concentration of protein, as the each protein molecule contains one 
sulphur (methionine residue). The Analytical data are shown in Table 4.3. Multiple 
ruthenium binding was observed for both species. For both adducts the Ru:FbpA 
ratio was 4:1. 
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Table 4.3. ICP-OES analysis of peaks 1 and 2 from Figure 4.7. 
Sample 	 Mol element per mol protein 
Ru 	 P 
Peak 1 	 4.2 	 1.8 
Peak 	 4.1 	 1.2 
The data in Table 4.3 suggest the presence of two forms of a bound Ru4 cluster; one 
form capped by two phosphate (peak 1) ions and one capped by one phosphate (peak 
2). This is strongly reminiscent of the Fe3, Hf3 and Hf5 and Zr3 oxo clusters 
previously reported by our group, and an Fe4 cluster in FbpA reported by other 
researchers (1,8-10). However, an oxo-metal cluster capped by two phosphate 
molecules would be a novel species. When both species were analysed by ESI-MS, 
the ion-envelope obtained for the protein was that of apo-FbpA, thus signifying that 
ruthenium was lost from the protein during the ionisation process. This is common 
for metalloproteins as the metal ligand bonds are coordination bonds, which are 
weaker than covalent bonds. 
4.1.5.4 Characterisation of Reloaded Ru-FbpA by EXAFS 
Extended X-ray absorbance fine structure (EXAFS) analysis was performed on 
peaks 1 and 2 on Station 16.5 at the CCLRC SRS at Daresbury Laboratory, by 
beamline scientist Dr Ian Harvey. The X-ray absorbance near edge structure 
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Figure 4.8. A, XANES spectra of Ru-FbpA species present in peaks 1 and 2. Ru-FbpA 
spectra are almost identical apart from a small difference at —22 160 eV. B, EXAFS spectra. 
Both species yield very similar EXAFS spectra. C, Fourier transform of EXAFS data. 
The data suggests that the species are very similar, but do differ slightly in the bond lengths 
at —2.2-4 A. 
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The XANES spectra show the K edge absorbance spectra from which the 
oxidation state of the metal being probed can be determined. Initial findings suggest 
that the energy observed in the spectra are comparable with oxidation states of Ru(V) 
or Ru(VI), when compared to ruthenium oxidation-state standards. This is an 
unexpected finding and further investigation of this conclusion is required. 
Fourier transform of the EXAFS spectra revealed a main peak that fits 3-4 
oxygens at —2.05 A. There is also a small contribution at a shorter bond distance 
(1.2 A), however, this requires further investigation. The peaks at —2.7 A and 2.9 A 
do not fit either tyrosine- or histidine-type bonds, but may be a very small 
contribution from another ruthenium atom, possibly through a bridging oxygen, or 
may also be due to the possible presence of a phosphate synergistic anion. Analysis 
of the data is still in progress. 
4.1.6 Loading of FbpA with Osmium 
4.1.6.1 Characterisation of Os-FbpA by UV-Vis 
UV-Visible spectra were recorded of a sample of apo-FbpA at various times after 
addition of OsC13. A peak was observed at 360 nm that shifted to 370 nm over a 
period of 2 h (Figure 4.9). 
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Figure 4.9. UV-visible spectroscopy of FbpA incubated with OsC13. Over time there is a 
band shift from 360 to 370 nm in the osmium absorbance region. 
4.1.6.2 Characterisation of Os-FbpA by Chromatography 
Two major peaks were observed at 280 nm (protein absorbance) and 330 nm 
(osmium absorbance): both peaks eluted from the cation exchange column between 
190-220 mM NaCl (Figure 4.10). This revealed that at least two different species 
formed after the addition of OsC13 to apo-FbpA. Peaks 1 and 2 were collected and 
concentrated by ultrafiltration (Viva Life Sciences, 10 000 Mr cut-off). 
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mAU 	 1 
Figure 4.10. Chromatogram of Os-FbpA purified by cation ion-exchange. Two main 
species were observed (Peaks 1 nd 2). Blue line: A280 (protein absorbance); red line: A350 
(osmium absorbance); green line: concentration percentage of buffer B. 
4.1.6.3 Characterisation of Os-FbpA by ICP-OES 
The Os:P:S ratio of the species formed that are represented by peaks 1 and 2 from the 
above chromatogram were determined by ICP-OES; the molar concentration of 
sulphur was used to assess the concentration of protein, as the each protein molecule 
contains one sulphur (methionine residue). The results are shown in Table 4.4. 
Table 4.4. ICP-OES analysis of peaks 1 and 2 from Figure 4.10. 
Sample 	 Mol element per mol protein 
Os 	 P 
Peak 1 	 4.0 	 1.9 
Peak 	 3.9 	 1.3 
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The data in Table 4.4 suggests the presence of two forms of Os4 cluster with ratios of 
Os:P:S of ca. 4:2:1 ratio for peak 1, and 4:1:1 for peak 2. This suggests that two 
forms of Os4 cluster can bind to FbpA; one form capped by two phosphates (peak 1) 
and one capped by one phosphate (peak 2). The behaviour of osmium(ITI), like 
ruthenium(III) above, is strongly reminiscent of that for iron(III), hafnium(IV) and 
zirconium(IV) oxo clusters previously reported for FbpA (1,8,9). However, an oxo-
osmium cluster capped by two phosphate molecules would be a novel FbpA species. 
There was insufficient sample to allow characterisation by mass spectrometry, 
however, it may be assumed that the bound metal ions would dissociate during the 
ionisation process as observed for the ruthenium adduct. 
4.2 	Discussion: FbpA 
4.2.1 FbpA Purification and Modification of Mutant Proteins 
The purification of FbpA was optimised by changing buffer systems and by the use 
of a batch purification method. The new procedure reduced purification time from 
three days, to a one-day process. Large quantities of very pure protein were 
produced in a single purification step in a short time. This new method limits the 
time that the protein is in contact with proteases that may be present in the cell-free 
extract, and thus reduces the potential risk of degradation during purification. 
FbpA was successfully mutated to incorporate a single thiol residue and 
allowed covalent modification with several functional prosthetic groups. Mutations 
were classified by the position of the mutation of the surface of the protein using a 
system outlined by Hellinga and co-workers (3). FbpA-V272C was modified to 
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yield a biotinylated FbpA (FbpA-V272C-(maleimide-polyethyleneoxide2-biotin)) 
that allowed attachment of the mutant protein to a streptavidin-coated surface for 
protein-protein interaction studies with FbpB and C (Chapter 5). FbpA-V272C was 
also modified with a fluorescent tag (iodoacetamidofluoroscein; IAF) to allow 
complex formation studies in future work. Accurate masses were determined for the 
unmodified protein and for FbpA-V272C-(maleimide-polyethyleneoxide2-biotin), 
but not for FbpA-V272C-IAF. All masses obtained were within experimental error. 
Interestingly, the mutant FbpA-R48C formed a dimer in vivo - the first time 
such a bacterial two-lobe "pseudo-transferrin" molecule has been described. The 
monomeric form of FbpA-R48C was modified with iodoacetamide and 4-acetamido-
4'-maleimidylstilbene-2,2'-disulfonic acid. These probes were used to determine the 
reactivity of the introduced thiol group, but showed that, although the protein could 
be modified in vitro, the resulting derivatised proteins were unstable. Accurate 
masses were determined for the unmodified protein, including the observed dimer, 
and for FbpA-R48C-iodoacetamide and FbpA-R48C-AMS. The instability of the 
modified proteins may have been because residue 48 may play an important role in 
maintaining tertiary structure of the protein, and modification at this position causes 
denaturation of FbpA. 
This study has shown that FbpA from N. gonorrhoeae is a suitable protein for 
mutational studies, and can be modified and employed as a tool for performing 
binding studies with the other gene products of the FbpABC operon: FbpB and FbpC. 
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4.2.2 Loading of FbpA with Ruthenium and Osmium 
FbpA was loaded with the transition metal ions ruthenium(III) and osmium(III) in 
order to further investigate the specificity of the metal-binding site. Both metals 
were found to bind to FbpA, and appeared to form very similar species that could be 
separated chromatographically. 
The finding by ICP-OES and EXAFS (for the ruthenium species) that FbpA 
bound four atoms of either ruthenium or osmium is similar to results previously 
published for iron(III), hafnium(IV) and zirconium(IV) clusters in FbpA (1,8,9). 
Assuming that the metals have bound as a cluster, and not at four distinct binding 
sites elsewhere on the protein, the possible presence of a oxo-metal cluster 
potentially capped by two phosphate ions is novel for metal clusters bound to FbpA. 
EXAFS revealed that the ruthenium cluster present in the Ru-FbpA, may contain 
ruthenium in the (V) or (VI) oxidation state, which would be very unusual, as, 
although ruthenium can rarely form these oxidation states as well as the (VII) and 
(VIII) oxidation states, this metal is usually found in the form of Ru(H), Ru(III) or 
Ru(IV) in aqueous systems (Ru(IV) being readily reduced to Ru(III) in such systems) 
(11). From previous work on FbpA, it is known that the protein can stabilise higher 
oxidation states of bound metal clusters, as revealed in the oxo-(Fe'11)3, oxo-
(Hf'')3 & 5, Ti(IV) and oxo(ZrnT)3  FbpA crystal structures (1,8,9,12). However, if the 
ruthenium clusters in FbpA do contain ruthenium in the (V) and/or (VI) oxidation 
states, this would be unexpected, and would be the first report of such clusters bound 
to a protein. 
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Ruthenium and osmium oxo-bridged clusters have been described in the 
literature, although oxo-Ru4 and oxo-0s4 clusters are relatively rare. A search of the 
Cambridge Crystallographic Data Centre (CCDC) revealed that only two structures 
containing Ru4, and one Os(IV)4, hydroxo-bridged clusters have been determined 
(13-15), and all the clusters had been produced synthetically. Tr-Ru and -Os 
clusters and higher number (5, 6, 8 and 9) clusters of both metals are more 
commonly described in the literature, and the clusters often contain other metals 
(such as molybdenum). There were also several examples of M-phenoxide (M = Ru 
or Os) bonds in the CCDC, but most were present with a second, chelating bond 
from another position on the adjacent aromatic ring. Three examples could be found 
of a single M-phenoxide bond for each metal (16-19), suggesting that these bounds 
can be formed. 
If the Ru- and Os-FbpA species isolated in this study contain oxo-metal 
clusters, maintained in unusually high oxidation states, and bound via one or two 
tyrosine residues, this would be of great interest with regards to how this protein 
binds these precious metals, and how FbpA stabilises these metal clusters in high 
oxidation states. 
Preliminary crystal screens performed on both the ruthenium and osmium 
reloaded proteins did not yield any crystals, although different conditions may allow 
the structures of both proteins to be determined in the future. 
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5.1 	Results: FbpC 
5.1.1 Bioinformatic Analysis of N. gonorrhoeae FbpC 
Due to the lack of published literature on this protein, some preliminary 
bioinformatic studies were performed on the amino acid sequence of FbpC. 
FbpC is encoded for by the third gene in the FbpABC operon: FbpC, 1059 bp. 
Bioinformatic analysis of the amino acid sequence using Vector NTI v9 (Invitrogen) 
revealed that the mature protein is predicted to contain 352 amino acids and have a 
molecular mass of 37 900 Da (Appendix 1). The protein has a predicted p1 of 6.91, 
making the protein have no overall net charge at physiological pH. Other 
biochemical characteristics of the protein are summarised in Table 5.1. 
Table 5.1. Amino acid composition of FbpC. The protein is composed of -40% 
hydrophobic residues, suggesting that the protein may have solubility problems in aqueous 
buffers. 
Amino acids 	Number 	 % by weight 	% by frequency 
Hydrophobic 136 37.08 38.64 
Charged 89 31.13 25.28 
Polar 79 22.74 22.44 
Basic 34 12.82 9.66 
Acidic 35 11.17 9.94 
Bioinformatic analysis of the amino acid composition of FbpC revealed that a 
large proportion of the amino acid sequence is comprised of hydrophobic residues, 
suggesting that the protein may not be soluble in aqueous buffers. However, 
hydrophobicity profiling using a topology prediction programme (TMHMM) 
available on the ExPASy (Expert Protein Analysis System) Proteomics server 
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revealed that FbpC is expected to be a soluble protein with no transmembrane helices 
(Figure 5.1). The probability of the protein containing any transmembrane domains 
was virtually zero for the entire amino acid sequence. The degree of hydrophobicity 
of the protein is perhaps not surprising considering that FbpC is expected to be 
closely associated with the cytoplasmic side of the cytoplasmic membrane. 









50 	100 	150 	200 	250 	300 	350 
transmembrane 	 inside 	 outside 
Figure 5.1. Topology modelling of FbpC. Using the topology modelling program 
TMHMM v2, FbpC is predicted to be a soluble protein with no predicted transmembrane 
helices (red line). This figure should be compared with Figure 5.12 "Topology modelling 
of FbpB" which shows predicted transmembrane helices for that protein. 
The Basic Local Alignment Search Tool (BLAST) was used to identify 
known proteins with similar alignment sequences. The results are summarised in 
Table 5.2. 
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The BLAST results reveal that the ABC transporter family ATPases show 
very high sequence homology between individual family members, not only between 
the iron ABC transporters, but amongst members of the family that transport diverse 
ligands. Proteins with E values of less than 10 are considered to have "good" 
identity to the query sequence. Of the BLAST search performed for this study the 
top 100 hits all had E values of 10 49 or less, suggesting that this very large diverse 
family share significant sequence homology between transporters that transport 
diverse ligands. Included in the first 100 hits were many iron ABC transporter 
ATPases and putative ATPases from ABC transporters, but also 
spermidine/putrescine, sulfate and polyamine ABC transporter ATPases. 
When the amino acid sequence of FbpC was aligned with the four proteins 
for which the crystal structures have been determined discussed in Section 2.1.4 
(2 x Ma1K, HisP and BtuD), it is clear that FbpC contains all the characteristic 
elements of a NBD from the ABC transporter family. FbpC contains Walker A and 
B motifs, as well as the Q-loop, H-Loop, D-loop and ABC signature sequences. It 
also revealed that the amino acid identity is highest for the Ma1K sequences and 
lowest for BtuD protein: 31.6% identity (46.4% consensus) with T.l.Ma1K, 27.6% 
identity with E.c.Ma1K, 22.6% identity (34.6% consensus) with His P, and only 
16.7% (28.4% consensus) with BtuD. Not surprisingly, this high homology with 
Ma1K is due in part to the presence of a —80 amino acid C-terminal extension 
observed in FbpC, suggesting that the protein may contain a similar domain to that 
found in these two proteins. Amino acid sequence alignments are shown in Figure 
5.2 and 5.3. 
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FbpC was modelled using the T.l.Ma1K structure as a template using Swiss-
Model database on the ExPASy Proteomics server. The modelled theoretical 
structure of FbpC is shown in Figure 5.4, and reveals that FbpC should adopt a 
similar overall fold as is found in these proteins. 
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A. 	 B. 
Figure 5.4. A, Model of the predicted structure of N.g.FbpC using T.l.MaIK (B) as a 
template. Note the similarity of both structures, including the C-terminal extension present 
in FbpC that is proposed to be involved in signal transduction (1). 
5.1.2 Cloning of FbpC from N. gonorrhoeae Genomic DNA 
Ferric-ion binding protein C (FbpC) gene was amplified from Neisseria gonorrhoeae 
genomic DNA by PCR using the primers FbpC NcoI For and FbpC XhoI Rev. 
Primers were designed to incorporate NcoI and XhoI restriction enzyme sites at the 5' 
and 3' end of the gene, respectively. The resulting PCR product was cloned into 
cloning vector pGEM T-Easy (Promega) and the constructs verified by DNA 
sequencing. Plasmid containing the FbpC gene insert was digested with NcoI and 
XhoI and the fragment corresponding to the correct insert size (-1050 bp) was ligated 
into pET-28a expression plasmid (Novagen) cut with NcoI and XhoI. This vector 
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was chosen in order to incorporate a hexahistidine tag on the C-terminal of the 
protein. The ligation mixture was transformed into DH5a E. coli cells (Invitrogen) 
and the plasmid DNA purified (Qiagen mini-prep). Restriction digests confirmed the 
presence of the correct sized insert, and the construct containing FbpC was named 
pET-28alFbpCINg. The hexahistidine tagged protein was expected to have a 
molecular mass of 38 808 Da (359 amino acids) by Vector NTI bioinformatic 
















B. 	 XhoI 
NcoI/ 
pET-28a/Fb pc/N g 
6286 bp laci 
Kan 
Figure 5.5. A. Agarose DNA gel showing the PCR product from reaction from N. 
gonorrhoeae genomic DNA. The DNA fragment corresponding to the FbpC gene is 
highlighted (arrow). B. Vector map of pET-28aJFbpCINg. 
5.1.3 Expression of N. gonorrhoeae FbpC-His6 in E. coil 
pET-28alFbpC/Ng plasmid was transformed into E. coli expression strain 
BL21(DE3) and grown on LB/kanamycin (30 jig/mL) agar plates. Small-scale 
inductions in this broth at 37 °C with 1 mM IPTG for 3 hours produced large 
quantities of FbpC. However, when large-scale inductions repeated these conditions 
it was discovered that —90% of the expressed protein was insoluble (possibly by 
forming inclusion bodies), so alternative induction conditions were tested. 
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Conditions that yielded the highest expression of soluble protein were chosen for 
large-scale expression. Induction at 0D600 0.8 with 0.2 mM IPTG for 4-5 hours at 
25 °C gave the best expression of soluble protein. Terrific broth was chosen as the 
preferred medium as this broth allowed high-density cell growth that produced large 
quantities of soluble FbpC. Other media tested were 2xYT and an auto-induction 
media, but this, and the use of different E. coli expression cell lines (HMS 1 74(DE3) 
and B834(DE3)) produced less overall soluble protein. 
5.1.4 Purification of N. gonorrhoeae FbpC-His6 
Several methods of purification were investigated to obtain pure FbpC-His6. Ni2 -
affinity chromatography was used as a first step purification in all trials, and several 
different affinity resins from various commercial sources were tested. Ni2 -NTA 
Sepharose High Performance resin (GE Healthcare), Ni2 -NTA agarose (Invitrogen) 
and His-Link silica resin (Promega) all bound FbpC-His6 to high capacity 
(>2 mg/mL FbpC-His6/mL resin), but differed in the amount of unspecific binding 
of non-His-tagged proteins in the cell-free extract. Ni2tNTA Sepharose High 
Performance resin bound FbpC-His6 to the highest capacity, but also bound large 
amounts of untagged protein (>30%), possibly via anionic interactions with the 
resin. Increasing the concentration of NaCl did not decrease the amount of non-
specific binding, nor did increasing the concentration of imidazole in the wash buffer 
(this caused leaching of the bound FbpC-His6 into the wash fractions). Ni2 -NTA 
agarose had less unspecific protein binding to the resin (< 10%), but had the lowest 
binding capacity of all three resins, whereas the His-Link resin had an acceptable 
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level of unspecific binding (< 10%) to the resin but also had a high binding capacity. 
His-Link resin was therefore chosen for the first round of purification of FbpC-His6. 
The optimum concentration of imidazole in the load and wash buffers was 
determined to be 20 mM and 50 mM, respectively, and 250 mM in the elution buffer. 
Attempts to dialyse the protein into wash buffer containing no imidazole resulted in 
the precipitation of FbpC-His6, even at 4 °C. Desalting by PD1O column resulted in 
loss of >80% of the protein, and thus protein was frozen (-20 °C) at this stage if it 
was to be stored for any more than a few hours, until further purification (Figure 
5.6). 
1 2 3 4 5 6 7 8 9 10 
'M vow 
Figure 5.6. SDS-PAGE of Ni2 -NTA purification of FbpC-His6. Lanes 1-6, cell-free 
extract, flow-through and wash fractions; lanes 7-10, elution fractions containing FbpC-His6 
(-40 kDa; red arrow). 
As a second round of purification, anion exchange chromatography (Capto Q; 
GE Healthcare) was originally chosen. This did provide relatively pure protein 
(-98% by SDS-PAGE), but purity varied from batch to batch and -10% of FbpC was 
lost during the process. Therefore other methods were investigated. Gel filtration 
with a 26/60 Sephadex 75 High Performance Prep Grade (GE Healthcare) did not 
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in the buffers. It was also noted that -15% of the total FbpC-His6 was lost during 
this type of purification. Cobalt-affinity chromatography (TALON resin; Clontech) 
was performed to investigate if the final purity and recovery of FbpC-His6 could be 
improved. This form of affinity chromatography binds hexahistidine tags with 
higher specificity, thus improving purity, but with lower affinity. The trade-off for 
this higher specificity is that the resin has a much lower binding capacity (-1-
5 mg/mL resin) compared with Ni2 -NTA resin (typically 10-20 mg/mL resin). This 
purification step required dilution of the protein from the first round of purification 
with wash buffer (containing no imidazole) to reduce the concentration of imidazole 
to -20 mM and then incubation with equilibrated TALON (Co2taffinity) resin 
(Clontech) for 1-2 hours. The resin was then washed in a similar fashion to the first 
round of purification except that the concentration of imidazole was kept at 20 mM, 
and the bound protein eluted with 200 mM imidazole. This method yielded the 
purest protein (>99% by SDS-PAGE) with the best recovery (>95%), and thus this 
two-stage affinity purification was chosen as the preferred method for the 
purification of FbpC-His6 (Figure 5.7). 









Figure 5.7. SDS-PAGE of TALON resin purification of FbpC-His6. Lanes 1-6, flow-
through and wash fractions; lanes 7-10, elution fractions containing pure FbpC-His6 
(-40 kDa; red arrow). 
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Purified FbpC-His6 was routinely stored at —20 °C in aliquots with no loss of 
activity after repeated freeze-thaw cycles. 
The yield of soluble FbpC was typically determined to be —5 mg/L cell 
culture. 
5.1.5 Expression of SeMet labelled N. gonorrhoeae FbpC-H1s6 in E. coil 
Selenomethionine labelling of FbpC was conducted to aid crystal structure 
determination, and involved replacing native methionine residues in the protein with 
the selenium containing analogue. This introduces a heavy atom(s) into the protein 
that allows for phasing of the crystal structure. Two different methods of 
selenomethionine labelling were attempted. The first of these was by a method 
published by Studier and co-workers, that utilises an auto-inducing SeMet labelling 
protocol (2). This procedure did not produce high amounts of soluble SeMet labelled 
FbpC, and thus another method for SeMet labelling was sought. 
A novel method was optimised for the production of large quantites of SeMet 
labelled protein based on an existing minimal media protocol (3). Briefly, to a lx 
M9 salts media was added MgSO4, glucose, thiamine and biotin (as essential co-
factors), and a trace metal solution containing a high concentration (10 MM) iron (to 
allow the production cytochromes for aerobic growth). 	BL21(DE3) cells 
transformed with pET-28aJFbpC!Ng were grown in this media (typically 6 L culture) 
to an 0D600 of 0.7-0.8, and then amino acids (K, F, T, I, L and V) and 
selenomethionine were added. Vitamin B12  was also added to stimulate the 
regeneration of selenomethionine from selenohomocysteine via the homocysteine 
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methyltransferase pathway (MetH) (2). Growth was continued for 15 min to allow 
the inhibition of methionine synthesis to start, and then the cells were induced with 
0.2 mM IPTG for 3 hours at 25 °C. Induction at 37 °C with 1 mM IPTG produced 
large amounts of insoluble protein in a similar fashion to that observed for the wild-
type protein. The cells would routinely grow to an 0D600 of 4-5 at 25 °C. 
5.1.6 Purification of SeMet labelled N. gonorrhoeae FbpC-His6 
SeMet labelled FbpC-His6 was purified using an identical method that was optimised 
for the wild-type protein. A reducing agent (1 mM TCEP) was added to all buffers 
throughout the purification to inhibit the oxidation of selenomethionine residues that 
had been incorporated into the protein. The yield of SeMet labelled FbpC-His6 was 
determined to be 2-5 mg/L culture (Figure 5.8). 
A. B. 
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Figure 5.8. A. SDS-PAGE of Ni2 -NTA purification of SeMet-FbpC-His6. Lanes 1-6, 
cell-free extract, flow-through and wash fractions; lanes 7-10, elution fractions containing 
SeMet-FbpC-His6 (-40 kDa). B. SDS-PAGE of TALON resin purification of SeMet-
FbpC-His6. Lanes 2-5, elution fractions containing pure SeMet-FbpC-His6 (-40 kDa; red 
arrow). 
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SeMet labelled protein was no less stable that wild-type FbpC-His6 and was 
stored at -20 °C with no loss of activity. Incorporation of selenomethioine residues 
and the number of SeMet per molecule of FbpC could not be confirmed by mass 
spectrometry (data not shown). 
5.1.7 ATPase Activity of Wild-Type and SeMet labelled N. gonorrhoeae 
FbpC-His6 
5.1.7.1 ATPase Activity of Wild-Type N. gonorrhoeae FbpC-His6 
Several different methods of determining the amount of ATP hydrolysis were 
investigated, including a pyruvate kinase/lactose dehydrogenase (PKJLDH) assay, a 
malachite green assay and a commercially available kit (EnzCheck) manufactured by 
Invitrogen (4,5). However, the presence of high concentrations of glycerol and ATP 
in the reaction buffer caused interference with all of these colorimetric assays, and 
yielded erroneous results. The assay eventually chosen for the determination of the 
ATPase activity of FbpC-His6 did not suffer from these interferences, and measured 
the amount of inorganic phosphate (P1) liberated by the hydrolysis of ATP. The 
assay is dependent upon the formation of a complex between phosphate and 
molybdate in acid solution to form a yellow-coloured phosphomolybdate complex 
112 M003 + H2PO4 	fr (H2PMo12040)1. The phosphomolybdate complex is 
then reduced by ascorbic acid, causing a characteristic molybdenum blue species that 
has an absorbance maximum at 850 nm (6,7). Results of the ATPase assay for wild-
type assay are presented in Figure 5.9. 
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Figure 5.9. ATPase assay of FbpC. The activity of the protein was determined to be 0.4-
0.6 imo1s P, liberated/mm/mg of FbpC-His6. • Assay plus M902, [I assay minus M902. 
Results are an average of three repeats. 
Analysis of the rate of ATP hydrolysis yielded that the activity of wild-type 
protein was in the range of 0.4-0.6 mols P, liberated/mm/mg of FbpC-His6. Analysis 
of the kinetics of ATP hydrolysis could not be fitted to Michaelis-Menton analysis, 
as at low ATP concentrations FbpC was insoluble. 
5.1.7.2 ATPase Activity of SeMet Labelled N. gonorrhoeae FbpC-His6 
The effect of incorporation of selenomethionine residues upon ATPase activity was 
determined by the same method as that performed for the wild-type protein. Results 
of the ATPase assay performed on SeMet labelled FbpC-His6 are presented in 
Figure 5.10. 
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Figure 5.10. ATPase assay of SeMet-FbpC-His6. The activity of the protein was 
determined to be 0.4-0.6 imols P, liberated/mm/mg of SeMet-FbpC-His6. • Assay plus 
M902, D assay minus M902. Results are an average of three repeats. 
Analysis of the rate of ATP hydrolysis yielded that the activity of wild-type 
protein was in the range of 0.4-0.6 mols P, liberated/min/mg of SeMet-FbpC-His6. 
Again, Analysis of the kinetics of ATP hydrolysis could not be fitted to Michaelis-
Menton analysis, as at low ATP concentrations FbpC was insoluble. 
5.1.8 Peptide Mass Fingerprinting of N. gonorrhoeae FbpC-His6 
SDS-PAGE was performed on a sample of FbpC-His6. The band proposed to be 
FbpC-His6 was cut-out of the gel and was subjected to in-gel tryptic digest. Analysis 
of the peptide fragments obtained from the tryptic digest identified FbpC from N. 
gonorrhoeae as a best match with a MOWSE score of 2.2 x 106.  The next closest 
match had a MOWSE score of 90.4. 
The MALDI-TOF spectrum obtained for the in-gel trypsin digest of the gel 
band observed at —40 kDa is provided in Appendix 3. 
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5.1.9 Crystallisation Trials of N. gonorrhoeae FbpC-H1s6 
Crystallisation trials were carried out in collaboration with Dr Simon Newstead 
working in Prof So Iwata's Membrane Protein Crystallography Group at Imperial 
College, London. 
Conditions that yielded crystals are summarised in Table 5.3. 
Table 5.3. Crystallisation conditions that yielded crystals of FbpC. 
Crystallisation condition 
0.2 M magnesium acetate tetrahydrate, 0.1 M sodium cacodylate pH 6.5, 20% PEG 8000 
0.2 M calcium acetate hydrate, 0.1 M sodium cacodylate pH 6.5, 18% PEG 8000 
0.2 M calcium acetate hydrate, 0.1 M MES pH 6.0, 20% PEG 8000 
0.2 M magnesium acetate tetrahydrate, 20% PEG 3350, pH 7.7 
0.1 M succinic acid pH 7.0, 15% PEG 3350 
0.15 M DL-malic acid pH 7.0, 20% PEG 3350 
0.2 M sodium malonate, 20% PEG 3350 
0.2 M sodium bromide, 0.1 M Bis-tris propane pH 6.5, 20% PEG 3350 
0.2 M calcium chloride, 0.1 M MES pH 6.50, 20% PEG 6000 
0.1 M sodium chloride, 0.1 M sodium HEPES pH 7.5,12% PEG 4000 
0.1 M tris HC1 pH 8.5, 10% PEG 8000 
0.1 M potassium chloride, 0.01 M magnesium chloride, 0.05 M MES pH 6.0, 10% PEG 
400 
0.1 M potassium chloride, 0.01 M magnesium chloride, 0.05 M sodium cacodylate 
pH 6.5, 30% PEG 4000 
0.08 M magnesium acetate, 0.05 M sodium cacodylate pH 6.5, 30% PEG 4000 
0.1 M potassium chloride, 0.1 M magnesium acetate, 0.05 M sodium cacodylate pH 6.5, 
10% PEG 8000 
Crystals of wild-type and Se-Met-FbpC were obtained in several of the 
screening conditions, however, crystals that produced the highest resolution 
diffraction data of 2.7 A crystallised out of 0.2 M calcium chloride, 0.1 M MES 
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buffer pH 6,50 and 20% PEG 6000 (Figure 5.11). Preliminary modelling of the data 
suggested two molecules per asymmetric unit. 
 
 
FbpC WT crystals lD23eh2 
Figure 5.11. A. Crystals of wild-type FbpC that diffracted to 2.7'k. Crystallisation 
conditions were 0.2 M CaCl2. 0.1 M MES buffer pH 6.50 and 20% PEG 6000. B. X-ray 
diffraction pattern from crystals shown in A. Crystals were analysed at the ESRF 
synchrotron radiation source (SRS) in Grenoble, France, and the CCLRC Daresbury SRS, 
UK. 
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The structure of FbpC shows strong homology with other members of the 
NBDs from ABC transporters: The functional complex is composed of a dimer of 
two FbpC subunits (Figure 5.12). The structure obtained in this study appears to 
have Ca 2+-ATPbound at the interface of the two subunits. The ATP bound form was 
probably isolated due to the high concentrations of Calcium (0.2 M) in the 
crystallisation buffer keeping the ATP in a non-hydrolysable conformation. The C-
terminal regulatory domain appears to have novel fold not previously described for 
an ABC transporter NBDs. Full analysis of the data is pending. 
Figure 5.12. 2.71 crystal structure of FbpC from N. gonorrhoeae. Various views of the 
FbpC dimer. The FbpC monomers have been coloured red and blue, ATP in ball and stick 
representation and calcium ions is shown in CPK green. Note the highly structured C-
terminal regulatory domain. 
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5.1.10 Discussion: FbpC 
5.1 .10.1 Bioinformatic Analysis of FbpC 
FbpC is proposed to be the nucleotide-binding domain (NBD) of the FbpABC iron-
uptake ABC transporter. FbpC is expected to form a dimer located on the 
cytoplasmic face of the cytoplasmic membrane in the active form of the complex, 
and is thought to provide the power-stroke for ligand translocation across the 
cytoplasmic membrane, via FbpB. Bioinformatic analysis of the amino acid 
sequence of FbpC revealed that the protein contains all of the ATPase motifs that 
define this very large family of enzymes. Sequence alignment between FbpC and 
other members of the NBD from bacterial ABC importers that transport unrelated 
substrates revealed that FbpC contains a C-terminal domain that is likely to play a 
role in signal transduction within the cytoplasm. This study is the first to highlight 
the possible dual role of FbpC in vivo: ATPase domain for substrate translocation 
and a signal transduction domain. These sequence alignments, along with the 
BLAST results, also emphasise the highly conserved homology among this family of 
proteins. Interestingly, the BLAST search using the amino acid sequence of FbpC 
yielded top 20 results that revealed matches for NBD that transport diverse ligands, 
and very few involved in iron transport. This shows that although a consensus 
homology is conserved within this protein family, the amino acid sequence varies 
between the iron-uptake NBD. 
5.1.10.2 Expression and Purification of FbpC-His6 
Optimisation of the expression and purification of FbpC-His6 was performed based 
on a partially described method (8). FbpC-His6 was purified to a high level using 
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Ni2 and CO2taffinity chromatography, and yields of typically 10-20 mg of protein 
were produced (2-4 mg/L). FbpC-His6 was assayed to determine the activity of the 
enzyme by the use of a previously described ATPase and colorimetric assay (6,7,9). 
The results of the assays were concordant with values previously published for 
FbpC-His6 (8). This previous work (8) determined the rate of ATP hydrolysis by 
FbpC-His6 to be 0.5 ± 0.1 pmole P, liberated/min/mg enzyme: results that are 
supported by this study. This study also positively identified FbpC-His6 by peptide 
mass fingerprinting, however, no accurate mass of full-length FbpC-His6 could be 
determined by ESI-MS due to ionisation problems. 
Pure FbpC-His6 was sent to Imperial College for crystallographic screening 
in order to elucidate the structure of the protein. 
5.1.10.3 Expression and Purification of SeMet-FbpC-His6 
Selenomethionine labelled FbpC-His6 was produced to facilitate crystal structure 
determination. The protein was labelled by a modification previously described that 
allowed yields of up to 10 mg to be produced and purified (2). Purification was 
performed using a two-stage metal-affinity chromatography method: Ni2 -NTA 
purification followed by TALON resin (Co 2 -NTA) chromatography. This 
purification produced very pure protein (as determined by SDS-PAGE). SeMet-
FbpC-His6 was determined to have the same enzymatic activity as the wild-type 
protein. The SeMet-labelled protein was sent to Dr Simon Newstead at Imperial 
College for crystallographic studies. 
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5.1.10.4 Crystallisation Studies of FbpC-His6 
The X-ray crystallography yielded the 2.7 A structure of FbpC, and that the NBD 
contains two molecules per unit cell. This is similar to previously published 
structures of the nucleotide binding domains of the histidine, vitamin B 12  and maltose 
ABC transporters from other Gram-negative bacteria: the resolution of these 
structures range from 1.5-3.2 A, and all have two molecules per unit cell (1,10,11). 
The structure of FbpC obtained had Ca2tATP  bound and contains a regulatory 
domain with a novel fold, analogous to that found in Ma1K, that is proposed to play a 
role in signal transduction within the cell (1). 
5.2 	Results: FbpBC 
5.2.1 Bioinformatic Analysis of FbpB 
FbpB is encoded for by the second gene in the FbpABC operon: FbpB, 1527 bp. Due 
to the lack of published literature on FbpB, preliminary bioinformatic analysis was 
performed on the amino acid sequence (Appendix 1). Bioinformatic analysis of the 
amino acid sequence using Vector NTT v9 (Invitrogen) revealed that the mature 
protein is expected to contain 509 amino acids and have a molecular mass of 
56 310 Da. The protein has a predicted p1 of 9.67, making the protein cationic at 
physiological pH. Other biochemical characteristics of the protein are summarised in 
Table 5.4. 
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Table 5.4. Amino acid composition of FbpB. The protein is composed of 50% 
hydrophobic residues, a common finding in membrane proteins. 
Amino acids 	Number 	 % by weight 	% by frequency 
Hydrophobic 256 50.32 50.29 
Polar 120 23.53 23.58 
Charged 85 20.55 16.70 
Basic 36 8.81 7.07 
Acidic 19 4.14 3.73 
Bioinformatic analysis of the amino acid composition of FbpB revealed that 
50% of the amino acid residues are hydrophobic. This, combined with the low 
percentages of charged, acidic and basic residues, suggests that the protein will be 
insoluble in aqueous buffers. This is common for integral membrane proteins and 
hydrophobicity profiling of FbpB using topology prediction programmes (TMHMM 
and TopPred) available on the ExPASy (Expert Protein Analysis System) 
Proteomics server revealed that FbpB is expected to contain 12 transmembrane 
helices. This indicates that the assembled homodimeric transporter will be composed 
of 24 transmembrane helices in all (Figure 5.13). This modelling also revealed that 
the N- and C-terminals of FbpB are expected to be cytoplasmic. 
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Structure no. 1 	 Segment Putative 
Segments included: 1 2 3 4 5 6 7 8 9 10 11 12 
Segment Certain 
CYTOPLASM 
L1r9 	-1 	14 	1-1 	35 	 L1 r30 	 Li13 	-1 	31 	 Lizi 
K5z3 KR z3 KR r5 KR KRz3 KR KRz3 
Li 31 L13 	 -1 22 	 -1 27 L14 	 L132 
KR 	KRr1 KR KR 	KrO KR z2 
LI: Loop length 	 EXTRACELLULAR 
KR: Number of Ls and Are 
Figure 5.13. Topology mapping of the amino acid sequence of FbpB. FbpB is predicted 
to contain 12 transmembrane helices when the amino acid sequence is analysed using the 
topology mapping programmes TMHMM (top) and TopPred (bottom). 
The Basic Local Alignment Search Tool (BLAST) was used to identify 
known proteins with similar alignment sequences and the results are summarised in 
Table 5.5. 
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The results of the BLAST sequence analysis reveal that the sequence of N. 
gonorrhoeae FbpB shares the highest homology (90-99%), perhaps not surprisingly, 
to several strains of the Neisseria spp FbpB. It also showed significant homology 
(-71%) to the permease component (HitB) of various strains of the H. influenzae 
iron-uptake ABC-transporter, HitABC. Interestingly, FbpB also shares considerable 
homology (-45%) with the permease component of iron-uptake ABC transport 
systems and other putative ABC-type permeases from the Pseudomonas spp. Unlike 
FbpC, the FbpB homology shows that the proteins that share closest homology are 
all involved in iron transport, strongly suggesting that permeases involved in the 
transport of similar ligands share the strongest sequence homology. 
5.2.2 Cloning of FbpBC from N. gonorrhoeae Genomic DNA 
Two different FbpBC constructs were prepared for this study: pETDuet-
l/FbpB/FbpC/Ng and pET-28aIFbpBCfNg. The pETDuet construct incorporates an 
N-terminal hexahistidine tag on FbpB (His6-FbpB), whereas the pET-28a construct 
incorporates a C-terminal hexahistidine tag on FbpC (FbpC-His6). 
pETDuet-lIFbpBJFbpCINg: Ferric-ion binding protein B and C (FbpBC) 
genes were amplified independently from Neisseria gonorrhoeae genomic DNA by 
PCR using FbpB BamHI For and FbpB Hindill Rev (for FbpB), and FbpC NdeI For 
and FbpC Stop XhoI Rev (for FbpC). Primers were designed to incorporate BamHI 
and Hindlil restriction enzyme sites at the 5' and 3' ends of FbpB, respectively, and 
NdeI and XhoI at the 5' and 3' ends of FbpC, respectively. The resulting PCR 
products were cloned independently into the cloning vector pGEM T-Easy 
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(Promega) and the constructs verified by DNA sequencing. Plasmids containing the 
FbpB and FbpC gene inserts were digested with the relevant restriction enzymes and 
the fragments corresponding to the correct insert size (-1500 bp for FbpB and 
—1050 bp for FbpC) were ligated into pETDuet-1 co-expression plasmid. Firstly, 
FbpC was ligated into pETDuet-1 cut with NdeI and XhoI and the ligation mixture 
transformed into DH5ct cells. Transformants containing the pETDuet-1/FbpC 
construct had their DNA purified by standard procedures using a Qiagen mini-prep 
kit. The purified pETDuet- 1/FbpC plasmid was then cut with the restriction enzymes 
BamHI and HindIII. FbpB, cut similarly, was then ligated into the cut vector. The 
ligation mixture was transformed into DH5a and successful transformants were 
analysed by restriction digest to confirm the presence of the correct sized inserts. 
The pETDuet-1 vector not only allows the co-expression of two genes independently 
but also incorporates an N-terminal hexahistidine tag on the first gene insert (FbpB). 
The construct containing FbpB and FbpC genes was named pETDuet-
1/FbpB/FbpC/Ng (Figure 5.14). 
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Figure 5.14. A. Agarose DNA gel showing the PCR product fro FbpB and FbpC from 
reaction from N. gonorrhoeae genomic DNA. The DNA fragment corresponding to the 
FbpB (lane 1, yellow arrow) and FbpC (lane 2, red arrow) genes are highlighted. B. Vector 
map of pETDUET-1/FbpB/FbpC/Ng. C. Restriction analysis of pETDUET-
1/FbpB/FbpC/Ng. 1, BamHlIHindIII digest yielding a band at 1500 bp corresponding to 
FbpB. 2, NdeJJXhoI digest yielding bands at - lOSObp corresponding to FbpC and 1150 bp 
corresponding to a fragment of the FbpB gene. Higher weight bands in both lanes represent 
the remainder of the pETDUET-1 plasmid. 
pET-28aIFbpBC/Ng: Ferric-ion binding protein B and C (FbpBC) genes 
were amplified from Neisseria gonorrhoeae genomic DNA by PCR using the 
primers FbpB NcoI For and FbpC XhoI Rev. Primers were designed to incorporate 
an NcoI site at the 5' end of the FbpB gene and an XhoJ restriction enzyme site at the 
and 3' end of the FbpC gene. The resulting PCR product was cloned into cloning 
159 
Chapter 5: Results and Discussion: FbpABC 
vector pGEM T-Easy (Promega) and the constructs verified by DNA sequencing. 
Plasmid containing the FbpBC gene insert was digested with NcoI and XhoI and the 
fragment corresponding to the correct insert size (-2500 bp) was ligated into pET-
28a expression plasmid cut with NcoI and XhoI. This vector was chosen in order to 
incorporate a C-terminal hexahistidine tag on FbpC (FbpC-Hiso). The ligation 
reaction was transformed into DH5a E. coli cells (Invitrogen) and the plasmid DNA 
purified (Qiagen mini-prep). Restriction digests confirmed the presence of the 
correct sized insert, and the construct containing FbpBC was named pET-
28aIFbpBC/Ng (Figure 5.15). 
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Figure 5.15. A. Agarose DNA gel showing PCR product from FbpBC reaction from N. 
gonorrhoeae genomic DNA. Band corresponding to The FbpBC fragment is highlighted 
(arrow). B. Vector diagram of pET-28a/FbpBC/Ng. C. Restriction analysis of pET-
28a/FbpBC/Ng. 1, NcoI and 2, XhoI single digests yielding bands at the size of the entire 
plasmid (-7.8 kbp). 3, NcoL/XhoI double digest yielding a band at -2500 bp corresponding to 
FbpBC. 4, Smal single digest yielding bands at -1000 bp, -1250 bp, -1600 bp and 4 kbp. 
5.2.3 Co-Expression of N. gonorrhoeae FbpBC in E. co/i 
pET-28a/FbpBC/Ng and pETDuet- l/FbpB/FbpC/Ng plasmids were transformed into 
E. coli expression strain BL2 1 (DE3) and grown on LB/kanamycin (30 .tg/mL) or 
LB/ampicillin (100 g/mL) agar plates, as appropriate. 
Small-scale inductions in LB broth at 37 °C with 1 mM IPTG for 3 hours 
produced large quantities of FbpC visible by SDS-PAGE, but no visible band for 
FbpB for both constructs. However, Western blot analysis with an anti-C-terminal- 
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His6-tag antibody (Invitrogen) of the pET-28aIFbpBC/Ng induced cells confirmed 
the presence of FbpC-His6 produced from this construct. As this was the second 
gene in the construct with the single promotor 5' of the FbpB (first) gene, it was 
assumed that a small amount of FbpB was also expressed. This was partly confirmed 
when SDS-PAGE and Western blot analysis was performed on the pET/Duet-
1/FbpB/FbpC/Ng induced cells. Again, there was a large band observed at the 
expected molecular mass of FbpC, but no visible overexpression of FbpB on SDS-
PAGE. However, relatively large amounts of hexahistidine tagged protein were 
detected by Western blot analysis using an anti-His6-tag antibody (Sigma). This 
protein was assigned as His6-FbpB. 
Large amounts of FbpC were produced from both constructs in a similar 
fashion to the pET-28aJFbpC/Ng plasmid. It was decided that to reduce the 
probability of producing insoluble protein (inclusion bodies), the induction 
conditions that had been optimised for producing high levels of soluble FbpC were 
chosen for the FbpBC constructs. 
Induction at 0D600 = 0.8 with 0.2 mM IPTG for 4-5 hours at 25 °C gave the 
best expression of soluble FbpC and reasonable expression of FbpB. Terrific broth 
was chosen as the preferred medium as this broth allowed the highest-density cell 
growth. Different E. coli expression cell lines (HMS174(DE3) and B834(DE3)) did 
not improve expression or solubility of the target proteins (data not shown). 
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5.2.4 Purification of the N. gonorrhoeae FbpBC Complex 
The method for co-purification of the FbpBC complex relied on purifying the 
hexahistidine-tagged protein (His6-FbpB or FbpC-His6, depending on the construct), 
which in doing so would co-purify the corresponding protein partner. 
Due to the fact that FbpB is proposed to be an inner membrane protein, the 
first purification stage was to purify (enrich) the inner membrane component from 
the E. coli expression cells. This removed a lot of the potentially contaminating 
outer membrane and periplasmic proteins that may bind nonspecifically to the 
chromatographic resin used in the subsequent purification steps. Enrichment of the 
inner membranes was achieved by first treating the FbpBC expressing cells with 
lysozyme followed by sonication and then by low g centrifugation to remove 
insoluble outer membrane debris. The resulting opaque supernatant contained the 
inner membranes. This supernatant was subjected to high g ultracentrifugation to 
pellet the mixed inner membranes, which were golden brown in colour. This pellet 
contained the inner membrane fraction of the cells (hence, "enriched"), and these 
were used for purification of the FbpBC complex. 
The mixed inner membrane pellets were extracted with the non-ionic 
detergent n-dodecyl-/3-D-maltopyranoside (DDM, Anatrace) to solubilise the 
transmembrane domain of the transporter (FbpB), and the extract purified using 
TALON CO2taffinity chromatography resin as described above. TALON resin was 
chosen because it binds hexahistidine tags with a higher specificity than Ni2taffinity 
chromatography. As membrane proteins have a higher histidine content, in general, 
than soluble proteins, TALON resin limits the amount of contaminating non-histidine 
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tagged protein binding to the media. A relatively high level of purity was obtained 
for biochemical analysis after just one step of affinity chromatography (Figure 5.16). 
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Figure 5.16. A. SDS-PAGE of TALON resin purification of FbpBC. Lanes 1-5, flow-
through and wash fractions; lanes 6-9, elution fractions containing FbpB (yellow arrow) and 
FbpC (red arrow). B. SDS-PAGE (left) and corresponding Western blot (right) using 
anti-His6 antibody of TALON resin purification of SeMet-FbpBC. Lanes 1-4 and 1'-4', 
elution fractions containing FbpBC. Note that the lower band is detected by the anti-his6 
antibody Western blot, identifying this band as His6-FbpB (pink arrow), and verified by 
peptide mass fingerprinting (PMF). The upper band was identified as FbpC (green arrow) by 
the same technique. 
5.2.5 ATPase Activity of N. gonorrhoeae FbpC in the FbpBC Complex 
To check that the co-purified FbpC protein was a functional ATPase, the FbpBC 
complex was assayed in the same way as for the singly expressed FbpC protein. 
Results are presented in Figure 5.17. 
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Figure 5.17. ATPase assay of FbpBC. The activity of the protein was determined to be 
0.3-0,6 pmols P1 liberated/mm/mg of FbpC. • Assay plus M902, EJ assay minus M902. 
Results are an average of three repeats. 
The activity of FbpC in the FbpBC complex was determined to be 0.3-
0.6 mg P1 liberated/min/mg FbpC. Although this value is the same as that obtained 
for mono-expressed FbpC-His6, the accuracy of this value is dependent on the 
accurate determination of the concentration of FbpC in the FbpBC complex. This 
was done by measuring the total protein assayed, and dividing this value by two 
(assuming equal stoichiometry of FbpB:FbpC). 
5.2.6 Peptide Mass Fingerprinting of N. gonorrhoeae His6-FbpB 
SDS-PAGE was performed on a sample of His6-FbpB. The band thought to contain 
Hiso-FbpB was cut-out of the gel and was subjected to in-gel tryptic digest. The 
peptide fragments obtained from the trypsin digest were identified as FbpB from N. 
gonorrhoeae with a probability score of 1.0. Two other Neisseria spp iron-permease 
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proteins with a very similar score were second and third best matches. The next 
closest match had a probability score of 5.5 x iO. 
The MALDI-TOF spectrum obtained for the in-gel trypsin digest of the gel 
band observed at —35 kDa is shown in Appendix 3. 
5.2.7 Discussion: FbpBC 
5.2.7.1 Bioinformatic Analysis of FbpB 
FbpB is proposed to be a transmembrane permease protein that forms a dimer in the 
cytoplasmic membrane in the active form of the ABC transporter complex. Not 
surprisingly for an integral membrane protein, FbpB is composed of 50% 
hydrophobic residues that make-up the transmembrane-spanning helices. The 
bioinformatic studies performed on FbpB for this study revealed that each FbpB 
monomer is predicted to contain 12 transmembrane helices, and thus, the active 
dimer complex contains 24 transmembrane helices. This is in contrast to a 
previously published analysis that predicted that FbpB contains 11 transmembrane 
helices (12). Given that the previous analysis was performed over ten years ago, and 
that two modern independent topology mapping programmes both yield similar 
results, it seems likely that the results presented in this report are more accurate. 
BLAST searches performed for this study revealed that the closest matches were for 
transmembrane domains (TMD) from other ABC transporters known to be, or 
proposed to be, involved in iron uptake. This supports the finding that TMD 
involved in the transport of similar substrates share the highest sequence homology. 
Interestingly, TMD from only three species were present in top 20 BLAST results: 
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Neisseria spp, Haemophilus influenzae and Pseudomonas spp. TMD of iron uptake 
ABC transporters from other Gram-negative species that may have been expected to 
appear, such as Mannheimia, Yersinia and Serratia, were found much further down 
the BLAST results. 
5.2.7.2 Expression and Purification of FbpBC 
For this study it was decided that FbpB would be best expressed as a dual clone also 
expressing FbpC, in an attempt to achieve good expression of the permease protein 
and to express and purify the TMD and NBD together. The co-expression and co-
purification of the FbpBC complex was devised and optimised. Two constructs were 
produced and used to express the complex: one construct yielded an N-terminally 
hexahistidine-tagged FbpB protein, the other a C-terminally hexahistidine-tagged 
FbpC protein. In both systems, the histidine-tagged protein was purified by metal-
affinity chromatography, and in the process co-purified the corresponding binding 
partner, presumably due to complex formation in vivo. Both components of the 
transporter were purified to a relatively high level of purity in a single purification 
step using Co2taffinity chromatography, and yields of typically 2-4 mg (0.5-1 mg/L) 
of each protein were achieved. As such, this is first reported description of the 
purification of FbpB in the literature, and hence the FbpBC complex. This is also the 
first report of the purification of the transmembrane domain from an iron-uptake 
ABC transporter. His6-FbpB was positively identified by peptide mass 
fingerprinting, however, no accurate mass was determined for the complete protein 
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The specific activity of FbpC in the FbpBC complex was determined to be 
the same as for FbpC expressed from a single gene expressing plasmid. 
5.3 	FbpABC Association In Vitro 
5.3.1 FbpBC Pull-Down with Biotinylated FbpA 
As a proof of concept experiment before undertaking surface plasmon resonance 
experiments, a pull-down experiment was devised to investigate FbpABC association 
in vitro. The experiment utilised biotinylated FbpA protein (FbpA-V272C-(M-
PEO2-B)) bound to streptavidin-coated magnetic beads to pull-down the FbpBC 
complex from a solution containing the purified complex. 
Ml 2345678 M 1' 2' 3' 4' 5' 6' 7' 8' 
SDS-PAGE 	 Western blot 
Figure 5.18. SDS-PAGE (left) and corresponding Western blot (using anti-His6 
antibody; right) of the FbpBC pull-down assay using biotinylated FbpA. Lane 1/1', 
purified FbpBC (positive control); lane 2/2', biotinylated FbpA flow through from 
streptavidin coated beads; lanes 3/3' and 4/4', wash fractions from streptavidin coated beads; 
lane 5/5', FbpBC flow-through from FbpA coated streptavidin beads; lanes 6/6' and 7/7', 
FbpBC wash fractions from FbpA coated streptavidin beads; and lane 8/8', elution fraction 
from streptavidin beads. Note that FbpB is present in lanes 1' and 5', and complexes of 
FbpB are present in the elution fractions (lane 8/8') in both the SDS-PAGE and Western 
blot. 
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The pull-down experiment of FbpBC using biotinylated FbpA revealed that 
FbpABC does form a complex in vitro. SDS-PAGE and Western blots are presented 
in Figure 5.18. 
Analysis of the SDS-PAGE reveals that a large proportion of biotinylated 
FbpA did not bind to the magnetic streptavidin beads, most likely due to overloading 
of the beads (lane 2). Wash fractions after loading of biotinylated-FbpA show a 
small amount of residual biotinylated-FbpA present (lanes 3 and 4). The flow 
through fraction from FbpBC loading reveals a band at a higher mass than FbpA that 
is not observed on the Western blot (lane 5/5'). This band was therefore assigned as 
FbpC. There was no visible band for FbpB observed on the SDS-PAGE, however, 
the Western blot analysis did reveal a weak band above FbpC that was assigned as 
His6-FbpB in the flow through fractions, but not the wash fractions (lanes 5', 6' and 
7'). A large amount of protein was detected in the elution fraction by both SDS-
PAGE and Western blot (lane 8/8'). Bands identifiable as FbpA and FbpC 
overlapping one another at a molecular mass of 34-37 kDa are only visible on the 
SDS-PAGE, while higher molecular mass protein bands are observed on both the 
SDS-PAGE and Western blots (lane 8/8'). These higher mass bands were assigned 
as FbpB and FbpB-containing complexes of FbpA, FbpB and FbpC. The assignment 
of these higher order complexes was not possible due to the fact that FbpB does not 
run at its predicted mass on SDS-PAGE, thus potentially yielding a false mass for 
any complex present. 
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5.3.2 Surface Plasmon Resonance of FbpBC with Biotinylated FbpA 
SPR was performed to investigate whether FbpA would form a complex with FbpBC 
in vitro, and to determine the kinetics of any observed association. The method 
chosen to perform these experiments was to use holo-FbpA as the "bait" to which the 
purified FbpBC complex would bind when flowed over the SPR sensor chip. This 
was achieved by biotinylating FbpA (FbpA-V272C-(M-PE02-B)) to allow 
attachment, via the biotin moiety, to a streptavidin coated SPR sensor chip. 
Optimisation of loading biotinylated FbpA was first required before the experiment 
could be performed. As the Response Units (RU) of the sensogram output trace are 
measured in arbitrary units, the optimum loading of bait molecule depends on which 
instrument the experiments are being performed on and the bait molecule itself. For 
the Biocore T100, the optimum RU for the bait molecule is about 100-200. This 
roughly equates to about 4% coverage of the sensor chip surface. However, as each 
bait molecule is unique, the conditions have to be optimised for each bait molecule 
and experiment. 
The sensogram for binding of biotinylated-FbpA (FbpA-V272C-(M-PE02-B) 
to the SPR streptavidin coated chip is shown in Figure 5.19. Optimum loading of 
the biotinylated FbpA molecule was determined to be injection of 40 nM protein for 
500 s at a flow rate of 10 ML/min. This gave a loading of —200 RU. 
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Figure 5.19. Sensogram of biotinylated-FbpA binding to streptavidin-coated SPR 
sensor chip. Arrow 1, buffer change artifact; arrow 2, biotinylated-FbpA injection start; 
arrow 3, biotinylated-FbpA injection stop. 
FbpBC flow and binding conditions also had to be optimised before the 
kinetics experiment could be designed. This involved injection of the FbpBC 
complex over the FbpA loaded surface at different flow rates and for different times 
to achieve a response levels that would yield results that could be analysed 
effectively and accurately. However, it was noted during this optimisation process 
that the FbpABC complex was very stable. After association of the complex on the 
sensor chip surface, FbpBC did not readily dissociate from FbpA after injection of 
the FbpBC complex was ceased, and required in excess of several hours of 
continuous washing with buffer to dissociate less than 50% of the complex. 
Numerous washing conditions were tested, including high salt, low pH and high 
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these conditions was successful for accelerating dissociation of the complex. As 
such, it was not possible to regenerate the sensor surface back to its "FbpA-bound 
only" initial conditions that would be required for accurate analysis of the data. 
Different buffer conditions were also investigated, but this made no difference to the 
dissociation time. It was decided to continue with the FbpA/FbpBC kinetics 
experiment, but leaving 4000 s between injections of different concentrations of 
FbpBC to allow partial regeneration of the sensor surface. The sensogram of the 
FbpABC SPR experiment is presented in Figure 5.20. 
A. 
0 	 50 	 100 	 150 	 200 
Time (secs) 
Figure 5.20. A, Sensograms of FbpBC association with biotinylated-FbpA bound to 
streptavidin-coated SPR sensor ship. B (next page), detail of sensogram curves. 
Concentrations of FbpBC are indicated in inset. Injection of FbpBC was at -70 secs and 
each injection cycle was 3750 secs (only first 200 secs plotted) to allow regeneration of 
sensor surface (only -50 % achieved). Due to inversion of the sensogram curves, no kinetic 
information about complex formation could be determined, however, concentration-
dependent association was observed. Spikes at injection time-point and at -130 secs are 
artifacts. 
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The data show that surface plasmon resonance using biotinylated FbpA 
attached to a streptavidin coated sensor chip to capture FbpBC was only partially 
successful. Although the results of the assay revealed that there was a definite 
concentration dependent binding of FbpBC to FbpA, large amounts of nonspecific 
binding of the FbpBC complex to the reference cell caused the sensogram to be 
inverted. This, combined with the stability of the assembled FbpABC complex, 
made the data impossible to analyse to obtain meaningful kinetic or affinity data. 
The results do prove that the FbpABC do form a complex in vitro and that the 
complex is very stable. They also show a concentration dependent association of the 
three-component complex. 
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5.3.3 Discussion: FbpABC Association In Vitro 
The association of the FbpABC in vitro was investigated by a pull-down experiment 
and by surface plasmon resonance (SPR). 
The pull-down experiment of purified FbpBC complex by a biotinylated 
FbpA (FbpA-V272C-(M-PE02-B)) bound to streptavidin-coated magnetic beads 
revealed that a FbpABC complex formed in vitro. It was not possible, however, to 
determine accurately the stoichiometry of the complexes formed due to the evidence 
that FbpB did not run at its expected mass on SDS-PAGE or Western blot, thus 
yielding erroneous masses for any complexes formed. Also, the elution method from 
the streptavidin beads would denature all proteins bound, and could lead to 
unspecific protein aggregation. However, the experiment did prove that FbpBC 
binds to FbpA in vitro. 
Unfortunately the SPR experiments did not provide results that could be 
interpreted in terms of affinity of FbpA for FbpBC, or any indication of the kinetics 
of complex formation. Nonspecific binding of the FbpBC complex to the reference 
channel caused the sensograms to be inverted, meaning that the results of any 
calculations based on the data were unreliable. However, there was a concentration-
dependent effect in the inverted sensograms, suggesting there was FbpABC complex 
formation in the test channel. It was also noted during optimisation of the binding 
conditions before the experiment was performed that the FbpABC complex was very 
stable once formed. FbpBC would not readily dissociate from FbpA even when 
washed with high salt and low pH buffer conditions. This effect hampered the 
experiment as, for reliable interpretable data, it must be possible to return the sensor- 
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chip surface back to the starting conditions by dissociating the formed complex, and 
this was prohibited in the case of FbpBC by irreversible FbpABC complex 
formation. Future experiments could use apo-FbpA to investigate association of the 
complex, as it would be expected that no complex formation should occur. 
5.4 	Iron-59 Uptake Assays in Cells Expressing the FbpABC Operon 
5.4.1 Cloning of FbpABC from N. gonorrhoeae Genomic DNA 
Ferric-ion binding protein A, B and C (FbpABC) genes were amplified from 
Neisseria gonorrhoeae genomic DNA by PCR using the primers FbpA NcoI For and 
FbpC XhoI Rev. Primers were designed to incorporate an NcoI site at the 5' end of 
the FbpA gene and an XhoI restriction enzyme site at the and 3' end of the FbpC 
gene. The resulting PCR product was cloned into cloning vector pGEM T-Easy 
(Promega) and the constructs verified by DNA sequencing. Plasmid containing the 
FbpABC gene insert was digested with NcoI and XhoI and the fragment 
corresponding to the correct insert size (-3200 bp) was ligated into pET-28a 
expression plasmid cut with NcoI and XhoI. This vector was chosen to incorporate a 
C-terminal hexahistidine tag on FbpC for detection purposes. The ligation reaction 
was transformed into DHSct E. coli cells (Invitrogen) and the plasmid DNA purified 
(Qiagen mini-prep). Restriction digests confirmed the presence of the correct sized 
insert, and the construct containing FbpABC was named pET-28aJFbpABC/Ng 
(Figure 5.21). 
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Figure 5.21. A. Agarose DNA gel of PCR products from N. gonorrhoeae genomic DNA. 
I, FbpBC fragment and 2, FbpABC full operon used for uptake assays. B. Plasmid map of 
pET-28aIFbpABCINg. 
Expression of the operon was checked by Western blot analysis, using an 
anti-C-terminal-His6 antibody to probe for FbpC-His6, on whole-cell extracts of 
mini-inductions (2 mL). 
5.4.2 Iron-59 Uptake Assay 
An iron-uptake was employed to elucidate if the FbpABC operon, when expressed in 
E. coli, would form an active iron transport complex in vivo. A radioactive iron 
assay was chosen to perform this analysis. The assay was based on a similar assay 
performed on the HitABC iron-uptake ABC transporter from H. influenzae by 
Anderson et al (13). In the reported work the authors used an E. coli cell line (H-
1443) that was deficient in the siderophore enterochelin, as the host organism. The 
experiment for this study was performed in BL21(DE3) E. coli cells using two 
negative controls: a non-induced sample of cells transformed with the FbpABC 
plasmid (pETDuet-lIFbpB/FbpC/Ng), and an induced sample of cells expressing the 
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FbpC (pET-28aJFbpC/Ng) component of the transporter. The results of the assay are 
presented in Figure 5.22. 
Figure 5.22. Iron-59 uptake by FbpABC expressing cells. A, iron-59 remaining in cell-
free fraction (broth supernatant); B, iron-59 in periplasmic fraction; C, iron-59 in 
cytoplasmic fraction. o and 0 , FbpABC-induced cells; A, FbpABC-non-induced cells; u, 
FbpC-induced cells. 
The results reveal 	that cells expressing 	the FbpABC operon uptake 
radioactive iron-59 at a greater rate than uninduced cells containing the same 
plasmid, and induced cells expressing the NBD of the FbpABC transporter. The 
FbpABC induced cells uptake iron-59 into the periplasm and the cytoplasm, strongly 
suggesting that the FbpABC complex is properly functioning in vivo. FbpABC-
expressing cells uptake —25 times more total iron-59 than non-expressing cells, and 
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of this iron —20% is present in the periplasm after 45 mills and —10% is present in the 
cytoplasm after the same time. This is —4-times more iron than is transported into 
the periplasm and cytoplasm of non-FhpABC-expressing cells. 
5.4.3 Discussion: Iron Uptake by FbpABC Expressing Cells 
The iron-59 uptake assays showed that a functional FbpABC complex is formed in 
vivo when the operon is expressed in E. coli. This supports the work performed by 
Anderson et al, although they used a different E. coli host organism that was 
deficient in the siderophore enterochelin. In this study the authors present kinetic 
analysis for the uptake of iron by the HitABC operon from H. influenzae, however, 
because the work was performed in the non-parent organism, how relevant these 
values are is unknown and may give a false impression of the real values (13). 
Expression of the genes investigated in this research varied greatly depending on the 
plasmid construct used and the expression/induction conditions employed. The 
results of this study are qualitative rather than quantitative, and reveal that the 
transporter is functional in vivo. To obtain kinetic information, studies similar to 
those performed on the vitamin B12 transporter would have to be carried out (14). In 
the latter case, TMD and NBD (BtuCD) were incorporated into proteoliposomes and 
known concentrations of radioactively-labelled substrate-loaded PBP (BtuF) were 
used to determine rate of uptake of the substrate. Similar experiments for FbpABC 
are required to allow determination of the rate of uptake of iron by this ABC 
transporter. 
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6.1 	Concluding Remarks 
This study is the first to re-assemble the FbpABC in vitro in order to elucidate 
complex formation of this iron transporting ABC transporter. This was facilitated by 
the mutation, and subsequent biotinlylation, of FbpA to allow attachment to a 
streptavidin-coated surface to allow the pull-down of co-expressed and purified 
FbpBC components. As such, this is the first report to describe the purification of 
the transmembrane component, FbpB, of the FbpABC transporter, and the first to 
prove association of all three components in vitro. Unfortunately, kinetic and 
affinity data could not be obtained for complex formation, but experimental evidence 
from surface plasmon resonance data suggests that the formation of the FbpABC 
complex is rapid and the resulting complex is very stable, and does not dissociate 
readily. The ATP hydrolysis activity of FbpC was comparable to that previously 
reported in the literature (1). No other work on iron-uptake ABC transporters has 
been published that focuses on complex formation in vitro using techniques such as 
surface plasmon resonance and pull-down experiments, and thus, the work 
undertaken and reported in this study is novel in its field. 
The functionality of the FbpABC transporter was investigated by a 
radioactive iron-uptake assay and showed that E. coli cells expressing the N. 
gonorrhoeae FbpABC operon take up significantly more iron than cells not 
expressing the three-gene operon. Previous studies by another group have quoted 
values for the rate of iron uptake by the HitABC iron-uptake ABC transporter from 
H. influenzae in E. coli, but it is the opinion of this researcher that such values are 
invalid, as the assays performed in these studies were not performed in the parent 
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organism (2). True indications of the kinetics of these uptake systems can, probably, 
only be determined by in vitro experiments like those performed on the vitamin B12 
import ABC transporter, BtuFCD, and the histidine transporter, HisQMP (3,4), or by 
using FbpBC expressing spheroplasts. 
Wild-type and selenomethionine (SeMet)-labelled FbpC was expressed and 
purified in high yields in order to perform crystallographic studies at Imperial 
College (London), and resulted in a 2.7 A crystal structure of FbpC. The ATP-
hydrolysis activity of wild-type and SeMet-labelled FbpC was comparable to that 
previously reported in the literature (1). This is the first study to elucidate the 
structure of FbpC, and the first to report the structure of the nucleotide-binding 
domain from an iron-uptake ABC transporter. 
In an extension of previous work performed on FbpA (5-7), the promiscuity 
of the iron-binding site was further investigated in this study, and demonstrated that 
FbpA can bind the transition metal ions ruthenium(III) and osmium(III). 
Investigation of the ruthenium and osmium forms of the protein by chromatography 
and inductively-coupled plasma optical emission spectrometry revealed that two 
major species of metal bound-FbpA were formed. The major species for both metals 
possibly contained a 4-atom clusters that may be capped with one or two phosphate 
ions. The possible presence of a metal cluster capped by two phosphate molecules 
has not previously been described for metal clusters bound to FbpA, and is thus 
novel. EXAFS has been performed on Ru-FbpA and analysis of the data is pending. 
The finding that ruthenium and osmium can bind to FbpA has not previously been 
reported in the literature. 
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6.2 	Future Work 
The overall trend in biology appears to be driven by the determination of the crystal 
structures of proteins, enzymes and complexes. Future work related to the present 
study will in no doubt be directed towards the elucidation of the crystal structure of 
the FbpABC or FbpBC complexes. However, this requirement to produce a crystal 
structure should not cloud the requirement for rigorous biochemical investigation of 
the complex, by in vitro iron-uptake assays and by the use of optical techniques such 
as surface plasmon resonance, and other such powerful analytical methods. These 
techniques should allow the mechanics of complex formation and stoichiometry of 
the complex to be determined, and may provide insight into the, still unknown, 
chemical mechanism of FbpABC. This will also reveal which residues are involved 
not only in iron translocation, but also which are involved in formation of the 
complex. These biochemical investigations, along with structural studies, will 
hopefully shed light on the, still mostly undescribed, mechanism of iron transport 
within the bacterial cell, and may eventually lead to the development of new 
chemotherapeutic agents to help combat diseases caused by bacteria. 
Further investigation of FbpC will possibly reveal an additional role for this 
protein in vivo, due to the presence of the C-terminal domain that is proposed to be 
involved in some form of signal transduction within the bacterial cell (8). 
Experiments to determine the exact role of this additional domain would probably be 
best performed in N. gonorrhoeae, using FbpC C-terminal deletion mutants. 
Further investigation of ruthenium and osmium binding to FbpA could be 
continued in the form of structural studies that may reveal novel metal clusters bound 
Chapter 6: Concluding Remarks and Future Work 
to the protein, and metal competition assays to determine the affinity of these metals 
for FbpA, and to reveal if their affinities are greater than that for iron. The ability of 
FbpA to bind a host of metals may eventually lead to possible agents to interfere with 
the transport of iron with the bacterial cell, although the similarity between these 
bacterial periplasmic iron-binding proteins and human transferrin may mean this is 
not possible. However, insights into the affinity FbpA has for these exotic metals 
may allow researchers to determine the mechanism of iron binding and release from 
the protein: a process that still eludes description. Also, the promiscuous binding 
sites of these proteins may be utilised or engineered to allow their use in the 
bioremediation of hazardous metals in the environment and industry, or designed to 
produce novel enzymatic activity or useful biological markers (9). 	Further 
investigation of FbpA will possibly reveal new roles for this protein in vivo. 
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DNA sequence of the N. gonorrhoeae FbpABC Operon 
Amino acid sequences of proteins shown above DNA sequence in colour. Key: 
FbpA, FbpB and FbpC. 
1 ATTCCGCCAC GCATTGCCCG CCGCTTCCGC CTTACGGGCG CGATGCACGG AAAAAATACA AGTCAGAACA 
TAAGGCGGTG CGTAACGGGC GGCGAAGGCG GAATGCCCGC GCTACGTGCC TTTTTTATGT TCAGTCTTGT 
71 AACAATAACC GGATCGGATA ATAACAAATT TAAAAAATAA TTATTTGCAT TTATAAAAAA GAAGGAATAC 
TTGTTATTGG CCTAGCCTAT TATTGTTTAA ATTTTTTATT AATAAACGTA AATATTTTTT CTTCCTTATG 
M 	K 	T 	S 
141 ACTACACCCC GTTATGTCTT AACAAGGTAT ACACCCTCAT TCATTTAGGA GAAAATCGAT ATGAAAACAT 
TGATGTGGGG CAATACAGAA TTGTTCCATA TGTGGGAGTA AGTAAATCCT CTTTTAGCTA TACTTTTGTA 
I 	R 	Y ALL 	A 	A 	AL 	TA 	A T 	P 	A LAD I 	TV 	Y 
211 CTATCCGATA CGCACTGCTT GCCGCAGCCC TGACCGCCGC CACCCCCGCG CTGGCAGACA TTACCGTGTA 
GATAGGCTAT GCGTGACGAA CGGCGTCGGG ACTGGCGGCG GTGGGGGCGC GACCGTCTGT AATGGCACAT 
Smal 
N 	G 	Q H 	K 	E 	A 	A 	Q 	A V 	AD AFT 	R 	AT 	G 1KV 
281 CAACGGCCAA CACAAAGAAG CGGCACAAGC CGTTGCAGAT GCCTTTACCC GGGCTACCGG CATCAAAGTC 
GTTGCCGGTT GTGTTTCTTC GCCGTGTTCG GCAACGTCTA CGGAAATGGG CCCGATGGCC GTAGTTTCAG 
K 	L 	N 	S 	A 	KG 	D 	Q 	L AG 	Q 	I K 	E 	E G 	SR SPA 	D 
351 AAACTCAACA GTGCCAAAGG CGACCAGCTT GCCGGCCAAA TCAAAGAAGA AGGCAGCCGA AGCCCCGCCG 
TTTGAGTTGT CACGGTTTCC GCTGGTCGAA CGGCCGGTTT AGTTTCTTCT TCCGTCGGCT TCGGGGCGGC 
V 	F 	Y S 	E 	Q 	I 	PAL 	AT 	L S 	A 	A N 	L 	L 	E 	P 	L 	P 
421 ACGTATTCTA TTCCGAACAA ATCCCGGCAC TCGCCACCCT TTCCGCAGCC AACCTCCTAG AGCCCCTGCC 
TGCATAAGAT AAGGCTTGTT TAGGGCCGTG AGCGGTGGGA AAGGCGTCGG TTGGAGGATC TCGGGGACGG 
.A 	ST INK 	T 	R 	G 	K G 	VP V 	A 	A 	K 	K 	D 	W V 	AL 
491 CGCCTCCACC ATCAACGAAA CACGCGGCAA AGGCGTGCCG GTTGCCGCCA AAAAAGACTG GGTGGCACTG 
GCGGAGGTGG TAGTTGCTTT GTGCGCCGTT TCCGCACGGC CAACGGCGGT TTTTTCTGAC CCACCGTGAC 
S 	G 	R 	S P. 	V 	V 	V 	Y 	0 T 	R 	K 	L SE 	K DL 	E KS 	V 	L 
561 AGCGGACGTT CGCGCGTCGT CGTTTACGAC ACCCGCAAAC TGTCTGAAAA AGATTTGGAA AAATCCGTCC 
TCGCCTGCAA GCGCGCAGCA GCAAATGCTG TGGGCGTTTG ACAGACTTTT TCTAAACCTT TTTAGGCAGG 
NY 	A T 	P 	K 	W 	K 	N 	R 	I 	G 	Y VP 	T S 	GA 	F 	L 	E  
631 TGAATTACGC CACGCCGAAA TGGAAAAACC GCATCGGTTA CGTCCCCACT TCCGGCGCGT TCTTGGAACA 
ACTTAATGCG GTGCGGCTTT ACCTTTTTGG CGTAGCCAAT GCAGGGGTGA AGGCCGCGCA AGAACCTTGT 
IV 	A IV 	K 	L 	K 	GE A A A L 	K 	W 	L 	KG 	L KEY 
701 GATTGTCGCC ATCGTCAAAC TGAAAGGCGA AGCGGCCGCA TTGAAATGGC TCAAAGGCCT GAAAGAATAC 
CTAACAGCGG TAGCAGTTTG ACTTTCCGCT TCGCCGGCGT AACTTTACCG AGTTTCCGGA CTTTCTTATG 
G 	K 	P 	Y A 	K 	N 	S 	V 	A L 	Q 	A 	V EN 	G El 	D A 	AL 	I 
771 GGCAAGCCTT ACGCTAAAAA CTCCGTCGCC CTTCAAGCGG TTGAAAACGG CGAAATCGAT GCCGCCCTCA 
CCGTTCGGAA TGCGATTTTT GAGGCAGCGG GAAGTTCGCC AACTTTTGCC GCTTTAGCTA CGGCGGGAGT 
N 	NY Y 	W 	H 	AFAR 	K 	KG V 	Q 	N V 	H 	T 	R 	L 	N 	F 
841 TCAACAACTA CTACTGGCAC GCTTTCGCGC GTGAAAAAGG CGTACAAAAT GTCCACACCC GCCTGAATTT 
AGTTGTTGAT GATGACCGTG CGAAAGCGCG CACTTTTTCC GCATGTTTTA CAGGTGTGGG CGGACTTAAA 
V 	R  RD 	PG 	A 	L  T 	Y 	S GA 	A 	V 	L 	KS S 	N 
911 CGTCCGCCAC AGAGATCCCG GCGCACTCGT TACCTATTCC GGCGCAGCCG TGTTAAAATC CTCCCAAAAC 
GCAGGCGGTG TCTCTAGGGC CGCGTGAGCA ATGGATAAGG CCGCGTCGGC ACAATTTTAG GAGGGTTTTG 
K 	D 	E 	A K 	K 	F 	VA 	F LAG 	K E 	G 	Q R 	AL TA 	V 	R 
981 AAGGATGAGG CGAAAAAATT CGTCGCCTTC CTCGCCGGCA AGGAAGGACA GCGCGCCCTG ACCGCCGTCC 
TTCCTACTCC GCTTTTTTAA GCAGCGGAAG GAGCGGCCGT TCCTTCCTGT CGCGCGGGAC TGGCGGCAGG 
A 	E 	Y P 	L 	N 	PH 	V 	V 	ST 	F N 	L 	E P 	IA 	K 	L 	E 	A 
1051 GTGCCGAATA TCCTTTGAAT CCGCACGTGG TATCCACCTT CAATTTGGAA CCCATCGCCA AGTTGGAAGC 
CACGGCTTAT AGGAAACTTA GGCGTGCACC ATAGGTGGAA GTTAAACCTT GGGTAGCGGT TCAACCTTCG 
HE 
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.P 	Q 	V SAT 	T 	VS 	E K 	E 	H AT 	R 	L 	L 	E  A 	GM 
1121 ACCCCAAGTG TCCGCCACCA CTGTTTCCGA AAAAGAACAC GCCACCCGGC TGCTTGAGCA AGCCGGTATG 
TGGGGTTCAC AGGCGGTGGT GACAAAGGCT TTTTCTTGTG CGGTGGGCCG ACGAACTCGT TCGGCCATAC 
K 
M 	K 	N 
1191 AAATAAGCCG TTTTCGGATT GTCAAACGGG CGGACATTTA TACTGTCCGC CCGTTTTGCC GATGAAAAAC 
TTTATTCGGC AAAAGCCTAA CAGTTTGCCC GCCTGTAAAT ATGACAGGCG GGCAAAACGG CTACTTTTTG 
TM 	S 	P K 	K 	I P1W L 	T 	G 	L ILL IA 	L P 	L 	T 	L 
1261 ACTATGTCTC CTAAAAAAAT ACCCATTTGG CTTACCGGCC TCATCCTACT GATCGCCCTG CCGCTTACCC 
TGATACAGAG GATTTTTTTA TGGGTAAACC GAATGGCCGG AGTAGGATGA CTAGCGGGAC GGCGAATGGG 
P 	FL Y 	VA MR 	SW 	Q 	V 	G IN 	R A 	V 	EL 	L 	F 	K 
1331 TGCCTTTTTT ATATGTCGCT ATGCGTTCGT GGCAGGTCGG CATCAACCGC GCCGTCGAAC TGTTGTTCCG 
ACGGAAAAAA TATACAGCGA TACGCAAGCA CCGTCCAGCC GTAGTTGGCG CGGCAGCTTG ACAACAAGGC 
P 	R 	M W 	DL 	L 	S 	T L 	TM HAG 	V 	T 	L  S 	IV 
1401 CCCGCGTATG TGGGATTTGC TCTCCAACAC CTTGACGATG ATGGCGGGCG TTACCCTGAT TTCCATTGTT 
GGGCGCATAC ACCCTAAACG AGAGGTTGTG GAACTGCTAC TACCGCCCGC AATGGGACTA AAGGTAACAA 
L 	G 	IA 	CAL L 	F 	Q R 	Y 	F F 	G 	K T 	F 	F Q 	TA 	I 
1471 TTGGGCATTG CCTGCGCCCT TTTGTTCCAA CGTTACCGCT TCTTCGGCAA AACCTTTTTT CAGACGGCAA 
AACCCGTAAC GGACGCGGGA AAACAAGGTT GCAATGGCGA AGAAGCCGTT TTGGAAAAAA GTCTGCCGTT 
T 	L 	P L 	CI PA 	F 	V 	SC 	F T 	WI S 	L 	T 	F 	K 	V 	E 
1541 TCACCCTGCC TTTGTGCATC CCCGCATTTG TCAGCTGTTT CACCTGGATC AGCCTGACCT TCCGCGTCGA 
AGTGGGACGG AAACACGTAG GGGCGTAAAC AGTCGACAAA GTGGACCTAG TCGGACTGGA AGGCGCAGCT 
GE 	W G 	TV 	H 	I 	MS L 	S 	S F 	P 	LA 	Y 	L 	P V 	E 	A 
1611 AGGATTTTGG GGGACAGTGA TGATTATGAG CCTGTCCTCG TTTCCGCTCG CCTACCTGCC CGTCGAGGCG 
TCCTAAAACC CCCTGTCACT ACTAATACTC GGACAGGAGC AAAGGCGAGC GGATGGACGG GCAGCTCCGC 
AL 	KR 	IS 	L S 	YE E 	VS 	L S 	L 	G K 	SR L 	Q 	T 	F 
1681 GCACTCAAAC GCATCAGCCT GTCTTACGAA GAAGTCAGCC TGTCCTTGGG CAAAAGCCGC CTGCAAACCT 
CGTGAGTTTG CGTAGTCGGA CAGAATGCTT CTTCAGTCGG ACAGGAACCC GTTTTCGGCG GACGTTTGGA 
NdeI 
F 	S 	A IL 	P Q 	L 	K 	P Al 	G S 	S 	V L 	L 	A 	L 	H 	M 
1751 TTTTTTCCGC CATCCTCCCA CAGCTCAAAC CCGCCATCGG CAGCAGCGTG TTACTGATCG CCCTGCATAT 
AAAAAAGGCG GTAGGAGGGT GTCGAGTTTG GGCGGTAGCC GTCGTCGCAC AATGACTAGC GGGACGTATA 
L 	E F 	GA 	V 	S 	IL NY 	P T 	FT 	T A 	IF Q 	E 	Y 
1821 GCTGGTCGAA TTTGGCGCGG TATCCATTTT GAACTACCCC ACTTTTACCA CTGCCATTTT CCAAGAATAC 
CGACCAGCTT AAACCGCGCC ATAGGTAAAA CTTGATGGGG TGAAAATGGT GACGGTAAAA GGTTCTTATG 
EMS 	Y N 	N 	N TA 	A L 	L 	S 	A V 	L 	T A V 	C G 	IV 	V 
1891 GAAATGTCCT ACAACAACAA TACCGCCGCC CTGCTTTCCG CTGTTTTGAC GGCGGTGTGC GGCATCGTCG 
CTTTACAGGA TGTTGTTGTT ATGGCGGCGG GACGAAAGGC GACAAAACTG CCGCCACACG CCGTAGCAGC 
.F 	GE S 	F R 	G 	K 	A K 	I 	Y H 	S 	G KG 	V 	A 	K 	P 	Y 
1961 TATTTGGAGA AAGCATATTT CGCGGCAAAG CCAAGATTTA CCACAGCGGC AAAGGCGTTG CCCGTCCTTA 
ATAAACCTCT TTCGTATAAA GCGCCGTTTC GGTTCTAAAT GGTGTCGCCG TTTCCGCAAC GGGCAGGAAT 
.P 	V 	K T 	L 	K 	L 	PG 	Q I 	GA I 	V 	FL SS 	L L 	L 
2031 TCCCGTCAAA ACCCTCAAAC TGCCCGGTCA GATCGGCGCG ATTGTTTTTT TAAGCAGCTT GTTGATTTTG 
AGGGCAGTTT TGGGAGTTTG ACGGGCCAGT CTAGCCGCGC TAACAAAAAA ATTCGTCGAA CAACTAAAAC 
GIll P 	F 	G V 	L  NW 	MM V 	G 	T S 	G 	T F 	A 	L  
2101 GGCATTATTA TCCCCTTTGG CGTATTGATA CATTGGATGA TGGTCGGCAC TTCCGGCACA TTCGCGCTCG 
CCGTAATAAT AGGGGAAACC GCATAACTAT GTAACCTACT ACCAGCCGTG AAGGCCGTGT AAGCGCGAGC 
S 	V 	F D 	A 	F IRS 	L S 	VS AL 	G A 	IL 	T 	IL 	C 
2171 TATCCGTATT TGATGCCTTT ATCCGTTCCT TAAGCGTATC GGCTTTAGGT GCGATTTTGA CTATATTATG 
ATAGGCATAA ACTACGGAAA TAGGCAAGGA ATTCGCATAG CCGAAATCCA CGCTAAAACT GATATAATAC 
AL 	P L 	WA 	S 	V 	R Y 	N FL 	TV 	WI 	D R 	L 	P 
2241 TGCCTTGCCC CTTGTTPGGG CATCGGTTCG CTATCGCAAP TTTTTAACCG TTTGGATAGA CAGGCTGCCG 
ACGGAACGGG GAACAAACCC GTAGCCAAGC GATAGCGTTA AAAAATTGGC AAACCTATCT GTCCGACGGC 
am 
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FL 	L 	H A 	V 	P G 	L  IA 	L 	S L 	Y F 	S 	NY 	T 	P 
2311 TTTTTACTGC ACGCCGTCCC CGGTTTGGTT ATCGCCCTAT CCTTGGTTTA TTTCAGCATC AACTACACCC 
AAAAATGACG TGCGGCAGGG GCCAAACCAA TAGCGGGATA GGAACCAAAT AAAGTCGTAG TTGATGTGGG 
A 	V 	Y Q 	T 	F IV 	VI LAY F 	ML Y 	L 	PM 	A 	Q 	T 
2381 CTGCCGTTTA CCAAACCTTT ATCGTCGTCA TCCTTGCCTA TTTCATGCTT TACCTGCCGA TGGCGCAAAC 
GACGGCAAAT GGTTTGGAAA TAGCAGCAGT AGGAACGGAT AAAGTACGAA ATGGACGGCT ACCGCGTTTG 
.T 	L 	R T 	S 	L 	E 	Q 	L 	P K 	GM E 	V 	G 	AT 	L 	G 	R 	G 
2451 CACCCTGAGG ACTTCCTTGG AACAACTCCC CAAAGGGATG GAACAGGTCG GCGCAACATT GGGGCGCGGA 
GTGGGACTCC TGAAGGAACC TTGTTGAGGG GTTTCCCTAC CTTGTCCAGC CGCGTTGTAA CCCCGCGCCT 
H 	FF1 FR 	T L 	L PSI 	L PG 	I TA 	A 	F 	A 	L 
2521 CACTTCTTTA TTTTCAGGAC GTTGGTACTG CCGTCCATCC TGCCCGGCAT TACCGCCGCA TTCGCACTCG 
GTGAAGAAAT AAAAGTCCTG CAACCATGAC GGCAGGTAGG ACGGGCCGTA ATGGCGGCGT AAGCGTGAGC 
FL 	K L 	M 	K EL 	TA 	T 	L 	L L 	TA D 	DV 	H 	T 	L 	S 
2591 TCTTCCTCAA GCTGATGAAA GAGTTGACCG CCACCCTGCT GCTGACCGCC GACGATGTCC ACACGCTCTC 
AGAAGGAGTT CGACTACTTT CTCAACTGGC GGTGGGACGA CGACTGGCGG CTGCTACAGG TGTGCGAGAG 
.T 	A 	V WE 	Y 	T 	SD 	A Q 	Y 	A A 	AT 	P Y 	AL 	ML 	V 
2661 CACCGCCGTT TGGGAATACA CATCGGACGC ACAATACGCC GCCGCCACCC CTTACGCGCT GATGCTGGTA 
GTGGCGGCAA ACCCTTATGT GTAGCCTGCG TGTTATGCGG CGGCGGTGGG GAATGCGCGA CTACGACCAT 
L 	F 	S 	G I 	P 	V FL 	L K 	KY 	A 	F 	K 
2731 TTATTTTCCG GCATACCCGT ATTCCTGCTG AAGAAATACG CCTTCAAATA ACAGCTTGAG GAAGCACCGC 
AATAAAAGGC CGTATGGGCA TAAGGACGAC TTCTTTATGC GGAAGTTTAT TGTCGAACTC CTTCGTGGCG 
MT 	A AL 	HI 	G 	ML SK 	S F 	Q 	NT 	P 	V 	L ND 	I 
2801 TATGACCGCC GCCCTGCACA TCGGACACCT GTCCAAAAGT TTTCAAAACA CCCCGGTTTT AAACGACATT 
ATACTGGCGG CGGGACGTGT AGCCTGTGGA CAGGTTTTCA AAAGTTTTGT GGGGCCAAAA TTTGCTGTAA 
Sma I 
S 	L 	S 	L D 	PG K 	I 	L F 	I 	I 	G AS 	G C 	S 	K T 	T 	L 	L-- 
2871 TCGCTCAGCC TCGACCCGGG CGAAATTCTC TTTATCATCG GCGCGTCCGG CTGCGGCAAA ACCACCCTTT 
AGCGAGTCGG AGCTGGGCCC GCTTTAAGAG AAATAGTAGC CGCGCAGGCC GACGCCGTTT TGGTGGGAAA 
R 	CL AG 	F E 	PD 	S 	GE I 	S 	L S 	G 	K 	T IF 	S 
2941 TACGCTGCCT TGCCGGTTTC GAACAACCCG ATTCCGGCGA AATTTCGCTT TCCGGCAAAA CCATCTTCTC 
ATGCGACGGA ACGGCCAAAG CTTGTTGGGC TAAGGCCGCT TTAAAGCGAA AGGCCGTTTT GGTAGAAGAG 
.K 	NT N 	L 	P 	V 	R 	ER R 	L 	G Y 	L 	Q 	E 	G 	V L 	F 	P 
3011 GAAAAATACC AACCTTCCCG TCCGCGAACG CCGTTTGGGT TACCTCGTAC AGGAAGGCGT GCTGTTCCCC 
CTTTTTATGG TTGGAAGGGC AGGCGCTTGC GGCAAACCCA ATGGAGCATG TCCTTCCGCA CGACAAGGGG 
ML 	TV Y 	N IA 	Y 	G L 	GM G 	KG K 	TA 	Q ER 	Q 
3081 CACCTGACCG TTTACCGCAA TATCGCCTAC GGTCTCGGCA ACGGCAAAGG CAGGACGGCG CAAGAGCGAC 
GTGGACTGGC AAATGGCGTT ATAGCGGATG CCAGAGCCGT TGCCGTTTCC GTCCTGCCGC GTTCTCGCTG 
RI 	K A 	ML EL 	T 	G 	I 	SE LAG R 	Y 	PH EL 	S 
3151 AGCGCATCGA AGCCATGTTG GAATTGACCG GCATTTCCGA ACTTGCCGGA CGCTATCCGC ACGAACTTTC 
TCGCGTAGCT TCGGTACAAC CTTAACTGGC CGTAAAGGCT TGAACGGCCT GCGATAGGCG TGCTTGAAAG 
G 	G 	Q Q 	Q 	R 	V 	ALA K 	AL A 	PD 	P 	ELI L 	L 	D 
3221 GGGCGGACAA CAACAGCGCG TCGCCCTCGC CCGCGCCCTC GCCCCCGACC CCGAACTGAT TTTGTTGGAC 
CCCGCCTGTT GTTGTCGCGC AGCGGGAGCG GGCGCGGGAG CGGGGGCTGG GGCTTGACTA AAACAACCTG 
E 	P 	F 	S AL 	D E 	L 	R R 	Q 	I RED MI 	A 	AL R 	A 
3291 GAACCCTTCA GCGCGCTGGA CGAACAGTTG CGCCGCCAGA TTCGCGAAGA CATGATTGCC GCCCTGCGCG 
CTTGGGAAGT CGCGCGACCT GCTTGTCAAC GCGGCGGTCT AAGCGCTTCT GTACTAACGG CGGGACGCGC 
N 	G 	K S 	A 	V F 	V 	S 	DR 	E E 	AL Q 	Y 	AD RI 	A-- 
3361 CCAACGGCAA ATCCGCCGTT TTTGTCAGCC ACGACCGCGA AGAAGCCCTG CAATACGCCG ACCGGATTGC 
GGTTGCCGTT TAGGCGGCAA AAACAGTCGG TGCTGGCGCT TCTTCGGGAC GTTATGCGGC TGGCCTAACG 
.V 	H 	K Q 	G 	RI 	L 	Q 	T ASP H 	ELY 	R 	Q 	P A 	DL 
3431 CGTGATGAAA CAGGGGCGCA TCCTCCAAAC CGCAAGCCCT CACGAATTGT ACCGACAACC TGCCGACCTT 
GCACTACTTT GTCCCCGCGT AGGAGGTTTG GCGTTCGGGA GTGCTTAACA TGGCTGTTGG ACGGCTGGAA 
190 
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D A AL F I G E G I V F P A AL N ADD TAD C' 
3501 GATGCCGCCC TGTTTATCGG CGAAGGCATC GTGTTCCCCG CCGCGCTCAA CGCCGACGGC ACCGCCGATT 
CTACGGCGGG ACAAATAGCC GCTTCCGTAG CACAAGGGGC GGCGCGAGTT GCGGCTGCCG TGGCGGCTAA 
R L G R L P V Q SD A P A G T R G T L L I R P 
3571 GCAGATTGGG CCGCCTGCCC GTCCAAAGCG GCGCACCCGC AGGCACGCGC GGTACACTGC TCATCCGTCC 
CGTCTAACCC GGCGGACGGG CAGGTTTCGC CGCGTGGGCG TCCGTGCGCG CCATGTGACG AGTAGGCAGG 
.E Q 	S L HP NSA PA A S I H A V V L K T T 
3641 GGAACAGTTC AGCCTTCACC CCCATTCCGC ACCCGCCGCC TCCATTCACG CCGTGGTTCT CAAAACCACG 
CCTTGTCAAG TCGGAAGTGG GGGTAAGGCG TGGGCGGCGG AGGTAAGTGC GGCACCAAGA GTTTTGGTGC 
P K AR H T E I S L RAG Q TV L T L N L P S A 
3711 CCCAAAGCGC GGCATACCGA AATCAGCCTC AGGGCCGGAC AAACCGTCCT CACGCTCAAC CTCCCTTCCG 
GGGTTTCGCG CCGTATGGCT TTAGTCGGAG TCCCGGCCTG TTTGGCAGGA GTGCGAGTTG GAGGGAAGGC 
PT L SD G I S A V L H L D G P AL F F PG N 
3781 CCCCCACCCT GTCAGACGGC ATTTCCGCCG TCCTCCATTT GGACGGTCCC GCCCTGTTCT TCCCCGGAAA 
GGGGGTGGGA CAGTCTGCCG TAAAGGCGGC AGGAGGTAAA CCTGCCAGGG CGGGACAAGA AGGGGCCTTT 
.T L 
3851 TACCCTCTGA AAGGCGGCAG CATCCACAAG CCTGCGGATA TTTATCTTGT TGGAAACAGA ATTTGTTTGC 
ATGGGAGACT TTCCGCCGTC GTAGGTGTTC GGACGCCTAT AAATAGAACA ACCTTTGTCT TAAACAAACG 
NdeI 
3921 TATATTCAAC CTGCGCGCCC CAAGCCAAAC ACGGCACGCA CGGCACGCAG GCAGCCGTTT CTGCCCATAT 
ATATAAGTTG GACGCGCGGG GTTCGGTTTG TGCCGTGCGT GCCGTGCGTC CGTCGGCAAA GACGGGTATA 
Nde I 
3991 GCCGCCCCTT CCAACCACAT ATGCCGCACA CCGCAGCATA CGAAAGGATA TATTATGGCA AAAGTACTCG 
CGGCGGGGAA GGTTGGTGTA TACGGCGTGT GGCGTCGTAT GCTTTCCTAT ATAATACCGT TTTCATGAGC 
Bioinformatic Analysis of FbpABC 
Gene size 
Protein size Pedicted mass Predicted p1 
(mature protein) (mature protein) (mature protein) 
FbpA 331 aa 35 837 kDa 9.60 
993 bp 
(309 aa) (33 637 kDa) (9.52) 
FbpB 1527 bp 509 aa 56 310 kDa 9.67 
FbpC 1056 bp 352 aa 37 900 kDa 6.91 
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Amino acid sequence of FbpA from N. gonorrhoeae (red residues indicate the 
signal peptide of the pre-protein that is cleaved during translocation of the 
mature protein into the periplasm): 
1 	MKTSIRYALL AAALTAATPA LAD ITVYNGQ HKEAAQAVAD AFTRATGIKV 
51 KLNSAKGDQL AGQIKEEGSR SPADVFYSEQ IPALATLSAA NLLEPLPAST 
101 INETRGKGVP VAAKKDWVAL SGRSRVVVYD TRKLSEKDLE KSVLNYATPK 
151 WKNRIGYVPT SGAPLEQIVA IVKLKGEAAA LKWLKGLKEY GKPYAKNSVA 
201 LQAVENGEID AALINNYYWH AFAREKGVQN VHTRLNFVRH RDPGALVTYS 
251 GAAVLKSSQN KDEAKKFVAF LAGKEGQRAL TAVRAEYPLN PRVVSTFNLE 
301 PIAKLEAPQV SATTVSEKEH ATRLLEQAGM K 
Amino acid sequence of FbpB from N. gonorrhoeae: 
1 MKNTMSPKKI PIWLTGLILL IALPLTLPFL YVANRSWQVG INRAVELLFR 
51 PRNWDLLSNT LTdMAGVTLI SIVLGIACAL LFQRYRPFGK TFFQTAITLP 
101 LCIPAFVSCF TWISLTFRVE GFWGTVMIMS LSSFPLAYLP VEAALKRISL 
151 SYEEVSLSLG KSRLQTFFSA ILPQLKPAIG SSVLLIALRM LVEFGAVSIL 
201 NYPTFTTAIF QEYEMSYNNN TAALLSAVLT AVCGIVVFGE SIFRGKAKIY 
251 HSGKGVABPY PVKTLKLPGQ IGAIVFLSSL LILGIIIPFG VLIHWMMVGT 
301 SGTFALVSVF DAFIRSLSVS ALGAILTILC ALPLVWASVR YRNFLTVWID 
351 RLPFLLHAVP GLVIALSLVY FSINYTPAVY QTFIVVILAY FMLYLPMAQT 
401 TLRTSLEQLP KGMEQVGATL GRGHFFIFRT LVLPSILPGI TA.AFALVFLK 
451 LMKELTATLL LTADDVHTLS TAVWEYTSDA QYAAATPYAL MLVLFSGIPV 
501 FLLKKYAFK 
Amino acid sequence of FbpC from N. gonorrhoeae: 
1 MTAALHIGHL SKSFQNTPVL NDISLSLDPG EILFIIGASG CGKTTLLRCL 
51 AGFEQPDSGE ISLSGKTIFS KNTNLPVRER RLGYLVQEGV LFPRLTVYRN 
101 IAYGLGNGKG RTAQERQRIE ANLELTGISE LAGRYPHELS GGQQQRVALA 
151 RALAPDPELI LLDEPFSALD EQLRRQIRED MIAALRANGK SAVFVSHDRE 
201 EALQYADRIA VQGRILQT ASPHELYRQP ADLDAALFIG EGIVFPAALN 
251 ADGTADCRLG RLPVQSGAPA GTRGTLLIRP EQFSLHPHSA PAASIHAVVL 
301 KTTPKARHTE ISLRAGQTVL TLNLPSAPTL SDGISAVLHL DGPALFFPGN 
351 TL 
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mass 
mass 
FbpA-R48C: dimer mass 67 198 ± 11.4 Da (theoretical mass 67 176 Da) 
FbpA-R48C: reduced mass 33 585 ± 5.0 Da (theoretical mass 33 588 Da) 
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FbpA-R48C as purified masses 33 585 ± 5.0 Da, 33 706 ± 4.9 Da 
(cysteinylation) and 33 886 ± 4.9 Da (glutathiolylation) (theoretical mass of FbpA-
R48C 33 588 Da) 
FbpA-R48C-IAA: reduced mass 33 640.k 2.3 Da(theoretical mass 33 645 Da) 
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5. FbpA-R48C-AMS: modified mass 33 094 ± 5.9 Da (theoretical mass 34 078 Da) 
mass 
6. FbpA-V272C: reduced mass 33 640.86 ± 2.3 Da (theoretical mass 33 643 Da) 
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A-TA71A An 
mass 
7. FbpA-V272C-IAA : reduced mass 33 707 ± 6.7 Da (theoretical mass 33 700 Da) 
rnaM 
8. FbpA-V272C-(M-PEO2-B) : reduced mass 33 640.86 ± 2.3 Da (theoretical mass 
33 643 Da) 
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Trypsin digest of FbpC 
Voyager Spec #1 >AdvBC(15,0.5,O.1)[BP = 832.1, 62419] 
8321026 
Mass m/z 
Hits table for the above trypsin digest: 
MOWSE #/56(%) Protein Accession 
Score 	Masses MW 	 Species Protein Name 
Matched (Da)/pI # 
Ferric cations import ATP- 
1 2.126e+06 12 (21) 37858/7.2 050966 NEIGO binding protein fbpC (EC 
3.6.3.30) 
2 90.4 4 (7) 15429/9.1 09R352 NEIME 
Regulatory protein PiIA 
(Fragment) 
3 65.0 6 (10) 71680/5.4 09S368 NEIGO Putative ATP-binding protein 
4 65.0 7 (12) 71732/5.4 09S359 NEIME Putative ATP-binding protein 
5 64.9 7 (12) 71789/5.4 09S360 NEIME 
Putative ATP-binding  
protein 
657.7 5 (8) 87705/9.5 087626 NEIFL 
Penicillin-binding protein 
1A (PBP-la) (PBP1a) 
744.0 4 (7) 32042/5.9 08KS36 NEIME 
Outer membrane protein 
- (Fragment) 
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Trypsin digest of FbpB 
Voyager Spec #1=>AdvBC(15,0.5,0.1)[BP = 832.1, 62419] 
Mass fmW 
Hits table for the above trypsin digest: 
Protein Information and Sequence 
Rank Probability Est'd Z 
Analyse Tools (T) 
	
+1 	1.0e+000 	2.17 	TgillO98688IgbIAAB6356O.11 FbpB 	10.1 56.70 
T gi1573 1 35OIgb1AAC3239 1 .21 transcriptional 2 	5.5e-009 	- 	 6.1 54.71 
activator NtrC [Herbaspirillum seropedicae] 
3 	2.1e-010 	- 	T gill 3235527leniblCAC33654. II DNA ligase 7.8 54.98 
[Rickettsia montanensis] 
I gill627275OIreflNP 438969.11 
+4 	1.2e-011 	- 	phosphoenolpyruvate carboxykinase 	5.4 59.61 
[Haemophilus influenzae Rd KW20] 
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